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ABSTRACT 
 
This study was designed to study the effects of ethyl acetate extracts from A. wilkesiana 
(9EA) and D. grandiflora (75EA-L and 75EA-B) and the respective bioactive fractions from 
these plants on methicillin resistance Staphylococcus aureus (MRSA ATCC 43300).  A 
bioassay-guided isolation was used for fractionation of the crude extracts by combinations 
of liquid chromatography methods. The minimum inhibitory concentration (MIC) of crude 
extracts and fractions ranged between 12 to 0.75 mg/ml for MRSA and 6 to 0.75 mg/ml 
for methicillin sensitive S. aureus (MSSA ATCC 11630). The MIC values of beta-lactam 
antibiotics against MRSA strain (i.e. MIC of ampicillin = 50 µg/ml) used in this study were 
higher compared to MSSA (MIC of ampicillin = 6.25 µg/ml).  The crude extracts and 
selected fractions were evaluated for synergistic activity with ampicillin. The kinetic 
growth curve experiment illustrated that combination of ampicillin and 9EA or 75EA-L or 
the fractions derived from these extracts (9EA-FC, 9EA-FD, FC-B, and 75EA-L) suppressed 
MRSA growth markedly. Results of fractional inhibitory concentration (FIC) index 
interpretation indicated synergism present in combination treatments of ampicillin and 
the plant test agents (FIC index < 0.05). Two fractions, FC-B and 75EA-L-F10 were 
identified to reduce MIC of ampicillin from 50 µg/ml to 1.56 µg/ml and 0.78 µg/ml 
respectively. These fractions were found to inhibit PBP2a production either alone or in 
combination with ampicillin in Western blot assay which offered a plausible explanation ǯǤ
investigated in MRSA biofilm study. Results showed that FC-B or 75EA-L-F10 alone 
inhibited MRSA biofilm production (~70-80% inhibition). Findings from microtiter 
attachment assay suggested that these fractions prevent cell-surface attachment (more 
than 90% inhibition) which is the initial step in biofilm formation. Whereas the PBP2a 
latex agglutination showed occurrence of low level of PBP2a in MRSA biofilm treated with 
ii 
 
FC-B or 75EA-L-F10 implicating possible disruption of cell-cell interactions required for 
microcolonies development. Ampicillin on the other hand has an inferior activity in 
preventing cell-surface attachment (37.8% inhibition) although it managed to inhibit 
MRSA biofilm production by 84.5%.  A high performance liquid chromatography (HPLC) 
and phytochemical analysis showed the studied extracts and fractions are complex 
mixtures of plant metabolites belonging to the class of tannins, saponins, alkaloids, 
flavonoids, sterols/steroids, and glycosides.  The resistance modifying properties and the 
anti-biofilm action found in this study are attributed to presence of these phytochemicals. 
Therefore, we propose that metabolites occurring in A. wilkesiana and D. grandiflora may 
be good candidates for development of new treatment for MRSA or as an adjuvant for the 
current antibiotics. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
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1.1 INTRODUCTION 
 
One of the major health concerns in the 21st century is infections caused by antibiotic-
resistant bacteria. These chronic infections require a longer and complex expansive 
intervention treatment (Alanis 2005). Infections related to antibiotic resistance were 
initially observed in hospital settings amongst critically ill and immunocompromised 
patients. More recently, these infections are reported increasing in the community and in 
certain instances, in live-stock animals (Alanis 2005; Stefani et al. 2012).  
 
One of the most notorious antibiotic resistance bacterium is methicillin-resistant 
Staphylococcus aureus (MRSA) which is a major pathogen causing nosocomial infection 
(Michel and Gutmann 1997; Jarvis 2010; Snider and Rivard 2012).  MRSA causes skin 
infections, wound suppuration, pneumonia, and bloodstream infections that eventually 
lead to sepsis and fatalities. In the Threat Report by the U.S Center for Disease Control and 
Prevention (CDC), 80,461 severe MRSA infection cases were reported annually with 
11,285 deaths per year in the United States (CDC 2013). In Malaysian hospitals, MRSA 
infection cases reported between the year 2002 and 2007 were showing an increasing 
trend with annual MRSA prevalence over 40% (Al-Talib et al. 2007; Ghaznavi-Rad et al. 
2010). The molecular mechanisms of resistance exhibited by MRSA strains are diversed ǯns. 
The bacterium was observed 1) to suppress beta-lactamase, an enzyme that degrades 
beta-lactam drugs, 2) to have an efflux pump system which exports drug like tetracycline 
out of the cells and 3) to express altered pencillin-binding protein (PBP2a) which has low 
binding affinity to antibiotics. Besides that, MRSA strains also exhibit various virulence 
factors that results in chronic infections. The biofilm forming capacity in MRSA is notably 
a virulent factor that forms barrier to reduce antibiotic penetration and thus increases 
resistance in the bacterium (Walsh 2000; Rybank and LaPlante 2005; Tenover 2006). Due 
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to this reason, biofilm-related infection is difficult to treat. In fact, the ability of these 
bacterial cells to form biofilm is the main reason MRSA remains as number one cause of 
nosocomial infections (Costerton et al. 1999; Kwon et al. 2008). 
 
Available treatments for MRSA infections are expanding with usage of drugs such 
as daptomycin, linezoid, and tigecycline (Livermore 2009). However, the level and 
complexity of resistance mechanism displayed by this pathogen is evolving 
simultaneously. Evidently, the emergences of Staphylococcus aureus strains that are 
resistance to glycopeptides have been reported following an increased utilization of the 
antibiotic (Snider and Rivard 2012). Some studies claimed that MRSA infections have 
reduced in recent years, but the fact MRSA remained as the most common single multi-
drug resistance bacterium (Todd et al. 2009) highlights the needs to develop alternative 
or complementary therapy. 
 
One of the proposed approaches in overcoming bacterial resistance is synergistic 
therapy which is the use of antimicrobial agents in combination for treatment (Wagner 
and Ulrich-Merzenich 2009). A classical clinical example for synergistic treatment for 
bacterial infections is the usage of clavulinic acid, a microbial natural product with the 
antibiotic amoxicillin in overcoming penicillinase resistance in bacteria. Clavulinic acid 
functions as beta-lactamase inhibitor, therefore prevents the bacteria from degrading the 
antibiotic, amoxicillin (Lee et al. 2003; Elander 2003).  Besides microbial source, plant 
metabolites have been suggested as a potential source of resistant modifying agents 
(RMA) as they produce variety of small molecules (MW < 500) antibiotics (Hemaiswarya 
et al 2008).  At experimental level, plant metabolites were observed to reverse resistance 
mechanisms displayed by bacteria such as 1) modification of active site of the target, 2) 
modified enzyme produced by the bacteria or 3) efflux pump (Van Veen et al. 1996; Shiota 
et al. 2004; Zhao et al. 2001). This supports the hypothesis that plants may serve as a 
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source of RMA.  In addition, plants are known to produce metabolites as flavonols, 
flavones, terpenoids, and proanthocyanidins that have antibacterial action which is linked 
to biofilm inhibiting capacity (Koo and Jeon 2009; Kim et al. 2013). Metabolites from these 
classes have been found to have membrane permeabilizing properties (Abreu et al. 2012) 
that potentially are able to disrupt the biofilm formation or to enhance permeation of 
antimicrobial molecules into the cells. In certain cases, combination of plant-derived 
compound with conventional antibiotic has shown to have synergistic effect in preventing 
biofilm formation in MRSA (Olson et al. 2011).  
 
The large collection of plants species provides a rich source of antimicrobial 
compounds (Cowan 1999; Saleem et al. 2010). However, it is important to carefully select 
a plant source that may be able to yield useful compounds. Selecting a plant source with 
traditional medicinal use is one important criterion as the medical values these plants are 
often related to the presence of bioactive metabolites (Cheng et al. 2006; Cos et al. 2006).  
In this study, two medical plants were selected, Acalypha wilkesiana and Duabanga 
grandiflora. A. wilkesiana is a medicinal plant which has been widely utilized for treating 
bacterial and fungal infections in the African regions (Alade and Irobi 1993). In some 
cases, the plant has been reported to treat malaria and gastrointestinal problems (Akinde 
and Odeyemi 1987). The plant D. grandiflora whereas, is traditionally used for stomach 
pain and skin diseases especially, eczema (Anderson 1986; Shankar and Devalla 2012). 
 
 
 
 
 
 
 
5 
 
1.2 LITERATURE REVIEW 
 
1.2.1 Methicillin resistant Staphylococcus aureus (MRSA) 
 
Staphylococcus aureus, is a ubiquitous bacterium species commonly found in healthy 
individuals. The bacterium is known to colonize anterior nares and other skin area in 
humans. Approximately 50% of adults are S. aureus carriers either persistently or 
intermittently (Wertheim et al. 2005). Although S. aureus is commensal in humans, the 
bacterium is frequently identified to cause wide range of infections involving all organ 
systems (Archer  ? ? ? ?ȌǤ ? ? ? ?ǯǡǡS. aureus is the major 
cause of wound suppuration in hospitals (Ogston 1882). This was later observed true, 
when 82% of death occurred among patients infected by S. aureus in Boston City Hospital 
(Skinner and Keefer 1941). More evidence was found in 1960ǯs at John Hopkins Hospital, 
after a handful of patients with S. aureus bacteremia died even though the infecting 
organism was tested susceptible to administered antibiotics in vitro (Cluff and Reynolds 
1965).  At this stage, S. aureus has started gaining attention as a major cause of nosocomial 
infections and there was an increase in S. aureus infection cases worldwide as a result of 
antibiotic resistance (Archer 1998).  
 
 Initially, a beta-lactam drug, penicillin served as curing drug for S. aureus 
infections. The main structural feature of the beta-lactam antibiotics is the presence of a 
beta-lactam ring which is responsible for inhibition of bacterial cell wall synthesis by 
binding to the transpeptidase enzyme. A transpeptidase enzyme functions to catalyze the 
cross-linking between peptidoglycan chains in bacterial cell wall synthesis.  Failure to 
form this linking cause improperly made cell walls that finally burst due to water flow into 
the cells (Sabath 1982; Heesemann 1993). However, usage of penicillin was short lived as 
some bacterial strains beginning to exhibit resistance to penicillin ȋ ? ? ? ?ǯȌ 
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by production of a specific enzyme, beta-lactamase or penicillinase that is capable of 
hydrolyzing peptide bonds in the beta-lactam ring of the antibiotic. Following production 
of beta-lactamase, S. aureus infections were observed to spread rapidly (Lyon and Skurray 
1987).   
 
In 1959, a modified penicillin molecule called methicillin was introduced to 
counteract the deleterious effect of beta-lactamase.  Methicillin was designed to bind to 
penicillin-binding proteins (PBPs) which are a group of enzyme that are necessary for 
assembly of peptidoglycan chain in latter stage of cell biosynthesis. Binding of methicillin 
to these PBPs deactivates their function to catalyze the mechanism involved in assembly 
of peptidoglycan chains. Thus, causing deformities among the bacterial cells which 
eventually rupture following a weak structure that cannot withhold the osmotic pressure 
(Stapleton and Taylor 2002; Lambert 2004). Nevertheless, in a very short period, the 
bacteria developed resistance to methicllin too (Jevons 1961). This time S. aureus was 
seen to express a more complex mechanism in overcoming methiciǯ
production of a modified PBP which is PBP2a. PBP2a has a much low binding affinity to 
methicillin, therefore it   ǯ Ǥ   is resistant factor,  S. 
aureus continues to survive despite the presence of methicillin since PBP2a ensures 
normal synthesis of bacterial cell wall when other PBPs are being blocked by the 
antibiotic (Katayama et al. 2000). Occurrence of PBP2a in S. aureus gave rise to 
methicillin-resistant Staphylococcus aureus (MRSA) which its hallmark is characterized 
not just by its resistance to methicillin but also to all beta-lactam antibiotics, including 
synthetic penicillins, cephalosporins and carbapenems (Pantosti and Venditti 2009).  This 
particular resistant factor resulted in sporadic outbreak of nosocomial infections and by  ? ? ? ?ǯȋǤ ? ? ? ?ȌǤ 
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1.2.2 Molecular epidemiology of methicillin resistance  
 
The major factor contributing to methicillin (and other beta-lactams) resistance in MRSA 
is the production of PBP2a. PBP2a in MRSA is encoded by the mecA gene which was first 
discovered in 1981 (Hartman and Tomasz 1981). Unlike the beta-lactamase gene, mecA is 
not coded in plasmid but embedded in chromosome, within a genomic island called 
Staphylococcal Chromosome Cassette mec or SCCmec (Katayama et al. 2000).  
 
 Previous model of mecA regulatory mechanism was explained by presence of 
mecR1-mecI genes coding for a sensorȂinducer and a repressor respectively (Hiramatsu et 
al. 1992). In the presence of beta-lactam antibiotics, these regulatory genes are activated 
due to binding that occurs between the antibiotic and the sensor-inducer, MecR1. This 
triggers a unique series of proteolytic steps that cleaves the MecI repressor. The cleaved 
MecI repressor loses its function which is to bind to mecA promoter. Thus, enabling 
expression of the mecA gene as long as the antibiotic present (Zhang et al. 2001; Archer et 
al. 2001). However, several studies have shown that the induction of mecA by mecRI-mecI 
system happens exceptionally slow and it is inefficient (Hiramatsu et al. 1992; Kuwahara-
Arai 1996). A recent study has revealed that mecA locus actually contains a three 
component system, a newly identified mecR2 in addition to mecR1 and mecI (see Figure 
1.1). The MecR2 functions as an anti-repressor by directly engaging with MecI (repressor) 
and interrupt its binding to the mecA promoter. Hence, enables a complete activation of 
mecA gene for optimal expression of beta-lactam resistance, such as PBP2a production 
(Arêde et al. 2012).  Figure 1.1 depicts the proposed model of mecA regulatory genes 
comprised of mecR1-mecI-mecR2 system.  
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Figure 1.1 Model for the mecA induction by MecR1-MecI-MecR2. In the presence of a beta-
lactam antibiotic, MecR1 is activated and rapidly induces the expression of mecA and 
mecR1-mecI-mecR2. The anti-repressor activity of MecR2 is essential to sustain the 
mecA induction since it  promotes the inactivation of MecI by proteolytic cleavage 
(Arêde et al. 2012). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
9 
 
Another regulating system that can control mecA gene transcription is blaI-blaRI 
genes which regulate the expression of blaZ gene that is responsible for production of 
beta-lactamase (see Figure 1.2). This phenomena indicates that blaI-blaR1 induction 
system controls both PBP2a and beta-lactamase production in MRSA (Hackbarth and 
Chambers 1993; Sharma et al. 1998).  Synthesis of beta-lactamase in S. aureus species has 
been well established previously. Apparently, a beta-lactam antibiotic binds to BlaR1 and 
triggers the autocatalytic switch of intracellular zinc metalloprotease domain of BlaR1 
from an inactive proenzyme to an active protease. The BlaR1 which is now activated 
cleaves BlaI (the repressor protein) and causing it to become fragments that are no longer 
capable of its function. With BlaI being fragmented, transcription of blaZ and blaR1-blaI 
occurs to commence production of beta-lactamase (Dyke and Gregory 1997; Zhang et al. 
2001). Beta-lactamase and PBP2a despite being genetically and chemically distinct, the 
regulatory proteins of these two (BlaR1-BlaI and MecRI-MecI) was found homologous of 
each other.  Furthermore, the arrangements of gene coding for BlaR1 and BlaI mimic the 
mecA system and the similarity between the operator region of mecA and blaZ permits 
BlaI to regulate PBP2a expression (Song et al. 1987; Zhang et al. 2001; Stapleton and 
Taylor 2002). In fact, the regulatory systems of beta-lactamase and PBP2a were reported 
to cross-talk (Hackbarth and Chambers 1993), which explains the interrelatedness of 
these two resistant factors in MRSA. Figure 1.2 shows induction of beta-lactamase 
production in S. aureus species by presence of penicillin (Lowy 2003). 
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Figure 1.2 Induction of staphǇůŽĐŽĐĐĂů ɴ-ůĂĐƚĂŵĂƐĞ ƐǇŶƚŚĞƐŝƐ ŝŶ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ ɴ-lactam 
antibiotic penicillin. I. The DNA-binding protein BlaI binds to the operator region, thus 
repressing RNA transcription from both blaZ and blaR1-blaI. In the absence of 
ƉĞŶŝĐŝůůŝŶ ? ɴ-lactamase is expressed at low levels. II. Binding of penicillin to the 
transmembrane sensor-transducer BlaR1 stimulates BlaR1 autocatalytic activation. III ?
IV. Active BlaR1 either directly or indirectly (via a second protein, BlaR2) cleaves BlaI 
into inactive fragments, allowing transcription of both blaZ and blaR1-blaI to 
commence. V ?s// ? ɴ-Lactamase, the extracellular enzyme encoded by blaZ (V), 
ŚǇĚƌŽůǇǌĞƐƚŚĞɴ-lactam ring of penicillin (VI), thereby rendering it inactive (VII) (Lowy 
2003). 
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Mechanisms of resistance displayed by MRSA are not limited to production of 
beta-lactamase and PBP2a.  Since MRSA is resistant to beta-lactams, glycopeptides 
antibiotic, namely vancomycin is widely used to treat MRSA infections. Similar to previous 
incidents, this was followed by emergence of vancomycin-resistant S. aureus (VRSA) in 
2002 (CDC 2012). These particular strains are suspected to carry vanA gene complex 
encoding for thicker cell wall, reduced production of PBPs and changes in peptidoglycan 
biosynthesis. The strains were observed to form lesser cross-linking of peptidoglycan 
which leaves more protein residues available to bind and trap vancomycin (Hiratmasu et 
al. 1997; Hanaki et al. 1998). Thus, prevent the drug from reaching its target on 
cyctoplasmic membrane (Sieradzki et al. 1999; Walsh and Howe 2002; Maor et al. 2009). 
Apart from this, MRSA express resistance to more antibiotics as listed in Table 1.1 
(adapted from Lowy 2003). This show extensive adaptation by the bacterium to 
counteract antibiotic action, suggesting the shelf-life of currently available antibiotics may 
likely be limited (Lowy 2003).  
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Table 1.1  Mechanisms of S. aureus resistance to antimicrobial agents (Lowy 2003). 
 
Antibiotics Resistance 
gene(s) 
Gene product(s) Mechanism(s) of resistance 
Beta-lactams 1) blaZ 
 
2) mecA 
 
1) Beta-lactamase 
 
2) PBP2a 
1) Enzymatic hydrolysis of beta-
lactam nucleus 
 
2) Reduced affinity for beta-
lactams 
 
Glycopeptides 1) Unknown  
 
 
2) Unknown 
1) Altered 
peptidoglycan 
 
2) D-Ala-D-Lac 
1) Trapping of vancomycin in the 
cell wall 
 
2) Synthesis of dipeptide with 
reduced affinity for vancomycin 
 
Quinolones 1) parC 
 
 
 
2) grA or grB 
1) ParC (or GrlA) 
component of 
topoisomerase IV 
 
2) GyrA or GyrB 
components of 
gyrase 
 
1,2) Mutations in the QRDR region, 
reducing affinity of the enzyme-
DNA complex for quinolones 
Aminoglycosides 
(e.g., 
gentamycin) 
Aminoglycosides Ȃmodifying 
enzymes (e.g., 
aac, aph) 
 
Acetyltransferase, 
phosphotransferase 
Acetylating and/or 
phosphorylating enzyme 
modifying aminoglycosides 
Trimethoprim-
sulfamethoxazole 
(TMP-SMZ) 
1) Sulfonamide: 
sulA 
 
2)TMP- dfrBrrn 
1) Dihydropteroate 
synthase 
 
2) Dihydrofolate 
reductase (DHFR) 
23sRNA 
1) Overproduction of p-
aminobenzoic acid by the enzyme 
 
2) Reduced affinity for DHFR, 
mutations in domain V of 23sNA 
component of the 50s ribosome 
interferes with ribosomal binding 
 
Quinupristin-
dalfopristin (Q-
D) 
1) Q: ermA, 
ermB, ermC 
 
2) D: vat, vatB 
1) Ribosomal 
methylases 
 
2) Acetyltransferases 
1) Reduce binding to the 23S 
ribosomal subunit 
 
2) Enzymatic modification of 
dalfopristin 
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1.2.3 MRSA biofilm as virulent factor  
 
Biofilms are known as surface-adhering bacterial communities encapsulated in 
extracellular complex comprising DNA, bacterial polysaccharides and proteins by forming 
a slimy layer (Costerton et al. 1999; Mulcahy et al. 2008). There are several steps required 
in the development of biofilm. In the initial step, bacterial cells approach to close 
proximity of a surface till their motility is slowed down. Then they attach to the surface 
which the process is termed as cell-surface attachment. Following the cell-surface 
attachment, the bacterium establishes cell-cell interactions to form microcolonies for 
stability purposes. These microcolonies then, contribute towards development of 
multilayer structure that eventually leads to a three-dimensional biofilm matrix. With 
time, when the condition becomes unfavorable some microcolonies may detach itself from 
the matrix (ǯ  Ǥ  ? ? ? ?; Watnick and Kotler 2000). In summary biofilm 
development can be explained in two important steps; 1)primary attachment, the bacteria 
attach to the surface to be colonized and 2) accumulative phase in which the bacteria form 
multilayer structure via cell-cell interactions (Mack 1999; Götz 2002; Mack et al. 2004).  
Figure 1.3 shows a schematic diagram of S. aureus biofilm formation (Aslam 2008). 
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Figure 1.3 An illustration of steps in development of bacterial biofilm formation in S. aureus 
species on a catheter surface. The two vital steps are labeled as 1) and 2) (Image 
modified from Aslam 2008). 
 
 
MRSA are often found colonizing implanted prosthetic biomaterials and extensive 
use of these medical devices for diagnostics and therapeutic purposes contributes to 
spread of device-related infection involving biofilms in hospitals (Pozzi et al. 2012). A 
biofilm-related infection is difficult to treat not just because of presence of physical 
barrier that reduces antibiotic penetration but different growth mode of the biofilm cells 
that induces expression of antibiotic resistance.  The different growth mode in biofilm 
cells determines the types of antibiotic resistance that is unique and distinct compared to 
conventional antibiotic resistance mechanism which involves gene mutation or genetic 
exchange (del Pozo and Patel 2007). In MRSA, this is a main concern, since the bacterium 
is already resistant to many antibiotics and combination of this with biofilm-associated 
resistance result in chemotherapeutic failure (Stewart and Costerton 2001; Kwon et al. 
2008).  
 
The antibiotic resistance related to bacterial biofilm is caused by multiple factors 
as summarized in Figure 1.4. Firstly, the presence of biofilm matrix reduces antibiotic 
penetration. As such, the concentration of antibiotic in the biofilm matrix is low, and 
1) Primary 
attachment: 
cell-surface 
attachment  
2) Accumulative 
phase: cell-cell 
interactions 
forming 
microcolonies 
Extracellular 
matrix 
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repeated exposure to the low concentration in a long run increases the chances of 
acquiring resistance against the challenging antibiotic in the bacteria.  Also, in other cases 
exposure of low concentration of antibiotic in Staphylococcus epidermis strains were 
shown to induce ica genes that are involved in production of biofilm, therefore low 
concentration of antibiotic actually encourages a higher biofilm formation (Kwon et al. 
2008).  On the other hand, in certain bacterial species, antibiotic uptake was observed not 
to be reduced by presence of biofilm. However, high bacterial density in the microcolonies 
causes accumulation of waste products and changes the microenvironment such as the pH 
and oxygen levels which reduce the efficacy of antimicrobial agents (Tack and Sabath 
1985; Walter et al. 2003).  In Klebsiella pneumonia, it was suggested that biofilm traps the 
antimicrobial agents where they will be inactivated by resistance enzymes such as beta-
lactamase (Anderl et al. 2000).  
 
Research has also shown that presence of extracellular DNA (eDNA) in biofilm 
matrix induces the expression of antibiotic resistance genes. Apparently, the ability of 
eDNA to bind to cations found in the surrounding gives an environmental cue to the 
bacteria to induce genes involved in alteration of cell surface component. Eventually, 
causing modification of bacterial outer membrane that blocks uptake of an antibiotic 
(Mulcahy et al. 2008).  Other factors such as quorum sensing signaling and altered growth 
rate as in pesister cells likewise contribute to biofilm associated antimicrobial resistance. 
Pesister cells are slow or non-growing cells deeply embedded in biofilm (Lewis 2001). Use 
of antibacterial agents may be able to eradicate majority of the susceptible cells, but the 
pesister cells continue to survive. Upon discontinuation of the antibiotic, these cells give 
rise to formation of biofilm again (del Pozo and Patel 2007). Combination of these factors 
ultimately results in high antibiotic resistance in biofilm in which some bacterial cells 
were up to 1000-fold more resistant to antibiotics compared to planktonic cells (Stewart 
and Costerton 2001; Mulcahy et al. 2008).   
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Figure 1.4 Some proposed-biofilm associated resistance mechanisms: (1) Antimicrobial agents 
may fail to penetrate beyond the surface layers of the biofilm. Outer layers of biofilm 
ĐĞůůƐĂďƐŽƌďĚĂŵĂŐĞ ?ŶƚŝŵŝĐƌŽďŝĂůĂŐĞŶƚƐ ?ĂĐƚŝŽŶŵĂǇďĞŝŵƉĂŝƌĞĚŝŶĂƌĞĂƐŽĨǁĂƐƚĞ
accumulation or altered. (2) Antimicrobial agents may be trapped and destroyed by 
enzymes in the biofilm matrix. (3) Altered growth rate inside the biofilm. Antimicrobial 
agents may not be active against nongrowing microorganisms (persister cells). (4) 
Expression of biofilm-specific resistance genes (e.g., efflux pumps). (5) Stress response 
to hostile environmental conditions (e.g., leading to an over expression of 
antimicrobial agent-destroying enzymes) (del Pozo and Patel 2007). 
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Bacterial biofilms are shown to consist of important structural components such 
as polysaccharides, proteins and DNA (Rice et al. 2007; Boles and Horswill 2008; Otto 
2008).  Typically, biofilm production in methicillin-sensitive S. aureus (MSSA) is 
dependent on exopolysaccharide intercellular adhesion/polymeric N-acetyl-glucosamine 
(PIA/PNAG) that are regulated by proteins coded by icaADBC genes (Fitzpatrick et al. 
2005; Hennig et al. 2007).  MRSA strains on the other hand; their biofilm production is 
meditated by cell wall autolysin (Alt) and fibronectic-binding proteins (FnBPs).  In a 
recent research, high level of PBP2a expression in MRSA strains was found to result in 
pleiotrophic effect by repressing icaADBC dependant polysaccharide type biofilm and 
promotes protein-mediated biofilm.  
 
The mechanisms responsible for association between MRSA and MSSA biofilm 
phenotypes and dependency on polysaccharides and proteins, respectively is unknown. 
Nevertheless, resistance to beta-lactam antibiotics particularly expression of PBP2a 
seemed to be crucial in determination of the biofilm phenotype (McCarthy et al. 2015). 
The expression of PBP2a on altered surface of MRSA cells were postulated to facilitate 
cell-cell interaction (i.e. via altered cell wall architecture) that is essential for multilayer 
formation in biofilm development (Pozzi et al. 2012). In addition, efficient production of 
exoprotein (functions as adhesive in biofilm development) and increased FnBPs (a protein 
that promotes biofilm maturation) in PBP2a-mediated biofilm were implied as 
advantageous for MRSA in clinical settings to invade host cell or evade the immune system 
(Saravia-Otten et al. 1997; Vuong et al. 2000; Edwards et al. 2010). This phenomenon not 
just represents the interrelatedness between methicillin-resistance and biofilm in MRSA 
strains, but the extraordinary capability of MRSA to switch to protein based biofilm rather 
than PNAG. This switch enables the bacteria to effectively adapt and colonize implanted 
medical device for treatments.  
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1.2.4 Therapeutic options for MRSA 
 
At present, limited options are available for patients infected with MRSA due to increase 
in antimicrobial resistance. Glycopeptides, namely vancomycin has been a choice of drug 
for MRSA infection since 1960. However as described in section 1.2.2, the emergence of 
VRSA showed that vancomycin is no ǲǳ
(Snider and Rivard 2012). Recent studies suggested that vancomycin has slow bactericidal 
activity, may possibly promote development of drug resistance (Deresinski 2007; Mohr 
and Murray 2007; Liu et al. 2011).  There is also increasing reports of treatment failures 
with usage of vancomycin showing that MRSA is progressively becoming resistant to the 
drug (Deresinski 2007; Rivera et al. 2011). 
 
 Linezolid is another antibiotic approved for of nosocomial pneumonia caused by 
MRSA. When administered orally, the drug has 100% bioavailability and additionally has 
excellent penetration into epithelial lining fluid making it efficient for treatment of 
pneumonia. Therefore, linezolid has better clinical cure rates compared to vancomycin for 
MRSA infected pneumonia (Wunderink et al. 2003; Kollef et al. 2004). There is another 
study stating that the drug is unable to inhibit toxin production in the bacterium which 
then contributes to an increased severity in the infections (Takahashi et al. 2010).  
 
 Daptomycin is cyclic lipopeptide drug that acts by depolarizing cell membrane 
which causes inhibition of protein synthesis in bacteria. It is recognized for treatment of 
chronic MRSA infections excluding pneumonia due to adverse effect in respiratory system 
(Liu et al. 2011; Rivera et al. 2011). The bactericidal activity is concentration-dependant, 
thus some support implement of a higher dosage (Benvenuto et al. 2006; Figueroa et al. 
2009). However, high doses of daptomycin may induce myopathy (Liu et al. 2011). Hence, 
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the study of optimal dosing of daptomycin needs further evaluation to limit the adverse 
effects of the antibiotic (Snider and Rivard 2012). 
 
 Telavancin is a derivative of vancomycin, thus the mode of action is similar to 
vancomycin which is by inhibition of cell wall synthesis. In addition to that, the drug 
depolarizes bacterial membrane leading to disruption of barrier function. Telavancin is 
currently used to treat MRSA and vancomycin-intermediate S. aureus (VISA) infections 
(Astellas Pharma 2012). Certain reports suggested that the drug potentially has part in 
biofilm-related infections since patients with infective endocarditis (a disease that is 
difficult to treat due to biofilm production) were successfully treated with telavancin 
although the drug is not indicated for treatment (Howden et al. 2010; Marcos et al. 2010; 
Nace and Lorber 2010).  Telavancin contraindicated in pregnant women following 
findings in animal studies that revealed its teratogenic effect (FDA 2011). 
 
 Tigecycline is indicated for treatment of skin and skin-structure infections (SSSI), 
intra-abdominal infections and community-acquired pneumonia. Mode of its antibacterial 
effect is inhibition of protein synthesis. In order to avoid major bacterial resistance, 
tigecycline structure was designed with a modified side chain (Lexi-Comp 2011; Snider 
and Rivard 2012). This antibiotic is particularly advocated effective for treatment of 
serious MRSA infections by researchers that conducted clinical study (Florescu et al. 
2008). Nevertheless, analysis of 7400 patients in a clinical trials indicated a higher risk of 
all-cause mortality with the utilization of tigecycline to treat serious infections which 
followed by warning from FDA to use an alternative agent (FDA 2012).  
 
Ceftaroline is an antibiotic belonging to class of cephalosporin and has wide-
spectrum activity against MRSA, VISA and VRSA (Snider and Rivard 2012). In treatment of 
SSSI, the drug was found to have relatively good activity similar to vancomycin (Corey et 
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al. 2010). Most importantly, the drug has the same safely profile as other cephalosporins 
but with an added advantage of remaining active against resistant pathogen like MRSA 
and VISA (Biek et al. 2010; Steed et al. 2010).  
 
Quinupristin-dalfopristin (QPT-DFP), a combined streptogramin drug targeted to 
interrupt protein synthesis in bacteria (Drew et al. 2010). Often, the combined drugs 
administered to treat SSSI caused by MSSA (Lexi-Comp 2011).  In certain instances, when 
MRSA infections are incurable with other antibiotics, QPT-DFP is used. However due to 
severe myalgias as side-effect, the use of QPT-DFP is very limited (Olsen et al. 2001). 
 
 Trimethoprim-sulfamethoxazole (TMP-SMX) is a combination of two antibiotics 
that is able to suppress folic acid synthesis in the bacteria. Each of these antibiotics 
separately inhibits enzymes involved in folic acid synthesis that contributes to additive 
effect in preventing bacterial growth (Grim et al. 2005). Despite not being approved by 
FDA for treatment of MRSA infections, the drug is widely administered for treatment of 
noninvasive community-acquired MRSA infection (Liu et al. 2011). Findings in clinical 
studies that compared treatment of vancomycin and TMP-SMX, concluded that, 
therapeutic efficacy of TMP-SMX is lower than vancomycin.  
 
 Tetracyclines (including doxycycline and minocycline) are antibiotics which 
function as bacteriostatic agents by inhibiting protein synthesis in bacteria (Liu et al. 
2011). Originally this class of antibiotics used to treat SSSI associated with S. aureus. 
Emergence of MRSA strains carrying tetK gene, exhibited efflux pump system that flushes 
the drug out the cells, making the teteracyclines drugs ineffective (Ruhe et al. 2005; Ruhe 
et al. 2007). However, minocycline was observed to have a higher capabilities compared 
to other tetracyclines in overcoming resistance mechanism displayed by MRSA due to its 
longer half-life, better absorption and enhanced tissue-penetration (Bishburg and 
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Bishburgb 2009; Liu et al. 2011). Besides, minocycline was found to be highly active 
against MRSA isolates in biofilm compared to vancomycin, daptomycin, linezoid and 
tigecycline (Bishburg and Bishburgb 2009). Despite the encouraging activity of 
minocycline against MRSA, the side effects of this drug is serious including worsening 
azotemia in patients with renal disorders, pancreatitis, autoimmune hepatitis and drug-
induced lupus-like-syndrome (Bishburg and Bishburgb 2009). Based on the emergence of 
antibiotic resistance trends, tetracycline-resistance in MRSA strains may soon affect 
minocycline. 
 
 Clindamycin indicated for treatment of S. aureus infections and frequently used to Ǥǯ  
process that results in protein synthesis inhibition. Clindamycin however, is not approved 
by FDA for treatment related to MRSA. Even so, the antibiotic was shown to have great 
success in curing invasive community-acquired MRSA infections in some cases. 
Clindamycin is bacteriostatic agent hence, not suitable for all types of MRSA infections 
(Lexi-Comp 2011; Liu et al. 2011). MRSA strains that resistant to erythromycin but 
susceptible to clindamycin are prone to exhibit macrolide-lincosamide-streptogramim B 
(iMLSb). The iMLSb strains can be induced by erythromycin to produce methylase that give 
rise to clindamycin resistance (Siberry et al. 2003).   
 
 Based on the discussion above, it is evident that MRSA has developed resistance 
towards some of the older drugs such as vancomycin and tetracyclines. The newer drugs 
are potentially effective for MRSA infections but the evidence from the past shows a 
disturbing fact; an increase in usage of antimicrobial agent results in a display of more 
complex resistance mechanism in the pathogens (Krause 1992; Tenover 2006). Large 
number of side effects manifests the toxicity of these antibiotics. Table 1.2 is showing 
FDA-approved drugs for MRSA infections. From the table, we can deduce that a small 
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number of antibiotics are available to treat nosocomial pneumonia, bacteremia, infective 
endocarditis, and complicated intra-abdomen infections. This suggests that the 
development of new antibiotic agent or adjuvant for the current antibiotics is necessary to 
successfully treat MRSA infections.  
 
Table 1.2  FDA-Approved Indications for MRSA Infections (Snider and Rivard 2012). 
Drug/ 
Infections 
Complicated 
SSSI 
CAP Nosocomial 
Pneumonia 
Bacteremia Infective 
Endocarditis 
Complicated 
Intra-
abdominal 
Infections 
Vancomycin 
 
X X X X X  
Linezolid 
 
X X X    
Daptomycin 
 
X   X X  
Tigecycline 
 
X X    X 
Telavancin 
 
X      
Ceftaroline X X     
SSSI: skin and skin-structure infections 
CAP: community-acquired pneumonia, 
Quinupristin-dalfopristin, clindamycin, doxycycline, minocycline and trimethoprim-
sulfamethoxazole do not have FDA- approved indications for the treatment of MRSA infections. 
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1.2.5 Concept of synergism for treatment of antibiotic resistance  
 
The antibiotic discovery process has failed to keep up with the evolution pace of 
antimicrobial resistance in bacteria. Hence, it is necessary to find new strategies to 
develop antibiotic in order to effectively control the spread of antimicrobial resistant and 
to cure for serious infections (Abreu et al. 2012).  Synergy interaction between 
combinations of two antimicrobial agents is identified as a potential way to solve 
resistance problems.  This is because mode of action of a combination of two agents 
differs extensively compared to the action of the agents when used separately 
(Hemaiswarya et al. 2008). In combination therapy, two agents act synergistically by 1) 
having multi-targets, which means the components in the combination affect several 
targets and hence results in agonistic effects or potentiated pharmacological effects, 2) 
pharmacokinetic effects due to enhanced solubility and resorption rate as a result from 
presence of one of the agent that is able to increase bioavailability of the other agent 
hence promotes a better activity, 3) interference with resistance mechanism of the 
bacteria by one agent amplifies the activity of the other in the combination, and 4) 
elimination of toxin factors by one of the agents that increases inhibitory activity of the 
other (Wagner and Ulrich Merzenich 2009).  
 
 The use of drug in combination is rather common in clinical settings to maintain 
clinical efficacy and to overcome resistant problems since combination of certain drugs         ǯ  ȋ  Ǥ
2010).  For example, treatment for infections caused by multi-drug resistant Pseudomonas 
aeruginosa often consists of an anti-pseudomonal beta-lactam and an aminoglycoside or a 
fluoroquinolone (Pier et al. 2005).  In S. aureus related infections, combination of cell-wall 
active antibiotic such as penicillins and glycopeptides with aminoglycosides are widely 
use for treatments (Goldstein et al. 2003). While it is shown clinically that combination of 
24 
 
drugs increase the effectiveness of treatments in selected cases, it is important to 
understand the impact of synergy drug treatment on evolution of antimicrobial resistance. 
Results from a study using a mathematical simulation of an in vivo infection model 
revealed that drug synergism may worsen antimicrobial resistance (Torella et al. 2010).  
This finding echoes an earlier claim that overuse of antibiotics is one of the major factors 
causing emergence of resistance amongst bacteria (World Health Organization [WHO] 
2011).   
 
Most of the available antibiotics today are of bacterial or fungal origin and with 
growing concern over resistance issues and toxicity; the interest in finding antibacterial 
agents is shifted from microbial source to plant (Cowan 1999). In addition many studies 
suggest that plants have effective innate defense system that is able to overcome 
resistance expressed by bacteria due to the synergistic interaction between the produced 
metabolites (Lewis and Ausubel 2006; Sibandah and Okoh 2007; Hemaiswarya et al. 
2008). This proposal was based on the ability of plants to successfully overcome infective 
diseases despite producing weak antibacterial agents. Hence, a strategy of combining 
plant products with antibiotics is actively studied to identify potential RMAs (Abreu et al. 
2012).  
 
 Many plant products were observed to work synergistically with antibiotics in 
inhibiting growth of S. aureus strains, MSSA and MRSA, and some examples of the plant 
metabolites and their activities are listed in Table 1.3. It is evident that plant products 
have enormous potential to be developed as antibacterial agents or as adjuvants for 
current antibiotics since they are able to interfere with mechanisms of resistance such as 
inactivation of multi-drug resistant (MDR) efflux pump, inhibition of PBP2a, and inhibition 
of penicillinase/beta-lactamase (Table 1.3). 
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Table 1.3 Selected synergistic activities between plant products and antibiotics adapted from 
Hemaiswarya et al. (2008) showing inhibition of S. aureus strains, MSSA or MRSA. 
Plant products Antibiotics Bacteria Mechanism of 
action 
References 
Epigallocatechin-
gallate (EGCg) 
Ampicillin/ sulbactam  MSSA, and 
beta-lactamase 
producing S. 
aureus strains 
 
Inhibits beta-
lactamase 
Hu et al. 2001 
EGCg Penicillin Penicillinase 
producing S. 
aureus strains 
 
Inhibits 
penicillinase 
Zhao et al. 2001 
EGCg Beta-lactam 
antibiotics 
MRSA, MSSA EGCg directly 
binds 
peptidoglycan and 
inhibits cell wall 
synthesis 
 
Yoshida et al. 
1990 
EGCg Tetracycline S. aureus with 
TetK gene, 
multi-drug 
resistance 
(MDR) pump 
 
Block efflux pump Roccaro et al. 
2004 
Tea catechin Oxacillin MRSA - Takahashi et al. 
1995 
 
Totatrol Methicillin MSSA, MRSA Inhibition of 
PBP2a production 
or activity 
 
Pao et al. 1998 
Isoflavone 
Bidwillon B 
Mupirocin MRSA Affects 
incorporation of 
thymidine, 
uridine, glucose, 
and isoleucine 
 
Sato et al. 2004 
-Mangostin Vancomycin MRSA - Sakagami et al. 
2005 
 
Corilagin Beta-lactam 
antibiotics (oxacillin, 
cefmetazole) 
 
MRSA Inhibition of 
PBP2a production 
or activity 
Shimizu et al. 
2001 
Baicalin Beta-lactam 
antibiotics 
MRSA Inhibits beta-
lactamase 
 
Liu et al. 2000 
Tellimagrandin I Beta-lactam 
antibiotics 
MRSA - Shiota et al. 
2000 
 
Rugosin Beta-lactam 
antibiotics 
MRSA - Shiota et al. 
2000 
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Plant products 
 
Antibiotics 
 
Bacteria 
 
Mechanism of 
action 
 
References 
 
Diterpernes from 
Lycopus europseus 
 
Tetracycline 
 
S. aureus with 
TetK gene, 
(MDR) pump 
 
 
Blocks MDR 
pumps 
 
Gibbons et al. 
2003 
 
Penta-substituted 
pyridine from 
Jatropha elliptica 
 
Erythromycin S. aureus with 
TetK gene 
Blocks MDR 
pumps 
Marquez et al. 
2005 
Pomegranate 
extract 
Ciprofloxacin, 
chloramphenicol, 
gentamycin, 
ampicillin, 
tetracycline, and 
oxacillin 
 
MRSA Blocks Nor (A) 
pump (an efflux 
pump) 
Braga et al. 
2005 
Myricetin Amoxicillin/clavu-
lanate, 
ampicillin/sulbactam 
and cefoxitin 
 
MSSA - Lin et al. 2005 
Isopimaric acid 
from Pinus nigra 
 
Reserpine MRSA Block Nor (A) 
pump 
Simonetti et al. 
2004 
Erybraedin A or 
eryzerin C 
 
Vancomycin MRSA - Shiota et al. 
2004 
Sophoraflavanone Vancomycin 
hydrochloride, 
fosfomycin, 
methicillin, cefzonam, 
gentamycin, 
minocycline, and 
levofloxacin 
 
MRSA - Sakagami et al. 
1998 
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Synergism of plant metabolites with antibiotics in disrupting bacterial biofilm is 
not widely studied. However, several studies have demonstrated that plant metabolites 
act synergistically with antibiotic to suppress biofilm production.  For instance, a novel 
pentadecenyl tetrazole of plant origin was shown to exhibit synergism with gentamycin 
against both planktonic and biofilm cells of S. aureus strain (Olson et al. 2011). In an 
another study essential oils from the plants Cinnamomum zeylanicum, Melaleuca 
alternifolia and Cymbopogon martini acted synergistically with ciprofloxacin by 
significantly disrupting biofilm formation in P. aeruginosa  (Coelho and Pereira 2013). 
While in Italy, plant extracts, especially with ethnobotanical properties are used to treat 
SSSI linked to S. aureus with growing concern over antibiotic resistance. Some of these 
plants extracts when tested in vitro demonstrated strong inhibition on bacterial biofilm 
production (Quave et al. 2009).  Combining this information, it is obvious that plant may 
harbor metabolites with anti-biofilm properties. 
 
In a recent study, anti-biofilm activity of plant metabolites namely 7-
hydroxycoumarin, indole-3-carbinol, salicylic acid, and saponin against E. coli and S. 
aureus biofilms were suggested due their interference with motility and quorum-sensing 
activity in the bacterial cells. Besides, one of the metabolites, indole-3-carbinol when 
combined with tetracycline, erythromycin and ciprofloxacin produced a synergistic effect 
in suppressing growth of S. aureus strains which further implied that the interference with 
cell motility and quorum-sensing activity prospectively enhanced the antibacterial effects. ǡǯȋǤ  ? ? ? ?ȌǤ
Several plant products were observed to prevent cell-surface attachment as well, which is 
an essential step in biofilm development. Although, cationic peptides due to their surface 
charge and hydrophobicity, frequently found to exhibit such effects on biofilm formation 
(Overhage et al. 2008; Mataraci and Dosler 2012), the compound 1,2,3,4,6-penta-o-galloyl-Ⱦ-d-glucopyranose, which is an active plant ingredient used in traditional Chinese 
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medicine, was found to inhibit S. aureus biofilm formation in the same manner (Lin et al. 
2011). This shows that plant metabolites may have similar actions as cationic peptides in 
altering the cell-surface attachment adversely.  
 
In summary, research from the past has shown that plant products either alone or 
in combination with conventional antibiotics are capable on inhibiting bacterial growth. 
The inhibition of bacterial growth was observed not only on planktonic cells but also 
biofilm protected cells, which makes plant metabolites as a valuable source of new 
antibacterial agents since biofilm production contributes to an increased antimicrobial 
resistance. Mode of action studies suggested in many cases, plant products or molecules 
specifically interact with the bacterial resistance mechanism, thus, enabling the 
potentiating of the antibiotics bactericidal effects when used in combinations. For the anti-
biofilm action, these metabolites were suggested to disrupt biofilm through suppression 
of cell motility, quorum-sensing activity and cell-surface attachment. 
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1.2.6 Selected plant species 
 
The era of drug discovery from plants was initiated after the finding of morphine from 
Papaver somniferum which was the first pharmacologically active pure compound from 
plants (Hamilton & Baskett 2000). Since then, compounds from plants have gained 
popularity in the medical field for their application as antimicrobial, anticancer, 
antidiabetic and immunosuppressant agent (Newman et al. 2003).  Among the important 
classes of biological compounds from plants include acetylenes, coumarins, flavonoids, 
lignans, phenolics (other than flavonoids and lignans), polypeptides, alkaloids, steroidal 
saponins, terpenoids and xanthones (Cowan 1999; Saleem et al. 2010). In this study two 
medicinal plants were selected; A. wilkesiana and D. grandiflora.  
 
1.2.6.1  Acalypha wilkesiana 
 
A. wilkesiana belongs to the genus Acalypha with comprises approximately 570 species 
(Riley 1963) and it is classified in the Euphorbiaceae family.  The plant grows all around 
the world particularly in tropics of Africa, America and Asia (Madziga et al. 2010). It is a 
fast growing medium sized shrub. The leaves are 4-8 inches long in heart shape and their 
color varies in combination of green, purple, red, bronze, yellow, orange, pink, and white 
depending on the cultivar (Gilman 1999). For this reason, A. wilkesiana is normally 
planted as ornamental plants. Figure 1.5 is showing a photograph of the plant A. 
wilkesiana. 
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Figure 1.5 A photograph of the plant, A. wilkesiana. 
 
In Nigeria and other African countries, this plant has been widely used for its 
antibacterial and antifungal properties (Akinde & Odeyemi 1987; Alade & Irobi 1993).  
Traditionally, the juice from this plant has been used to cure ailments such as skin 
diseases mostly on children (Oliver 1959). The preparation includes boiling the leaves for 
bathing purposes and a small volume is to be drank (Alade & Irobi 1993). Besides, A. 
wilkesiana is also used to treat other diseases such as malaria and gastrointestinal 
problems (Akinde & Odeyemi 1987). Another species of Acalypha, A. hispidia is used to 
cure ulcer, abscesses and leprosy (Schindeler 1939). The traditional uses of this plant 
suggest it possesses antimicrobial properties.  
 
Accordingly, preceding studies have reported antimicrobial activities found in 
extracts of this plant.  The extracts have wide spectrum activity whereby it is able to 
inhibit growth of both Gram positive and Gram negative bacteria as well as fungi 
(Oladunmoye 2010). Among the clinical strains that were reported to be inhibited by A. 
wilkesiana extract are E. coli, Salmonella typhi, Streptococcus pyogenes, Streptococcus 
pneumonia, MRSA, S. aureus, Candida albicans, Aspergillus fumigatus, and A. flavus (Ezekial 
et al. 2009). Likewise, in our earlier study, the plant exhibited anti-staphylococcal 
activities together with wide-spectrum antibacterial activity against other bacteria such as 
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E. coli and Citrobacter freudii (Othman et al. 2011a; Othman et al. 2011b). Whereas, 
studies by other group in our laboratory demonstrated that extracts from A. wilkesiana 
acted synergistically with ampicillin in inhibiting S. aureus growth (Din et al. 2013a) and 
anti-cancer drug to stop proliferation of cancer cells (Lim et al. 2011; Lim et al. 2013). 
 
Studies on antibacterial effects of A. wilkesiana extracts reported presence major 
classes of phytochemicals such as tannins, steroids, flavonoids, cardiac glycosides, 
saponins, alkaloids, and antraquinone that were thought to be responsible for the 
antimicrobial properties of this plant (Oladunmoye 2006; Gotep et al. 2010). Other 
constituents that were present in the extracts of this plant include carbohydrates, 
phlobatannins, and minute quantity of terpenes (Madziga et al. 2010).  Tannins from A. 
wilkesiana especially gallic acid, corilagin, ellagitannins and geraniin are frequently 
associated with antimicrobial activities since these compounds are able to cause bacterial 
cell lysis (Adesina et al. 2000; Din et al. 2013a; Din et al. 2013b). 
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1.2.6.2  Duabanga grandiflora 
 
D. grandiflora (Roxb. Ex DC) Walp, belongs to the Lythraceae family. It is indigenous to 
Eastern Himalayas and widely distributed in tropical African and Southeast Asia (Graham 
et al. 2005; Auamcharoen et al. 2009).  The tree grows between 40-80 feet high, as one 
undivided trunk or sometimes forking from the base. The branches are sparing with large 
spreading leaves in deep green on the surface on almost white beneath. D. grandiflora 
flowers blossoms in April, and has an odor similar to asafoetida initially before the petal 
drops. The tree also produces fruit with its size almost like a small apple (Hooker et al. 
1855). Figure 1.6 is showing a close up photograph of the leaves and fruit of D. grandilfora 
tree. 
 
 
 
 
 
 
 
Figure 1.6 A photograph of the plant, D. grandiflora 
 
Traditionally, people from hill tribes in Northern Thailand utilize poultices from 
its leaves to treat stomach pain (Anderson, 1986). In India, the bark paste of this plant is 
used to cure skin diseases, mainly eczema (Shankar and Devalla, 2012). D. grandiflora 
extracts are also shown to have skin whitening, anti-aging, anti-inflammation and anti-
cancer properties (Bhakuni et al. 1971; Tsukiyama et al. 2010; Kaweetripob et al. 2012).  
The plant however is not widely studied for antimicrobial properties. In fact, our previous 
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research was the only published work on antibacterial activity of D. grandiflora extracts 
(Othman et al. 2011a; Othman et al. 2011b). 
 
 Major phytochemicals such as alkaloids, tannins, flavonoids, saponins, and 
steroids were detected in D. grandiflora extracts that demonstrated antibacterial activities 
(Othman et al. 2011a).  Among the compounds isolated from this plant (D. sonneratioides 
Buch,-Ham-subsequently classified in synonym with D. grandiflora) are hentriacontanone, 
lignoceryl ferulate, acacetin, betulinic acid, sitosterol-Ⱦ-D-glucoside, ellagic acid, 
tetramethylellagic acid, epioleonolic acid, and genkwanin which are associated with anti-
cancer properties (Bhakuni et al. 1971; Sharma et al. 1972a; Sharma et al. 1974). Recently, 
5-formylfurfuryl esters, latifoninal, pentacyclic triterpenes, benzofuran derivative, ellagic 
acid derivatives along with several other known compounds were isolated from D. 
grandiflora. These metabolites likewise exhibited moderate to weak activity anti-cancer 
activities (Kaweetripob et al. 2012). 
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1.3 RESEARCH RATIONALE 
 
The fundamental idea of this research is application of secondary metabolites from A. 
wilkesiana and D. grandiflora in reversing ampicillin resistance in MRSA. The two targeted 
virulent factors that we are interested includes: 1) PBP2a that confers resistance to all 
beta-lactam antibiotics including ampicillin and 2) biofilm production which complicates 
treatment of MRSA infections by a reduced antibiotic uptake. A strategy to eliminate 
resistant problems is by adopting synergism approach which is using combinations of 
antimicrobial agents. The advantages of synergism approach have been extensively 
described in reviews by Hemaiswarya et al. (2008), Wagner and Ulrich-Merzenich (2009) 
and Abreu et al. (2012). Briefly, the concept of synergisms can be achieved by four 
mechanisms 1) multi-target effects that cooperate in agonistic way, 2) pharmacokinetic 
effects which increase solubility, resorption rate and improve bioavailability, 3) adverse 
interaction with resistance mechanism, and 4) elimination of toxic factors (Wagner and 
Ulrich-Merzenich 2009).   
 
Plant metabolites are frequently found to display different mechanisms in contrast 
to conventional antibiotic in acting against microbial pathogens which can be 
advantageous in combating antibiotic resistance in some bacteria (Abreu et al. 2012). This 
has initiated the idea if the synergism between ampicillin and extracts or bioactive 
fractions from the studied plants is affecting resistant factors in MRSA adversely. The 
major resistant factor in MRSA is PBP2a production. Inhibition of PBP2a is proposed to   ǯǤǡ
disruption of biofilm formation in sessile bacterial cells is thought to expose the cells to 
the antibiotic and therefore reinstate the effectiveness of the antibiotic. 
The selected plant A. wilkesiana has been traditionally used to cure bacterial 
infections and evidently laboratory studies have shown that extracts of this plant also 
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demonstrated wide-spectrum antimicrobial activity thus, affirming presence of 
pharmacologically important metabolites (Ezekial et al. 2009; Oladunmoye 2010). 
Subsequent studies revealed the finding of compounds such as corilagin, geraniin, 
ellagitannins and many others that particularly inhibited growth of S. aureus and MRSA 
(Adesina et al. 2000; Din et al. 2013a; Din et al. 2013b). Therefore, this plant is a 
potentially good candidate. The plant D. grandiflora was the second choice of plant, is 
widely used in India to treat skin diseases associated with eczema or atopic dermatitis 
(AD) (Shankar and Devalla 2012). Advancement in dermatological research showed S. 
aureus causes skin lesion in AD patients and skin samples from these patients were found 
to contain S. aureus delta toxin (Rudikoff and Lebwohl 1998; Nakamura et al. 2013). These 
findings indicate that ethnobotanical use of D. grandiflora in treating eczema may actually 
have some evidence to its ability to heal bacterial infections namely S. aureus. Hence, the 
study of combined effects of ampicillin with extracts or fractions from the named plants 
on MRSA may reveal potential chemotherapeutic value of these plant secondary 
metabolites in restoring efficacy of the antibiotic. 
 
Earlier studies in our laboratory, we have identified ethyl acetate extracts of these 
plants as the most potent against MRSA (Othman et al 2011a; Othman et al. 2011b). 
Following that, experiments in this study focused on exploiting the ethyl acetate extracts. 
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1.4 RESEARCH APPROACHES  
 
Our research was focused on finding secondary metabolites from A. wilkesiana and D. 
grandiflora. The general approaches in this research are divided into two areas; a) the 
biological studies and b) the application chemistry methods. In the biological approaches, 
experiments were conducted to 1) evaluate the anti-MRSA activity of the plant extracts 
and fractions through determination of minimum inhibitory concentration (MIC) value, 2) 
investigate the synergistic effects of combination of the plant extracts or fractions with 
ampicillin on MRSA growth and 3) study on the effects of the combination treatments on a 
resistant factors in MRSA which are i) PBP2a production and ii) biofilm formation.  The 
chemistry approach included 1) extraction of the plant materials, 2) separation of the 
crude extracts into major fractions and semi-pure fractions by liquid chromatography 
(LC) methods, 3) determination of presence of major classes of compounds in the crude 
extracts and bioactive fractions, and 4) application of high performance liquid 
chromatography (HPLC) to study the complexity of the plant samples.  
 
A bioassay-guided approach was used in this study in which we incorporated 
biological assays after the extract or fractions were separated via LC methods to include 
fractions that retained the anti-MRSA activity. These fractions were termed as bioactive 
fractions. The synergistic studies revealed useful combination of different bioactive 
fraction with ampicillin via kinetic growth curve experiments and fractional inhibitory 
concentration (FIC) index interpretations. The growth curve experiment was designed to 
monitor MRSA growth for a period of 24 hours.  Whereas the FIC index interpretations 
yield a quantitative measure of the interaction between the extracts or fractions and 
ampicillin to identify any synergism. Furthermore, the FIC index interpretation enables 
the determination of a different MIC of ampicillin in the combination. The new MIC 
indicates if the effectiveness of ampicillin has been restored in presence of plant extract or 
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bioactive fraction. Following these experiments, combinations with the lowest ampicillin 
concentration, selected and investigated for their mechanism of action.  
 
The mode of action studies were carried out to look at two virulent factors: 1) the 
expression of PBP2a and 2) disruption of biofilm production.  In the Western blot 
experiment, the combination treatments were studied if they are able to suppress PBP2a 
expression in MRSA, which is the major cause of beta-lactam resistant in MRSA strains. 
Whereas, the biofilm forming capacity of MRSA in presence of the combination treatments 
was investigated by employing assays which enabled quantification of biofilm production 
via crystal violet staining method. Besides quantifying biofilm production, MRSA cell-
surface attachment in presence of the combination treatments was studied likewise. The 
level of PBP2a in biofilm matrix in the treated cultures was evaluated semi-quantitatively 
via PBP2a latex agglutination assay. The cell-surface attachment and PBP2a are two 
factors suggested to contribute towards MRSA biofilm production. These experiments 
were conducted to partially elucidate the possible mechanism of actions of some the 
bioactive fractions we have isolated. 
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1.5 SIGNIFICANCE OF STUDY 
 
The findings from this study are expected to be important in the following areas; 
 
1. Advances in in vitro studies of application of plant metabolites as synergist of 
ampicillin in overcoming resistant problems in MRSA particularly PBP2a and 
biofilm production. This will enable reuse of conventional antibiotics which are 
well-established and often cheaper with known safety profile. 
2. Evidence-based study of use of medicinal plants which may encourage search for 
more plant-derived drugs. These drugs often serve as prototypes for chemist to 
design more effective antibiotics. 
3. Potential discovery of active molecules or extracts that can be used to treat topical 
wound infection with MRSA or coatings for medical implants to prevent biofilm-
related infections. In 2006, U.S Food and Drug Administration (FDA) has approved 
green tea extract as a prescription drug for the topical (external) treatment of 
genital warts caused by the human papilloma virus (HPV).This drug contains 
active ingredient known as Polyphenon®. Thus, suggesting plant extracts can be 
utilized as a potential preparation for infections. 
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1.6 AIMS AND OBJECTIVES  
 
The studies conducted in this research was aimed to investigate application of plant 
metabolites from A. wilkesiana and D. grandiflora in overcoming resistance in MRSA 
namely through inhibition of PBP2a and biofilm production. The objectives are as the 
following; 
 
1. To evaluate anti-MRSA activities of the extracts and fractions obtained from the 
plants via determination of MIC. 
2. To determine the synergistic effects of combination treatments consisting 
ampicillin and selected extracts or fractions on MRSA growth. 
3. To investigate the effects of the selected combination treatments on PBP2a and 
biofilm production in MRSA. 
4. To identify major classes of compounds in extracts and fractions from the named 
plants by phytochemical analysis. 
5. To determine fractions that has potent antimicrobial and at the same time is able 
to retain the activity throughout the studies via bioassay-guided fractionation.
  
 
 
CHAPTER 2 
 
BIOASSAY GUIDED FRACTIONATION AND DETECTION OF PHYTOCHEMICALS 
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2.1 BACKGROUND 
 
The current situation of public health is continuously being threatened by the emergence 
of diseases caused by antibiotic resistant bacteria. Resistant infections which are difficult 
to treat often lead to increased economic burden and fatalities especially in 
underdeveloped countries (Okeke et al. 2005). Attempts to discover new therapeutics to 
combat this problem are often associated with the studies of plant extracts as well as pure 
compounds isolated from the extracts of medicinal plants. A recent trend has shown that 
global population that is attracted to use medicinal plants or natural remedies to treat 
various infectious diseases is on the rise (Cos et al. 2006; Tiwari 2008). 
 
Literature reviews showed that the plants A. wilkesiana and D. grandiflora were 
traditionally used to treat bacteria associated infections (Alade and Irobi 1993; Shankar 
and Devalla 2012). Following that these plants were selected for this study in which a 
bioassay guided approach was employed in order to identify bioactive components.  
Bioassay guided isolation is a basic yet useful method to search for antimicrobial natural 
products. It is a process of characterizing substances with biological activities by using 
chromatography methods for fractionation/separation of extracts and bioassays to 
identify bioactive fractions/compounds.  This method tends to yield valuable information 
on biological effects, although the bioactivities are not always assignable to a specific 
chemical compound (Weller 2012) and serves as a basis to discriminate the non-active 
portions of a mixture (Bucar et al. 2013). 
 
 Prior to bioassay guided fractionation, the plant materials need to be extracted. In 
this chapter, the plant materials were extracted by a sequential extraction method using 
solvents of increasing polarity. The isolation of active fractions was done by employing 
two chromatography methods, namely, vacuum liquid chromatography (VLC) and 
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centrifugal thin layer chromatography (CTLC). The major classes of phytochemicals 
present in the extracts and fractions were then examined using chemical reagents. High 
performance liquid chromatography (HPLC) analysis was employed to study the chemical 
profile of the bioactive fractions. 
 
2.1.1 Preparation of plant materials and extraction methods  
 
Preparation of plant materials includes pre-washing, drying or freeze drying and grinding 
of plant materials. These steps enable a homogenous sample, with improved kinetics of ǯ
solvent. Other necessary cautions, such as temperature should be taken into account to 
avoid loss of active constituents during plant material preparation (Sasidharan et al. 
2011). Similarly if a plant is identified to contain volatile or thermolabile constituents, it is 
recommended to freeze the material right after collection. Frequently, collected plant 
materials are sliced into small pieces, then placed on trays and allowed to dry at moderate 
temperature with ventilation. While this procedure is widely practice, it is necessary to 
maintain a dry condition to avoid microbial contamination that potentially leads to 
metabolites degradation. Over exposure to sunlight should also be prevented as 
ultraviolet rays are capable of initiating chemical reactions that produce artifacts. Finally, 
the obtained dried material must be sealed in proper containers and kept in a dry and cool 
space (Seidel 2006).  
 
 Extraction is an important and crucial procedure in the study of medicinal plants 
as it has a great influence on the final outcome of the study (Azmir et al. 2013). Selection 
of suitable extraction method will ensure that reliable qualitative and quantitative studies 
of the isolated bioactive compounds will be obtained (Smith 2003; Sasidharan et al. 2011). 
A conventional method of extraction that depends on extracting capacity of different 
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solvent in combination of heat and/or mixing is still popular in natural product research. 
The methods can be categorized based on three different mechanical means, namely, 
soxhlet extraction, maceration and hydrodistillation (Azmir et al. 2013). Choices of 
solvents play a major part in extraction efficiency (Cowan 1999) because plant extracts 
exist as combination of various types of bioactive molecules of different polarities (Azmir 
et al. 2013). As such, polarity of the targeted compounds or group of compounds is a 
determinant factor for choice of extraction solvent.  Table 4.1 represents different types of 
solvent that are used to extract selected group of plant metabolites. 
 
Table2.1  Example of some bioactive compounds extracted by different solvents  
 (adapted from Cowan 1999). 
        
 In this study, the plant materials were dried and grinded prior to extraction. 
Extraction of plant material was carried out by employing a sequential extraction 
approach from non-polar to polar solvents (hexane ĺ ethyl acetate ĺ ethanol) to exploit 
different solubility of plant matrices found in the extracts. Typically plant natural products 
can be separated into these categories; waxes and fatty acids, polyacetylenes, terpenoids, 
steroids, essential oils, phenolics, alkaloids, and glycosidic derivatives (Seidel 2006). Most 
fatty acids and essential oils can be extracted by non-polar solvents like hexane, while 
other components with mid-polarity (such as some alkaloids and flavonoids) are soluble 
in solvents such as ethyl acetate and chloroform, and more polar components (such as 
tannins and glycosides) can be extracted with ethanol and methanol. As such, application 
of selective extraction conducted sequentially with solvents of increasing polarity allows a 
Water Ethanol Methanol Chloroform Dichloro- 
methanol 
Ether Acetone 
Anthocyanins Tannins Anthocyanin Terpenoids Terpenoids Alkaloids Flavonoids 
Tannins Polyphenols Terpenoids Flavonoids Terpenoids 
Saponins Flavonol Saponins     
Terpenoids Terpenoids Tannins     
 Alkaloids Flavones     
  Polyphenols    
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preliminary separation of the constituents of different polarity into distinct extracts and 
facilitate further purification/separation processes (Cottiglia et al. 2004; Seidel 2006). 
 
2.1.2 Liquid chromatography methods  
 
In natural product isolation, liquid chromatography (LC) represents the most common 
method for separating mixtures into their constituent compounds. It features a liquid 
mobile phase which dissolves the extract and runs the mixture through a solid stationary 
phase. Separation of the mixture into individual components or fractions is attributed to 
difference in the degree of binding of the solute molecules in the stationary phase (Dill 
1987). The more commonly used LC involves the use of silica gel in an open column 
chromatography and a preparative thin layer chromatography (TLC) mainly because the 
two methods are rather straight forward with regards to the ease of use and relatively 
economical. Vacuum liquid chromatography (VLC) is a variant of LC and can be used to 
fractionate the crude extract swiftly, while centrifugal thin layer chromatography (CTLC) 
is used for further fractionation and for purification of pure compounds (Hostettmann et 
al. 1998).   
 
  A VLC apparatus and specifications were designed to maintain the column in 
vacuum state to eliminate channelling issues. Application of the vacuum speeds up the 
eluent flow-rate. The method for VLC operation is fairly simple and it allows separation of 
large amount of extract up to 30 g per run. As such, VLC is often considered as technique 
that is efficient and rapid, and relatively inexpensive for organic compound separation 
(Sticher 2007). CTLC was developed to overcome the problems of the many hours 
required to separate a mixture of compounds and the difficulties in removing the 
constituent substances from the plate of a conventional preparative TLC. A key feature of 
the method relies on the action of a centrifugal force to fasten mobile phase flow across 
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the circular TLC plate. The circular plate is made of glass plate covered with a layer of TLC 
grade silica sorbent with varying thickness of 1, 2 or 4 mm. An electric motor functions to 
rotate the plate at 800 rpm in which samples is loaded at the centre of the plate. Eluent 
will be pumped onto the centre of the plate, which subsequently flows across the sorbent 
due to centrifugal force. As a result, the sample will be separated into concentric bands 
across the plate that eventually elutes at the edge of the plate. These are collected and 
examined by using TLC analysis (Marston and Hostettmann 1991).  
 
 HPLC is an improvised version of column chromatography. It uses high pressure 
(up to 400 atmospheres) in contrast to vacuum or gravity in VLC/CTLC to force the 
solvent through a column.  The main advantage of this technique is it uses much smaller 
particle size for the column packing materials hence, provides a larger surface area for 
interactions between the stationary phase and the molecules flowing through it. As a 
result, a better separation of the components in the mixture is achieved. This is coupled 
with an automated and sensitive detection method. One of the common methods is ultra-
violet (UV) absorption. Organic compounds absorb UV lights at numerous wavelengths. 
When a mixture of compounds analyzed through HPLC, the output will be recorded as a 
series of peaks. Theoretically, each one peak represents a compound in the mixture 
passing through the UV detector (Clarke 2007). 
 
 Isolation and purification of fractions from the plant extracts in this research were 
achieved by using both the VLC and CTLC methods. In this study, normal phase silica gel 
was used as the stationary phase for VLC to fractionate the plant extracts into less 
complex fraction, which were further fractionated by using CTLC. Ethyl acetateȂ
hexane/methanol was selected as the solvent system with gradual decrease of hexane 
followed by gradual increase of methanol. Whereas, HPLC methods were used to analyze 
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the complexity of the bioactive fractions by using solvent system comprising of 
acetonitrile (ACN)/miliQ water (H2O). 
 
2.1.3 Phytochemical analysis 
 
The methods previously developed for phytochemical analysis are rather simple and 
straightforward, and can be easily performed in the laboratory (Sasidharan et al. 2011). 
The results are interpreted as negative or positive based on colorimetric changes that are 
achieved by using the relevant screening reagents. Since an extract contains a mixture of 
natural products, this method is effective for researchers to conjure hypotheses about the 
type of compounds present. In this chapter, phytochemical analysis was conducted on the 
crude extracts and bioactive fractions of A. wilkesiana and D. grandilora. The screening 
methods were performed as described by Jones and Kinghorn 2005. The analysis was 
objectively done to detect major classes of phytochemicals, namely, tannins, alkaloids, 
flavonoids, sterols/steroids and glycosides. 
 
2.2 AIMS AND OBJECTIVES 
 
The specific objectives of this chapter are: 
 
1. To identify major classes of compounds in extracts and fractions from A. 
wilkesiana and D. grandiflora by phytochemical analysis. 
2. To determine fractions that has potent antimicrobial and at the same time is able 
to retain the activity throughout the studies via bioassay-guided fractionation. 
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2.3  MATERIALS AND METHODS 
 
2.3.1 Plant collection and extraction 
 
The plant material, A. wilkesiana was collected from Broga, Selangor, Malaysia 
(September, 2010) and D. grandiflora from Simpang Pulai, Perak, Malaysia (September, 
2011). Voucher samples were deposited in the herbarium of Faculty of Science, University 
of Nottingham Malaysia Campus, where A. wilkesiana and D. grandiflora were assigned as 
UNMC 9 and UNMC 75, respectively.  
 
 The collected plant materials were dried and grinded prior to extraction. The 
dried plant materials (3.6 kg Ȃ A. wilkesiana whole plant, 2.1 kg Ȃ D. grandiflora leaves, 2.5 
kg Ȃ D. grandiflora bark) were subjected to sequential extraction using n-hexane (He), 
followed by ethyl acetate (EA) and finally 95% ethanol (EtOH). Extraction in each solvent 
was conducted by soaking the plant material in the solvent (24 hours x 3 times) at room 
temperature. The plant material and extract solution were separated using a filter paper 
(Whatman Grade No. 1, USA). The filtrates were concentrated under reduced pressure at 
35- ? ? ?   ry evaporator (Buchi, USA). The concentrated crude extracts were 
further dried in a desiccator for 1-2 weeks as required. The dried crude extracts were kept 
in a - ? ? ?Ǥ 
 
2.3.2 Fractionation of crude extracts 
 
The following crude extracts were fractionated in this study: 39.14 g of ethyl acetate 
extract of A. wilkesiana (9EA), 49.95 g of ethyl acetate leaf extract of D. grandiflora (75EA-
L) and 16.36 g of ethyl acetate bark extract of D. grandiflora (75EA-B). Based on earlier 
finding in our laboratory, these extracts exhibited potent anti-staphylococcal activities 
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(Othman et al. 2011a) and were therefore chosen for bioassay-guided fractionation in the 
present study.  
 
 Crude extracts were fractionated by using a silica gel (40-63 microns, 
Mallinckrodt, USA) VLC (Figure2.1). The solvent system used for elution was n-hexane 
(He) with increasing amount of chloroform (CHCl3), and CHCl3 with increasing amount of 
methanol (MeOH) [He/CHCl3 (1:1) ĺ CHCl3 ĺ CHCl3/MeOH (97:3 v/v) ĺ CHCl3/MeOH 
(95:5 v/v) ĺ CHCl3/MeOH (93:7 v/v) ĺ CHCl3/MeOH (90:10 v/v) ĺ CHCl3/MeOH (85:15 
v/v)]. Fractions obtained were further fractionated via preparative CTLC (silica gel) using 
similar solvent systems (Figure 2.2).  
 
TLC technique was used to monitor the extent of fractionation as well as to assist 
in combining fractions with similar profile (Appendix 7).  The solvent systems used in TLC 
to combine the fractions were; CHCl3/MeOH 5%, CHCl3/He (ratio 3:1, 2:1, 1:3 and 1:5), 
CHCl3 100%, ethyl acetate (EA) 100%, diethyl ether (Et2O)/MeOH 5%, EA/He (ratio 1:3 
and 1:5). Fractions obtained were tested for anti-MRSA activity as described in Chapter 3 
at every stage of fractionation and purification.  
 
2.3.3 TLC analysis 
 
Fractions that demonstrated potential anti-MRSA activity as described in Chapter 3 were 
analyzed using TLC methods to observe the complexity of these fractions and for 
chemistry profiling purposes. The solvent systems used for TLC were the same as 
described in section 2.3.2. In addition the following solvent systems were used; acetone 
(Ac) 100%, Ac/He (ratio 1:2), CHCl3/MeOH/formic acid (FA) (ratio 3:1:1), EA/MeOH 20%, 
CHCl3/MeOH 1%, 3%, 20%, 30% and 50%.  
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Figure 2.1 An example of a vacuum liquid chromatography (VLC) unit used for fractionation of 
plant crude extracts in this study (Image obtained from: 
http://www.umich.edu/~chemh215/W11HTML/SSG2/ssg2.1/glossary1.html). 
 
 
 
 
 
Figure 2.2 A diagram of a centrifugal thin layer column chromatography (CTLC) unit used for 
separation of fractions obtained from vacuum liquid chromatography (VLC) (Image 
obtained from: http://www.sbwave.com/chromatotron/specs.html) 
 
 
    
Application of 
vacuum to speed 
up the effluent 
flow rate 
Solvent 
Collection of 
fractions 
Silica plate 
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2.3.4 HPLC analysis 
 
An aliquot of the selected bioactive fraction ȋ ? ? Ɋ   ? ? Ȁ) was analyzed by C18-
reversed phase HPLC using the following gradient solvent system: 2 min at 10% 
acetonitrile (ACN)/miliQ water (H2O); a linear gradient to 75% ACN/H2O over 12 min; 
isocratic at 75% for 10 min; a linear gradient to 100% ACN for 2 min; isocratic at 100% 
ACN for 4 min. HPLC was performed on a Varian 940-LC system using a reversed phase 
analytical column (Pursuit XRs C18, 4.6 x 150 mm, 5 µm) with photodiode array (PDA) 
detection at 254 nm. 
 
2.3.5 Determination of phytochemical contents 
 
Phytochemical analysis was carried out according to the methods reported by Jones and 
Kinghorn 2005, as summarized below:  
 
a) Tannins 
200 mg of plant material was dissolved in 10 ml distilled water and filtered. 2 ml of filtrate 
was added to 2 ml of ferric chloride (5% w/v).  The presence of tannins was indicated by 
blue black precipitation.  
 
b) Alkaloids 
200 mg plant material was dissolved in 10 ml methanol and filtered. 2 ml of the filtrate 
was added to acid hydrochloric (1% w/v) in boiling water bath. 1 ml of aliquot was            ?   ǯ
reagent. A brownish/brown precipitation indicated presence of alkaloids in sample.  
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c) Flavonoids  
200 mg plant material was dissolved in 10 ml ethanol and filtered. 2 of ml of the filtrate 
was added to a test tube containing few drops of concentrated hydrochloric acid and 
magnesium ribbon. Detection of flavonoids was confirmed when the solution turns into 
pink-tomato red colour.  
 
d) Saponins 
0.5 ml of the plant filtrate was added into 5 ml of distilled water and the mixture was 
shaken. Formation of frothing which persisted for 15 minutes after the shaking indicated 
the presence of saponins.  
 
e) Sterols/Steroids  
1 mg of plant material was dissolved in 1 ml of CHCl3. This was followed by addition of 1 
ml of concentrated sulfuric acid. The presence of sterols/steroids was indicated by the 
formation of red colour in the solution.  
 
f) Glycosides  
2 ml of plant filtrate was added to 1 ml glacial acetic acid in the presence of ferric chloride 
and concentrated sulfuric acid. The presence of glycosides was indicated by green-blue 
colour in the solution.  
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2.4 RESULTS 
 
2.4.1 Extraction of UNMC 9 and UNMC 75 
 
Both the UNMC 9 and UNMC 75 plant materials were sequentially extracted with n-
hexane, ethyl acetate and ethanol. The percentage yield of each extraction is summarized 
in Table 2.2. Based on the results, extraction using ethanol afforded the highest yields. The 
leaves of UNMC 75 also afforded higher yields compared to the bark.  
 
Table 2.2 Results of sequential extraction of UNMC 9 and UNMC 75. 
Types of 
extracts 
Plant  
parts 
Weight (g) Yield (%) 
    
9EtOH Whole plant 266.20 7.6 
9EA Whole plant 71.77 2.1 
9He Whole plant 70.00 2.0 
75EtOH-L Leaves 101.90 4.9 
75EA-L Leaves 79.31 3.8 
75He-L Leaves 81.19 3.9 
75EtOH-B Bark 92.33 3.7 
75EA-B Bark 18.90 0.8 
75He-B Bark Not 
determined 
- 
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2.4.2 Bioassay guided fractionation of 9EA, 75EA-L and 75EA-B 
 
The three ethyl acetate crude extracts, namely 9EA, 75EA-L and 75EA-B, were first 
fractionated by VLC and followed by CTLC. The fractions obtained from VLC and CTLC 
were combined based on their TLC profiles (Appendix 7). At each stage of the 
fractionation, the obtained fractions were tested for anti-MRSA activity. Only fractions 
that showed the desired bioactivity were further fractionated 
 
 VLC of 9EA afforded six major fractions (Figure 2.3), namely 9EA-FA, 9EA-FB, 9EA-
FC, 9EA-FD, 9EA-FE and 9EA-FF. All fractions demonstrated anti-MRSA activity (section 
3.4.3, Chapter 3) except 9EA-FA. Table 2.3 is showing solvent system which eluted the 
major fractions from 9EA. 
 
 Out of these, two fractions 9EA-FC and 9EA-FD were further fractionated. 9EA-FB 
although exhibited anti-MRSA activity, the fraction did not demonstrate any synergism 
with ampicillin. Hence, 9EA-FB was not selected for the subsequent fractionation process. 
Whereas, fraction 9EA-FE and 9EA-FF were insufficient in amount and highly polar 
respectively, thus preventing further works.   
 
Fractionation of 9EA-FC and 9EA-FD on CTLC yielded 21 sub-fractions which were 
considered semi-pure fractions. Many of these semi-pure fractions suffered significant 
loss of bioactivity. An unstable bioactivity was noted in one of the semi-pure fraction FC-C, 
in which we saw the anti-MRSA activity decreased after being tested several times on 
different occasion (results not shown). Eventually, only fraction FC-B demonstrated the 
desired biological activity and was chosen as suitable candidate for further experiments.  
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Note: a ±not active, b-insufficient amount for further isolation, c-highly polar fraction flushed with ethanol 
from the column, d- unstable activity 
 
 
 
Figure 2.3 Schematic diagram of bioassay guided fractionation and purification of  
  9EA. 
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Table 2.3 Solvent system used for isolation of major fractions from 9EA on VLC.  
Fractions Solvent system   
Crude extract 9EA EA 100% 
9EA-FA He/CHCl3 (ratio 1:1) 
9EA-FB CHCl3 (100%) to CHCl3/MeOH 1% 
9EA-FC CHCl3/MeOH 1-5% 
9EA-FD CHCl3/MeOH 5-7% 
9EA-FE CHCl3/MeOH 10-15% 
9EA-FF EtOH 100% 
 
Fractionation of 75EA-L (Figure 2.4) on VLC resulted in 10 major fractions. Table 
2.4 shows the solvent system in which the major fractions were eluted. All these major 
fractions were devoid of anti-MRSA activity except fraction 75EA-L-F10. Due to the very 
polar nature of 75EA-L-F10, this fraction was not fractionated further and was subjected 
to further biological study since it showed potent antimicrobial activity. In the case of 
75EA-B, six out of nine of the sub-fractions were active in anti-MRSA test. The solvent 
system in which these fractions were eluted is shown in Table 2.5. However, five of these 
were eliminated from further study due to poor yield (< 500 mg). This brought us down 
with one fraction, namely 75EA-B-F4, which only showed anti-MRSA activity but not 
synergism with ampicillin. We carried out VLC/ CTLC on 75EA-B-F4 that gave rise to 14 
semi-pure fractions. Nevertheless, the low amount of these fractions prevented further 
chemical analysis and biological evaluation.  
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Table 2.4 Solvent system used for isolation of major fractions from 75EA-L on VLC. 
Fractions Solvent system   
Crude extract 75EA-L EA 100% 
75EA-L-F1 He/CHCl3 (1:1) 
75EA-L-F2 CHCl3 100% 
75EA-L-F3 CHCl3/MeOH 1% 
75EA-L-F4 CHCl3/MeOH 1-3% 
75EA-L-F5 CHCl3/MeOH 4-5% 
75EA-L-F6 CHCl3/MeOH 5-7% 
75EA-L-F7 CHCl3/MeOH 7-10% 
75EA-L-F8 CHCl3/MeOH 7-10% 
75EA-L-F9 CHCl3/MeOH 10-15% 
75EA-L-F10 EtOH 100% 
 
Table 2.5 Solvent system used for isolation of major fractions from 75EA-B on VLC.  
Fractions Solvent system   
Crude extract 75EA-B EA 100% 
75EA-B-F1 He/CHCl3 (1:1) 
75EA-B-F2 He/CHCl3 (4:1) 
75EA-B-F3 CHCl3/MeOH (1%) 
75EA-B-F4 CHCl3/MeOH (1-3%) 
75EA-B-F5 CHCl3/MeOH (4-5%) 
75EA-B-F6 CHCl3/MeOH (5-7%) 
75EA-B-F7 CHCl3/MeOH (7-10%) 
75EA-B-F8 CHCl3/MeOH (20%) 
75EA-B-F9 EtOH (100%) 
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Note: a Ȃnot active, b-insufficient amount for further isolation, c- fraction flushed with ethanol from 
the column, d- unstable activity 
 
 
 
Figure 2.4 Schematic diagram of bioassay guided fractionation and purification of a) 75EA-L and 
b) 75EA-B. 
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2.4.3 HPLC analyses of the selected bioactive fractions from 9EA and 75EA 
 
Two bioactive fractions (9EA-FB and FC-B) from 9EA were analyzed via HPLC.  These 
fractions were selected because 1) 9EA-FB demonstrated the most potent anti-MRSA and 
anti-MSSA activity based on the lowest MIC value and 2) FC-B showed anti-MRSA activity 
and synergism with ampicillin (section 3.4.2 and section 3.4.6, Chapter 3). Figure 2.5 
shows chromatograms of the respective bioactive fractions and the results revealed a 
complex series of peaks belonging to mixture of the compounds in the fractions indicative 
of incomplete separation of the compounds. 
 
 From 75EA, two bioactive fractions (75EA-B4 and 75EA-L-F10) were analyzed 
using HPLC.  75EA-L-F10 was chosen because it was the only fraction that displayed anti-
MRSA activity in addition to synergism with ampicillin (section 3.4.3 and 3.4.6, Chapter 3). 
Fraction 75EA-B-F4 whereas, exhibited a strong inhibition on MRSA and MSSA with the 
lowest MIC value (section 3.4.3, Chapter 3). The results are shown in Figure 2.6. Similar to 
bioactive fractions from 9EA, these two fractions were also observed to comprise of 
multiple overlapping peaks showing incomplete separation of compounds in the mixture. 
Fraction 7EA-B-F4 although it consist several peaks, overall, the chromatogram appeared 
less complex compared to other fractions. Whereas, peaks belonging to mixture of 
compounds in 75EA-L-F10 have low intensity (< 1000 mAU) in contrast to other analyzed 
bioactive fractions. 
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Figure 2.5 HPLC analyses of a) 9EA-FB and c) FC-B. An aliquot of 40 µlof 10 mg/ml of each fraction analyzed by C18-reversed phase (4.6 x 150 mm, 5 µm) detected 
at 254 nm.  
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Figure 2.6 HPLC analyses of a) 75EA-B-F4 and b) 75EA-L-F10. An aliquot of 40 µl of 10 mg/ml of each fraction analyzed by C18-reversed phase (4.6 x 150 mm, 5 
µm) detected at 254 nm.  
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2.4.4 TLC profiles of selected bioactive fractions from 9EA and 75EA 
 
Similar to section 2.4.3 (HPLC analyses), the same bioactive fractions identified from 9EA 
and 75EA were analyzed via TLC method. The bioactive fractions were 9EA-FB, FC-B, 75EA-
L-F10, and 75EA-B-F4. In general, the TLC profiles showed presence of multiple spots 
representing mixture of compounds occurring in the respective fractions. Figures 2.7 to 2.10 
are showing a TLC profiles for these fractions accessed in various solvent systems in which 
these fractions were separated. The solvent system Ac/He (ratio 1:2) was found to result in 
well separation of the components in all the fractions except 75EA-L-F10.  In addition, TLC 
profiles of 9EA-FB (Figure 2.7) and FC-B (Figure 2.8), indicated that these two fractions 
were likely to contain similar compounds. Also, we found components in 75EA-L-F10 did 
not separate into distinct spots unlike other tested fractions but rather formed a long streak 
along the TLC plate (Figure 2.10).  
 
 
 
 
 
 
 
 
 
 
Figure 2.7 TLC profile of fraction 9EA-FB isolated from crude extract A. wilkesiana analyzed in the 
solvent system (from far left) CHCl3 100%, CHCl3/MeOH 1%, and Ac/He (ratio 1:2). 
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Figure 2.8 TLC profile of fraction FC-B isolated from crude extract A. wilkesiana analyzed in the 
solvent system (from far left) EA 100%, CHCl3 100%, CHCl3/MeOH 1%, and Ac/He (ratio 
1:2). 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 TLC profile of fraction 75EA-B-F4 isolated from crude bark extract D. grandiflora 
analyzed in the solvent system (from far left) EA 100%, CHCl3 100%, CHCl3/MeOH 1%, 
CHCl3/MeOH 3%, CHCl3/MeOH 5%, and Ac/He (ratio 1:2). 
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Figure 2.10 TLC profile of fraction 75EA-L-F10 isolated from crude leaf extract D. grandiflora 
analyzed in the solvent system (from far left) Ac 100%, Et2O/MeOH 5%, CHCl3/MeOH/FA 
(ratio 3:1:1), EA/MeOH 20%, CHCl3/MeOH 50%, CHCl3/MeOH 20%, and CHCl3/MeOH 
30%. 
 
2.4.5 Major classes of compounds in extracts and fractions from 9EA and 75EA 
 
Phytochemical analysis was carried out on the crude extracts of 9EA, 75EA-L and 75EA-B 
and selected fractions that demonstrated anti-MRSA and synergism with ampicillin, (section 
3.4.3 and section 3.4.6, Chapter 3). The analysis revealed the presence of commonly 
occurring classes of phytochemicals such as tannins, saponins, sterols/steroids, and 
glycosides. Classes of compounds that are frequently associated with biological activities 
such as alkaloids and steroids were also found in the extracts/fractions. Table 2.6 shows the 
various phytochemicals detected in the extracts/fractions.   
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Table 2.6 Phytochemical analysis of crude extracts and fractions from 9EA, 7EA. Experiments were 
conducted three times on separate occasions. 
 
 
 
 
Phytochemicals 
Extracts/ Fractions 
 
9EA 9EA-
FB 
9EA-
FC 
9EA- 
FD 
FC-B 75EA-
L 
75EA- 
B 
75EA-
L-F10 
75EA-
F-B4 
 
Tannins 
 
+ 
 
+  
 
+ + 
 
+ + 
 
+ + 
 
+ + 
 
+ 
 
+ 
 
+ 
 
Alkaloids 
 
+ 
 
- 
 
+ 
 
+ + 
 
- 
 
+ 
 
+ 
 
- 
 
- 
 
Flavonoids 
 
- 
 
- 
 
- 
 
- 
 
- 
 
+ 
 
+ 
 
+ 
 
+ 
 
Saponins 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
Sterols/Steroids 
 
+ 
 
+ + 
 
+ + 
 
+ + 
 
+ + 
 
+ + 
 
+ 
 
+ 
 
+ + 
 
Glycosides 
 
+ 
 
+ +  
 
+ +  
 
+ + + 
 
+ + 
 
+ + 
 
+ 
 
+ + 
 
+ + 
Note: - absent, + present, + + moderate amount, + + + appreciable amount 
 
 
 
2.5 DISCUSSION 
 
Natural products have been identified as an important mainspring of novel structures 
particularly in anti infective research since the research activities highly depends on the 
structural information of these products for development of new drugs. Although 
application of combinatorial chemistry improves activities of newly approved agents, so far 
in the time frame of 30 years, only one compound optimized from this technique was 
approved as a drug by FDA. The approved compound is an anti tumor agent known as 
sorafenib (Nexavar®) from Bayer, for treatment of renal cell carcinoma.  This shows that 
the study of natural products continue to play a vital role in the discovery and development 
of drugs (Newman and Cragg 2012). 
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Our study in this chapter employed bioassay guided fractionation method to 
uncover the active fractions from the extracts 9EA and 75EA with anti-MRSA activity. The 
fractionation process combined with biological assays has enabled the identification of two 
main bioactive fractions, FC-B and 75EA-L-F10, which possessed improved anti-MRSA 
activity compared to the corresponding crude extracts. The two fractions demonstrated 
synergism with ampicillin in suppressing MRSA growth in addition to retaining the 
bioactivity throughout this study (Chapter 3). A study on phytochemical contents in the 
crude extracts and bioactive fractions used in this chapter was conducted and the results 
showed the presence of biologically active classes of phytochemicals such as tannins, 
alkaloids, flavonoids, saponins, glycosides and steroids. In agreement, the HPLC analyses 
revealed occurrence of mixture of phytochemicals represented by severe overlapping of 
peaks observed in the chromatograms of the bioactive fractions. 
 
2.5.1 Bioassay guided fractionation 
 
In the present study, the crude extract 9EA was separated into major six major fractions. 
Based on evaluation of MIC values against MRSA and MSSA (Chapter 3), all fractions except 
9EA-FA exhibited antimicrobial activity. Two out of the five major fractions, namely, 9EA-FC 
and 9EA-FD, were selected for further purification due to their stable activity and sufficient 
yields for further testing. VLC/CTLC of 9EA-FC and 9EA-FD resulted on the isolation of 
seven and six semi-pure fractions, respectively. A prominent pattern among these semi-pure 
fractions was they were biologically inactive when tested. Only one semi-pure fraction, FC-B 
was identified to exhibit the desired anti-MRSA activity.  These results indicated that 
bioactivity for most of the semi-pure fractions were abolished following the separation 
process. A similar trend was observed amongst the major fractions isolated from 75EA-L, 
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where only one (75EA-L-F10) out of 10 isolated fractions displayed good anti-MRSA activity. 
On the other hand, 75EA-B gave rise to a total of nine major fractions after VLC. Further 
purification of fraction 75EA-B-F4 yielded 14 semi-pure fractions.  However, the very low 
amount of the fractions obtained did not permit further antimicrobial work to be carried 
out.  
 Based on the results described above, the major issue faced during the bioassay 
guided fractionation was loss of bioactivity with subsequent separation or purification. Loss 
of bioactivity after fractionation was apparently a common phenomenon observed during 
isolation of active components from plant extracts. A possible reason for loss of bioactivity 
observed in this study can be linked with synergism effects between occurring compounds 
in an extract which collectively contributed to the biological activity. In phytomedicine, it is 
common to utilize whole plant rather than a single compound which suggests that 
compounds in the extract may work in concert to produce the observed biological activity. 
In fact, a previous study concluded that synergism should be anticipated when an extract 
loss its initial bioactivity after fractionation (Williamson 2001; Rasoanaivo et al. 2011). 
Researches from the past have published in vitro and other experimental evidence 
demonstrating synergistic effects amongst compounds in an extract and lapsing of the 
bioactivity that occurred following isolation of compound (Singh and Blumenthal 1997; 
Houghton 2000; Rasoanaivo et al. 2011).  As an example, a study conducted by Houghton 
(2000) saw that fractionation of Kigelia pinnata extract had eradicated the initial cytotoxic 
effects observed. Apart from the synergism theory, another possibility would be that the 
bioactive constituent might be unstable on its own and needs the presence of other 
compounds such as antioxidant to protect it from decomposition (Williamson 2001). Thus, 
thǯ
components or compromised the stability of the active ingredients. This may be the possible 
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explanations for the poor and unstable anti-MRSA activity observed for the semi-pure 
fractions derived from 9EA and 75EA. 
 
2.5.2 Occurrence of phytochemicals in crude extracts and bioactive fractions of A. 
wilkesiana and D. grandiflora 
 
In phytochemical analysis, 9EA, 75EA-L and 75EA-B together with their respective fractions 
were found to contain various classes of plant natural products such as tannins, alkaloids, 
flavonoids, saponins, sterols/steroids, and glycosides. These phytochemicals has been 
previously identified as potential drug candidates. The advantage of identifying the types of 
phytochemicals present in a plant extract or fraction provides useful information on 
possible mode of action for the observed biological activities (Cowan 1999; Saleem et al. 
2010). 
  
 The extract 9EA is from the plant A. wilkesiana which has been studied by others 
earlier (Adesina et al 2000; Oladunmoye 2010; Akinyemi et al. 2005; Othman et al. 2011a). 
Preceding studies have reported frequent occurrence of tannins and saponins in A. 
wilkesiana extracts. Likewise, in this study, high concentrations of tannins were detected in 
9EA and in the major fractions, 9EA-FC and 9EA-FD. Compounds belonging to the tannin 
group such as corilagin, ethyl gallate, ellagitannin and geraniin were observed to exhibit 
antibacterial activities, specifically against S. aureus sp. (synergism with beta-lactams were 
reported) (Shimizu et al. 2001; Sato et al. 2004; Din et al. 2013a, Din et al. 2013b). The 
mechanism of actions is thought to be related to the ability of tannins to lyse bacterial cells 
which eventually causes cell death (Adesina et al. 2000; Oladunmoye 2010). Furthermore, 
tannins like epigallocatechin-gallate and corilagin were found to suppress resistant factors 
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in MRSA such as production of beta-lactamase and production or activity of PBP2a (Hu et al. 
2001; Shimizu et al. 2001). Hence the presence of tannins in the extract 9EA and fractions, 
derived from it may explain the good antimicrobial activity displayed by the 
extract/fractions against MRSA (Chapter 3). 
 
 The extracts 75EA-L and 75EA-B from D. grandiflora along with the bioactive 
fractions obtained from these extracts were tested positive for all the  phytochemicals 
except alkaloids which was absent in the bioactive fractions obtained from these crude 
extracts. The results are identical with an earlier study conducted by Othman et al. (2011b) 
which also showed presence of similar phytochemicals in D. grandiflora extracts that 
possess anti-staphylococcal activities. ǯ
is very limited. Thus, although the anti-MRSA activity observed in this study is attributed to 
the presence of phytochemicals found in extracts/fractions, we are unable to deduce which 
class of phytochemicals are more likely to contribute to the observed antimicrobial activity.
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CHAPTER 3 
 
ANTIMICROBIAL ACTIVITY OF PLANT EXTRACTS AND FRACTIONS  
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3.1  BACKGROUND 
 
In the late 1990s, the usage of plant extracts and other alternative forms of plant products 
have become popular to treat or prevent infectious diseases. This is because the public was 
becoming more conscious of problems associated with over prescription and exploitation of 
traditional antibiotics (Cowan 1999). These herbal medicines and supplements were 
perceived to be safe and do not have much side effects in comparison to synthetic drugs 
(Iniaghe et al. 2009). Following that, natural product chemists and microbiologist 
concentrate in exploration on medical plants as they suspect the wide range of plants 
accompanied by their chemically diverse phytochemicals may have unique mechanism in 
combating antibiotic-resistant pathogens. As such, these plant-derived metabolites may 
serve as an adjuvant or provide new leads for alternative antibacterial agents (Abreu et al. 
2012).  
 
 MRSA particularly has been selected for this study as it is known as the major cause 
of nosocomial infections and results in complications in many cases which eventually leads 
to death (Aqil et al. 2005). A review by Livermore (2009) stated available treatment options 
for MRSA infections are expanding with usage of drugs such as daptomycin, linezoid and 
tigecycline. However, the level and complexity of resistance mechanism displayed by this 
pathogen is evolving simultaneously due to increased uncontrolled utilization of antibiotics 
(Snider and Rivard 2012). Resistance in MRSA is mainly attributed to acquisition of mecA 
gene which confers resistance to beta-lactam antibiotics. The gene encodes for production 
of PBP2a, an altered protein that evades antimicrobial action of beta-lactams due to its low 
binding affinity. PBP2a replaces the function of normal PBPs which are susceptible to beta-
lactams (Berger-Bächi and Rohrer, 2002; Deresinski, 2005). As such, the bacterial cell 
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biosynthesis which is the target of beta-ǯ is not compromised upon challenged 
by these drugs. This creates the need to find new agents that are able to counteract the 
mechanism of resistance displayed by MRSA from further evolving. One of the proposed 
approaches in overcoming bacterial resistance is synergism by combining constituents from 
a plant extract with drugs to achieve a better therapeutic efficacy (Hemaiswarya et al. 2008; 
Wagner and Ulrich-Merzenich 2009). 
 
 In this chapter, we have embarked on the investigation of two medicinal plants; A. 
wilkesiana and D. grandiflora. We focused on ethyl acetate extracts based on findings from 
an earlier study (Othman et al. 2011a). The crude ethyl acetate extracts of these plants were 
fractionated by using a bioassay-guided isolation method (Chapter 2) which managed the 
isolation of major fractions and semi-pure fractions that were used for this study. The first 
section of this chapter describes broth microdilution assay that was conducted to determine 
MIC of crude ethyl acetate extracts and fractions from both plants against MRSA. The second 
part describes the synergistic studies which were carried out on combinations of plant test 
agents and ampicillin via two experiments; kinetic growth curve experiment and fractional 
inhibitory concentration (FIC) index interpretation.  The third section is investigation of 
mode of action of the selected combination treatments. This was carried out by employing 
Western blot experiment to study expression of PBP2a.  
 
 Selection of bioactive fractions for the combination studies was determined from 
their MIC results. In this chapter, experiments were conducted on fractions from three 
different extracts 1) ethyl acetate extract of A. wilkesiana (9EA), 2) ethyl acetate extract of D. 
grandiflora leaves (75EA-L) and 3) ethyl acetate extract of D. grandiflora bark (75EA-B). 
These three crude extracts initially evaluated for anti-MRSA activity via MIC determination. 
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Subsequent purification processes (LC) have separated these crude extracts into major and 
semi-pure fractions. Since, the approach in selecting bioactive fraction in this research is 
bioassay-guided; fractions were evaluated for anti-MRSA activity every time after each step 
of purification.  Fractions that retained anti-MRSA activity after the purification were 
investigated for any synergistic effects with ampicillin. Table 3.1 lists the fractions reported 
in this chapter.  
 
Table 3.1 Selected extracts and fractions of A. wilkesiana and D. grandiflora for    
  combinatory studies (synergistic). 
 
Plant Code Extract type 
 
A. wilkesiana 
 
 
 
 
 
D. grandiflora 
9EA 
9EA-FB 
Crude extract 
Major fraction 
Major fraction 
Major fraction 
9EA-FC 
9EA-FD 
FC-B 
 
Semi-pure fraction 
75EA-L Crude extract 
75EA-L-F10 
 
Major fraction  
Note: The crude extract 75EA-B and its fractions were not selected for this study due to 
insufficient amount for the testing  
 
 Bioactive fractions which demonstrated synergism with ampicillin in the 
combination treatments were selected for study on mechanism of action in which their 
effects on PBP2a expression were investigated. Two fractions reported in the Table 3.1, FC-
B and 75EA-L-F10 were chosen based on their ability to reduce MIC of ampicillin the most 
and successfully inhibited MRSA growth in the combinatory studies. The studied 
combination treatments were i) 1/32 x MIC  ampicillin + 1/4 x MIC FC-B and ii) 1/64 x MIC 
ampicillin + 1/4 x MIC 75EA-L-F10.  
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3.1.1 Bacterial strains and growing conditions  
 
The two S. aureus strains used in this study (MRSA ATCC 43300 and MSSA ATCC 11632) 
have been fully characterized and they were purchased commercially from Microbiologics 
(USA). The strain MRSA ATCC 43300 confers resistance to oxacillin, methicillin, ampicillin, 
and penicillin and has been used as a reference strain in many previous studies (Tiwari and 
Sen 2006; Mataraci and Dosler 2012; Chung et al. 2013). The strain is also confirmed to be 
carrying the SCCmec chromosome with mecA gene regulator that is responsible for the 
resistance to the whole class of beta-lactams (Petrelli et al. 2008). MSSA ATCC 11632 strain 
on the other hand, is susceptible to oxacillin, methicillin and ampicillin, and served as a non-
resistance strain control in our study. It has been used as a susceptible control in other 
screening assays and was reported as a mecA negative strain indicating absence of 
resistance towards to beta-lactams (Bekkaoui and Cloney 2003; Din et al. 2013a). 
 
 Factors such as type of media, supplements, growth temperature, and incubation 
duration affect the expression of methicillin resistance in S. aureus. Clinical Laboratory 
Standards Institute (CLSI) requires usage of Mueller-Hinton (MH) broth plus 2% sodium 
chloride (NaCl) in laboratory diagnosis and susceptibility testing of MRSA (CLSI 2007).  MH 
media has been also recommended by European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) since it is a general purpose medium that is employed to grow a wide 
range of non-fastidious microorganisms (EUCAST 2003). Affirmatively, older research 
reported that MRSA was more distinguishable on MH media (Brown and Kothari 1974; 
Monsen et al. 2003) and a better detection of methicillin resistance was obtained when the 
media is supplemented with NaCl (Monsen et. al. 2003).  Accurate detection of methicillin 
resistance can be challenging due existence of sub-population within a culture. This is 
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because cells grow in the same culture carried different genetic information for resistance, 
and only a few cells may express resistance in vitro (Chambers 1988; Brown 2001). Since 
MRSA strains possess salt tolerant capabilities, NaCl (up to 5%) is added to the growth 
media as a selective agent and this improves sensitivity for culturing of MRSA.  In this study, 
2% of NaCl was added to the growth media as recommended by CLSI for MRSA testing (CLSI 
2007). Although some studies suggested 2.5% of NaCl to be used for optimal sensitivity, 
higher salt concentrations may inhibit bacterial growth (Bruins et al. 2007). 
 
 Temperature and incubation duration employed in these experiments were 
stringently followed according to CLSI methods for MRSA testing. According to the ǯȋ ? ? ?-S17), duration of 24 hours incubation at 33-35°C 
is defined as the only method in general use for broth dilution assays (CLSI 2007).  Due to 
heterogeneous resistant nature of the MRSA strains, extended incubation time and lower 
growth temperature were employed (Skov et al. 2009). An extended incubation hour is 
necessary because some heterogeneous strains grow very slowly; hence the test should be 
incubated for 24 hours rather than 16-20 hours as in other bacteriological tests (Brown et 
al. 2005; Andrews 2009). With regards to growth temperature, lower temperature is more 
favorable in detecting resistance. In 1970, Parker and Hewitt (1970) reported that a MRSA 
strain was highly resistant to the tested antibiotic at a lower temperature, and at 37°C the 
same strain grew and behaved like a normal staphylococcal strain. A more recent study, 
recommended that a growth temperature not exceeding 35°C should be used as false-
negative results for resistance was observed for MRSA strains incubated at 36°C (Skov et al. 
2009). The growth conditions for MRSA and MSSA in this study are described in section 
3.3.1. 
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3.1.2 Broth microdilution assay  
 
A common choice of assay used to evaluate the antibacterial actions of plant extracts is 
using the broth microdilution assay to determine the MIC (Ncube et al. 2008). MIC is 
interpreted as the lowest concentration of an antimicrobial agent that inhibits visible 
bacterial growth after overnight incubation (Andrews 2001). The determination of MIC is 
useful in monitoring susceptibility of an organism to a specific antibacterial compound 
(EUCAST 2003). Typically after an overnight incubation, the bacterial growth becomes 
visible and detected by turbidity in the broth. This is normally done to determine an ǯ Ǥ Plant extract or fractions however are normally colored and cloudy. This ǯturbidity reading.  Hence, usage of colometric indicators will aid 
the interpretations of MIC breakpoints by eliminating ambiguity related with visual 
comparison (Ncube et al. 2008).  
 
Advantages of broth microdilution method include testing of large samples and with 
a wider range of concentration compared to other methods such as diffusion techniques. It 
also has advantages as the method requires small quantities of extract/fraction for testing 
and this is particularly useful in natural product research due to a common problem of 
scarcity of fraction or pure compound (Langfield et al. 2004). In laboratory practice, broth 
microdilution method is conducted by preparing series of two-fold dilution to create a 
concentration range. Usually a range of 5 to 8 different concentrations are tested. Then, a 
standardized bacterial inoculums suspension is added into each well and incubated at 
appropriate temperature to determine the final MIC value.  
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An important criterion in designing protocol for MIC determination is the test 
bacteria. The bacteria should be isolated in pure culture and identified before subjecting it 
for the test. Standardization of bacterial inoculum size is crucial for obtaining precise and 
reproducible results. An inoculum size of 5 x 105 colony-forming units (CFU)/ ml is reported 
as the suitable cell number for this assay (EUCAST 2003; Cos et al. 2006; CLSI 2007; 
Wiegand et al. 2008).  Higher or lower size of inoculums is likely to result in inaccurate MIC, 
especially in testing of resistant strain (Cos et al. 2006). In preparing the bacterial 
inoculums, a fresh pure culture should be used. To ensure all cells contain same genetic 
material, one must culture four-five single colonies of the bacteria to prepare a bacterial 
suspension, and incubate to reach density of 108 CFU/ml for inoculation in the assay (Cos et 
al. 2006; Wiegand et al. 2008, Othman et al. 2011b). Another option is direct colony 
suspension into liquid (Wiegand et al 2008). The prepared bacterial suspension must be 
used within 30 minutes to avert changes in cell numbers (EUCAST 2003). 
 
 Besides bacterial suspension, preparation of plant extract or fraction is of critical 
importance. A stock solution of extract is obtained in solvent such as methanol, acetone and 
dimethyl sulfoxide (DMSO) because besides having ability to completely dissolve the 
extract, they do not inhibit the microorganism at a cut of point of 2% in final concentration 
(Mathekga et al. 2000; Baris et al. 2006; Ncube et al. 2008). Similarly, antibiotics solution too 
has to be prepared accordingly to be included as quality control. Antibiotics were suggested 
to be prepared freshly by dissolving them in sterile distilled water to obtain stock solution. 
Other precautions such as storing the antibiotic in the dark containing desiccants and using 
potency information to formulate antibiotics solutions are equally important (Andrews 
2001). Generally in preparing both antimicrobial agents (plant extract and antibiotics) the 
following measures should be applied; warming the agents at room temperature at least 2 
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hours before weighing to avoid condensation on the powder, using sterile spatula and 
containers to weigh out, containers used are cold resistant, sealed tightly (e.g. Eppendorf 
tubes),   storing  at -20°C prior to use , and avoiding refreezing and thawing solution because 
this step can degrade antibiotic especially beta-lactams (Wiegand et al. 2008).  
 
For this study, the MIC determination via broth microdilution was done based on the 
above recommendations. The antibiotic ampicillin, methicillin and oxacillin were included 
as positive control to verify the results. Meanwhile, the MIC determination for plant extracts 
and fractions in this chapter was aided by thiazolyl blue tetrazolium dye (MTT). Presences 
of viable cells are detected by dehydrogenase enzyme activity of these cells which changed 
the yellow tetrazole in MTT to insoluble formazon product in purple (Mosmann 1983).  
 
3.1.3  Kinetic growth curve experiment 
 
Kinetic growth curve is a method used to monitor bacterial growth over time. The method is 
very convenient since growth of the test organism is measured by optical property that is 
the optical density (OD) of test culture (Koutny and Zaoralkova 2005).  A kinetic growth 
curve experiment is fairly similar to MIC determination. Instead of identifying lowest 
concentration that inhibits bacterial growth at end point, in this experiment, absorbance 
reading was taken on an hourly basis. The data obtained is used to plot a kinetic growth 
curve that shows the bacterial growth phase which essentially allows evaluation of an ǯ bacteria (Breidt et al. 1994).  
 
 In the study of potential synergism, kinetic growth curve experiment is useful to 
monitor combination effect of two agents in affecting bacterial growth. Additional 
78 
 
information such as at what phase of bacterial growth inhibition is observed and duration of 
antibacterial effects are also obtainable. Earlier studies of synergism have selected this 
experiment to demonstrated interaction of two agents combined (Muroi and Kubo 1996; 
Din et al. 2013a). For this study, kinetic growth curve experiment was employed to examine 
any synergistic effect of plant test agents and ampicillin in combination against MRSA 
growth.  
 
3.1.4  FIC index interpretation  
 
FIC index interpretation is also known as the checkerboard method. This method is widely 
used in detecting synergy because it is relatively easy. Results from this assay are observed 
at end-point which is basically assessing the inhibitory activity of two combined agents 
(White et al. 1996).  MIC value is mostly used in assessing synergy interaction of bacterial 
study. As such, calculation and interpretation of this index is compromised by MIC value 
(Berenbaum 1984). 
 
 Preparation of bacterial culture in FIC index interpretation is similar as for the 
kinetic growth curves. A bacterium is grown in media in the presence of two agents. 
Definition of synergistic effect is interpreted at the lowest concentrations of the agents 
where no bacterial growth observed after an overnight incubation (Takahashi and Kanno 
1984). This information is used to calculate FIC index which can be defined as synergy, 
antagonism or indifference based on the index. 
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3.1.5 Western blot 
 
Western blot is a fundamental method for protein detection and at the same time allows 
quantification of protein expression. There are three basic rudiments in Western blot 
technique; 1) separation by protein size, 2) transfer to a solid support and 3) identifying 
target protein by using appropriate primary and secondary antibody. During the initial step, 
proteins in a mixture are separated by their molecular weight via sodium dodecyl (lauryl) 
sulphate-polyacrylamide (SDS) gel electrophoresis. After the electrophoresis, the proteins 
are transferred onto a membrane, stained with dyes to confirm presence of band for each 
protein and then incubated with specific antibody for the protein of interest. After 
incubation, the gel is washed to remove the unbound antibody. The bound antibody is             ǯ  
(Mahmood and Yang 2012). 
 
The first step in Western blot experiment is protein extraction and it is crucial to ǯ
gel electrophoresis to ensure an equivalent analysis of the samples (Mahmood and Yang 
2012). In this study, Pierce 660 nm Reagent assay was used to quantify the sample for 
construction of protein standard curve.  An earlier study has suggested that this reagent is 
stable at room temperature and recognized to provide reproducible and linear results 
(Antharavally et al. 2009). As for selection of transfer membrane, nitrocellulose membrane 
was chosen in this study based on its retention abilities and high affinity for protein and it is 
fairly easy to be blocked to prevent non-specific antibodies interaction (Riis 2001; 
Mahmood and Yang 2012). In the blocking step, the protein binding capacity of membrane is 
often saturated with agents like 5% bovine serum albumin (BSA) or non-fat dry milk to 
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prevent antibody from binding to the membrane and yield a non-specific signal. Another 
aspect in Western blot analysis is inclusion housekeeping control to confirm that 1) equal 
amount of protein sample is loaded in each lane; 2) proteins are transferred with equal 
efficiency from the gel to the membrane and 3) consistent antibody incubation based on 
signal detection across the different lanes (Johnson 2012).   
 
 In Western blot assay, to recognize the targeted protein, the gels will be first probed 
with primary antibody. The primary antibody detects the precise sequence of amino acid of 
the targeted protein and binds to it.  A secondary antibody which is often conjugated with 
enzyme like Horse Radish Peroxide (HRP) then probed to detect the primary antibody. This 
increases the sensitivity of the assay by amplifying the detection signal (Mahmood and Yang 
2012).    
 
3.2 AIMS AND OBJECTIVES 
 
The specific objectives of this chapter were: 
 
1. To evaluate anti-MRSA activities of the extracts and fractions obtained from the 
plants via determination of MIC. 
2. To determine the synergistic effects of combination treatments consisting ampicillin 
and selected extracts or fractions on MRSA growth. 
3. To investigate the effects of the selected combination treatments on PBP2a. 
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3.3  METHODS 
 
3.3.1 Microorganisms  
 
Methicillin sensitive S. aureus ATCC 11632 (MSSA) was grown in tryptic soy broth (TSB) 
(Hi-Media, India) at 37°C for 24 hours with a shaking mode of 220 rotations per minute 
(rpm). Aliquot from this suspension was streaked on tryptic soy agar (TSA) (Hi-Media, 
India) and incubated at 37°C for another 24 hours. Two to four single colonies from the TSA 
plate was inoculated in 10 ml of Muller Hinton broth (MHB) (Hi-Media, India) and allowed 
to grow at 37°C until it reached exponential stage (2 x 108 CFU/ml). The suspension then 
was used for broth microdilution assay (section 3.3.3). MRSA ATCC 43300 was grown 
similarly except all the media used for its growth was supplemented with 2% NaCl (Merck, 
Germany) and incubation temperature was 35°C. Bacterial stocks were kept at -80°C in TSB 
added with 10% (v/v) glycerol (Sigma, USA). 
 
3.3.2  Preparation of test agents  
 
Crude ethyl acetate extract of A. wilkesiana (9EA) and D. grandiflora (75EA) and their 
respective fractions were dissolved in DMSO (Sigma, USA) at stock concentration of 100 
mg/ml. Further dilution was carried out using media and the final concentration of DMSO in 
the media did not exceed 1%. DMSO did not exert effect in the testing system as shown in 
our previous work (Othman et al. 2011a). 
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 Antibiotics for susceptibility testing were prepared at 10 mg/ml in sterile distilled 
water. Tested antibiotics were ampicilin (Amresco, USA), oxacillin (Discovery Fine 
Chemicals, UK) and methicillin (Sigma, USA).  
 
3.3.3 Assessment of the antibacterial activity via determination of MIC 
 
Broth microdilution method was used to determine the MIC of plant crude extracts, their 
respective fractions and antibiotics against MRSA and MSSA. A 96-well plate was used to 
prepare the antimicrobial agents in serial two-fold dilution. This assay was carried out in 
triplicates on three separate occasions. Antibiotics were tested with concentration ranging   ?Ǥ ? ?   ? ? ? ɊȀ       ?Ǥ ? ?   ? ? ȀǤ 
suspensions were prepared according to methods described in Section 3.3.1.  Two hundred 
micro liters (200 µl) of test agents was added into each well of the first row and followed by 
a serial two-fold dilution. Then 70 µl of appropriate broth was added into every well.  This 
followed by addition of 30 µl of bacterial suspension into every well (which corresponded to 
5 x 105 CFU/ml in a final volume of 200 µl per well) (see Figure 3.1). This experiment was 
done according to guidelines from CLSI 2007 with recommendations adapted from Cos et al. 
2006. 
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Figure 3.1  Schematic diagram of a set of triplicates used for broth microdilution assay in a 96-well 
microtiter plate showing serial dilution process and content of each well in the assay. 
 
 
All experiments in evaluating antimicrobial activities for MRSA were carried out in MH 
media (+ 2% NaCl) with growth temperature  ?35°C and results were noted after 24 hours 
incubation. The susceptible control strain, MSSA ATCC 11632 was grown at 37°C in MH 
media and incubated for 24 hours. After the incubation period, 20 µl of 5 mg/ml of MTT 
(Nacalai Tesque, Japan) prepared in sterile distilled water was added to the wells containing 
plant test agents. The lowest concentration at which color of the broth remained as yellow 
was identified as the MIC. In the presence of viable cells, the yellow color of MTT will change 
to purple due to the presence of insoluble formazon. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
1 
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3 
4 
5 
6 
7 
8 
A     B     C + 200 µl test agent 
+ 100 µl 
+ 100 µl 
+ 100 µl 
+ 100 µl 
+ 100 µl 
+ 100 µl 
+ 100 µl 
- 100 µl discard 
= wells consist of 100 µl media prior to the serial dilution 
2-fold serial dilution 
= 100 µl of test agent taken from the top well and diluted in the bottom ones 
= empty well (well do not contain any media prior to dilution) 
After serial dilution,  
each wells was added 
with:  
+70 µl of broth media 
+ 30 µl of bacterial 
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3.3.4 Kinetic growth curve assay  
 
MRSA was grown in the presence of sub-MIC of ampicillin alone, sub-MIC of plant test agent 
alone and in combination. Concentrations of test agents used in this experiment were below 
MIC values to observe effects of these agents on MRSA growth curve. The selection of plant 
extracts and fractions are described in section 3.1 (see Table 3.1), 3.4.2 and 3.4.3. Tested     ? ?   ?Ǥ ? ?ɊȀȋ ?Ȁ ? to 1/64 x MIC). 
Plant test agents were tested at 1/4 x MIC, 1/8 x MIC and 1/16 x MIC. The respective MIC 
values for ampicillin, plant test agents were obtained from broth microdilution assay as 
described above  
 
Each well consisting test agent either alone or in combination was inoculated with  ? ?Ɋ ? ? ?5 CFU/ml. Following were the different 
conditions of MRSA growth in details; 
 
a)  MRSA alone; 170 µl of MHB (+ 2% NaCl) and 30 µl of bacterial suspension 
b)  MRSA in the presence of ampicillin (concentration range 1/2 x MIC to 1/64 x 
 MIC); 50 µl of ampicillin solution, 120 µl of MHB (+ 2% NaCl) and 30 µl bacterial 
 suspension 
c) MRSA in the presence of plant test agent (concentration used 1/4 x MIC, 1/8 x MIC, 
1/16 x MIC); 50 µl of, plant test agent, 120 µl of MHB (+ 2% NaCl) and 30µl of 
bacterial suspension 
d) MRSA in combination of ampicillin and plant test agent; 50 µl of plant test agent, 50 
µl of ampicillin solution, 70 µl of MHB (+ 2% NaCl) and 30 µl of bacterial suspension 
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All combinations were tested in triplicates on three different occasions. The assay was 
carried out using a 96-well microtitre plate. Plate was i   ? ? ?   OD was 
recorded at every hour for 24 hours (600 nm wavelength) with a multimode reader 
(Varioskan Flash, Thermo Scientific, USA).  
 
3.3.5 FIC index interpretation- Checkerboard method 
 
FIC indices for the combination treatments were calculated. Antibiotics were tested with 
concentration ranging from 0.78 to 25 ɊȀ in combination with plant test agents from 
0.05 to 3.0 mg/ml. The formula used was:  
FIC ampicillin = MIC of ampicillin in combination  MIC ampicillin alone 
FIC test sample = MIC of test sample in combination MIC of test sample alone  
FIC index = FIC of ampicillin + FIC of test sample 
Definition of the interaction between ampicillin and the test samples based on the FIC index 
is shown in Table 3.2 (White et al. 1996).   
 
Table 3.2 Interpretation of FIC index based on study by White et al. 1996. 
 
 
 
 
 
 
 
 
FIC Index Interpretation 
0.5 Synergy 
>0.5 but 4.0 Indifference 
4 Antagonism 
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3.3.6 Determination of ampicillin MIC in presence of plant test agents 
 
A broth microdilution method was employed to determine the MIC of ampicillin in presence 
of plant test agent. The antibiotics and test samples were prepared and combined as 
described in section 3.3.4. Both antibiotic and plant test agent were combined at 
concentration lower than MIC. The assay was carried out using a 96-well microtitre plate. 
Plate was incubated at 3 ? ? for 24 hours. 
 
After the incubation period, 20 µl of 5 mg/ml of MTT (Nacalai Tesque, Japan) 
prepared in sterile distilled water was added to the wells containing combination of 
ampicillin with plant test agent. The lowest concentration of ampicillin in the combination 
treatment at which the color of the broth remained as yellow was identified as the new MIC 
for ampicillin. All combinations were tested in triplicates on three different occasions. 
 
3.3.7 Western blot analysis 
 
The bioactive fraction FC-B and 75EA-L-F10 was selected for study of the effects of plant 
test agents in combination with ampicillin on PBP2a expression.  The Western blot assay 
was carried out on the combination treatments i) 1/32 x MIC ampicillin + 1/4 x MIC FC-B 
and ii) 1/64 x MIC ampicillin + 1/4 x MIC 75EA-L-F10 and on each test agent separately. The 
tested concentrations for ampicillin were 1/16 x MIC, 1/32 x MIC and 1/64 x MIC. Plant test 
agents were tested at 1/4 x MIC and 1/8 x MIC.  The MIC values for ampicillin and the 
selected fractions were obtained from broth microdilution assay (see section 3.3.3 and 
3.3.6). All the tested concentrations in this analysis are less than MIC value. This is because 
MIC of the tested antibacterial agents will inhibit MRSA growth therefore, prevents any 
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observation on how each agent affects the PBP2a expression For rationale of combination 
treatments selection see section 3.1 and  3.4.7 (Table 3.7). 
 
2.3.7.1  Materials 
 
Tris base (Promega, USA), ethylenediaminetetraacetic acid (EDTA) disodium salt 
(Dihydrate) (Promega, USA), DNAse I (Thermo Scientific, USA), powdered lysozyme 
(Thermo Scientific, USA), protein inhibitor cocktail (Thermo Scientific, USA), sodium 
chloride (Sigma, USA), sodium dihyrogen phosphate (Nacalai Tesque, Japan), Urea (Bio-Rad, 
USA), Pierce 660 nm protein assay kit (Thermo Scientific, USA), NuPAGE® 4-12% Bis-Tris 
Precast Gels (1.0mm X 12 well) (Invitrogen, USA), NuPAGE® 4-12% Bis-Tris Gel Cassettes 
(1.0mm X 10 well) (Invitrogen, USA), glycine (Bio-Rad, USA), UltraPureTM sodium dodecyl 
sulphate (SDS) (Invitrogen, USA), acrylamide (monomer) (Nacalai Tesque, Japan), 
ammonium persulfate (Bio-Rad, USA), ǡ ǡ Ǯǡ Ǯ-tetramethylethylenediamine (Nacalai ǡ Ȍǡ  ? -stained protein ladder (Invitrogen, USA), spectra 
multicolor broad range protein ladder (Thermo Scientific, USA), lithium dodecyl sulphate 
(LDS) sample buffer- non-reducing (4X) (Thermo Scientific, USA), Coomassie brilliant blue 
R-250 (Thermo Scientific, USA), glacial acetic acid (Merck, Germany), methanol (Merck, 
Germany), Tween® 20, Sigma Ultra (Sigma-Aldrich, USA),  and TMB membrane peroxidase 
substrate (1-C) (KPL, UK) 
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2.3.7.2  Protein extraction 
 
MRSA culture was grown in ampicillin alone, bioactive fractions alone (FC-B and 7EA-L-F10) 
and in combinations until late exponential phase in a 20 ml centrifuge tube. Size of 
inoculums used was 5 x 105 CFU/ ml in final volume of 10 ml.  All the samples were 
prepared as described section 3.3.1 and 3.3.2 prior to the experiment. 
 
 Bacterial protein was extracted by preparing the lysates in an extraction buffer 
containing Tris and EDTA. Culture supernatants were harvested via 7,500 rpm 
centrifugation at 4°C for 10 minutes (Eppendorf Centrifuges 5810, Germany). Collected 
pellets were then treated with 150 mg/ml lysozyme, DNase and protein inhibitors cocktail 
and subjected to 2 hours incubation at 37°C (Witeg WiseCube® WIS-20, Germany). The 
pellets were exposed to 15 minutes sonication (Bandelin Sonorex, Germany) in ice-bucket to 
enhance cell disruption. Following 15 minutes of centrifugation at 12,000 rpm (Eppendorf 
Centrifuges 5810, Germany), the pellets were obtained as the insoluble cytoplasmic protein 
extracts that were harvested in 50 µl elution buffer containing Tris, urea and sodium 
dihydrogen phosphate.  Then, the protein mixture was shaken at 1000 rpm, at 18 ?C for 30 
minutes. This followed by centrifugation for 15 minutes, at 12,000 rpm at 18 ?C. The 
supernatant was obtained as protein lysate which it concentrations were measured using 
Pierce 660 nm reagent assay (Thermo Scientific, USA). 
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3.3.7.3  SDS-PAGE and Western Blot Assay 
 
Extracted protein (3 µg/ml) was solubilised with 4 X LDS sample buffer (for optimal 
separation) and subjected to SDS - polyacrylamide (12%) gel electrophoresis run at 120 V. 
Upon completion the gel was stained in Coomassie Blue (Thermo Scientific, USA) staining 
solution until a clear background was obtained for scanning with GS- ? ? ? ? 
densitometer (Bio-Rad, USA).  
 
In Western blot analyses, electrophoresed gels were transferred to  ? 
nitrocellulose transfer membrane (Pall, USA). Membranes were incubated overnight at 4°C 
in gelatin from cold water fish skin (blocking agent) (Sigma, USA). Gelatin from cold water  ? ?ǡ
best for Western blotting (Riis 2001).The production of PBP2a from MRSA was detected by 
probing the membranes with mouse anti-PBP2a primary antibody (Denka Seiken, Japan) 
and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Thermo Scientific, USA) 
with dilution factor of 1:10,000. The same membranes were re-probed with anti-mouse 
horseradish peroxidase-linked secondary antibody (Abcam, UK) diluted to 1:10,000 to      ?ǡ  ?ǯǡ  ?ǡ  ?ǯ-tetramethylbenzidine (TMB) substrate 
(Nacalai Tesque, Japan). GAPDH was selected as loading control for Western blot 
experiments in this study. It is a cyctoplasmic enzyme (~37 kDa) involved in bacterial 
energy generation, a process which is essential for growth (Polgar 1964; Alvarez 2003). The 
enzyme is extensively preserved across all species, including bacteria, fungi and protozoa 
(Winram and Lottenbery 1996; Oliveira et al. 2012). Whereas, the antibodies used in this 
study were also used in preceding work on PBP2a expression; hence verify their reliabilities 
for this study (Ohwada et al. 1999; Katayama et al. 2003; Dordel et al. 2014).  
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Assay response was recorded using GS- ? ? ? ?   ȋ-Rad, 
USA) and recorded based on visual band intensity. Densitometry quantification of Western 
blot images were performed using Image J 1.38 programme (Windows version of National 
Institute of Health (NIH) Image software) and results were scored in percentage of 
expression (%) normalized to GAPDH control.   
 
3.4 RESULTS 
 
3.4.1 Minimum inhibitory concentration of antibiotics 
 
Both MRSA and MSSA were tested for antibiotic susceptibility against the following; 
ampicillin, methicillin and oxacillin. The MIC values were summarized in Table 3.3. As 
expected, a higher concentration of all the antibiotics tested was required to inhibit the 
growth of MRSA compared to MSSA. The difference is between 8-fold (ampicillin and 
methicillin) and 32-fold (oxacillin). The rest of the experiments in this chapter were Ǥǯ
useful drug used for treatment of bacterial infections caused by both Gram positive and 
negative. The WHO listed ampicillin as one of the most important medication required in 
basic health care system. It is also co-administered with sulbactam (a drug that inhibits 
beta-lactamase) for treatment of penicillin-resistant strains (WHO 2013). 
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Table 3.3 Minimum inhibitory concentration value for MRSA ATCC 43300 and MSSA ATCC 11632 
against beta-lactam drugs Values represent triplicates of three independent 
experiments. 
 
 
Beta-lactam drugs 
ȋɊȀȌ 
MRSA ATCC 43300                  MSSA ATCC 11632 
 
Ampicillin 50.00 6.25 
Methicillin 20.00 2.50 
Oxacillin 10.00 0.31 
 
 
3.4.2 Minimum inhibitory concentration of crude extract A. wilkesiana and fractions 
 
The crude extract A. wilkesiana (9EA), 6 major fractions and 13 semi-pure fractions were 
tested against MRSA and MSSA.   Results revealed only one of the major fractions (9EA-FA) 
did not exhibit any anti-staphylococcal activity. All the other major fractions exhibited 
antibacterial activity against MRSA and MSSA with the MIC ranging from 1.5 to 12 mg/ml . A 
lower MIC value was recorded for MSSA in comparison to MRSA for all active major 
fractions except 9EA-FB.  Interestingly, 9EA-FB was identified as the most potent major 
fraction. The MIC value was 8-fold lower than crude extract, 9EA. (Table 3.4). 
 
The MIC value against MRSA and MSSA for 9EA- FC was 2-fold lower than 9EA. 9EA-
FD whereas, has the same MIC value as 9EA for both MRSA and MSSA. 9EA-FC and 9EA-FD 
were selected for further isolation and purification. This is because the other major fractions 
were either 1) inactive against MRSA and MSSA, 2) did not demonstrate synergism with 
ampicillin in combination treatment, 3) insufficient in amount for further fractionation, or 
4) highly polar fraction that is unsuitable for fractionation using LC methods employed in 
this study ( Chapter 2). 
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 Evaluation of semi-pure fractions obtained from 9EA-FC and 9EA-FD revealed that 6 
out of 13 fractions exhibited anti-MRSA activity. The MIC values however, were not 
markedly lowered after the purification. The observed decreased in MIC values were 
between 2 to 4-fold only (Table 3.4). The lowest MIC value against MRSA and MSSA for a 
semi-pure fraction was 1.5 mg/ml for fraction FC-A. The other semi-pure fractions (that 
demonstrated activity) have MIC of 3 mg/ml against MRSA and 1.5 mg/ml against MSSA.  
 
 For the kinetic growth curve study, the fractions 9EA-FB, 9EA-FC, 9EA-FD, and FC-B 
were selected. These fractions demonstrated stable activity (consistent activity against 
MRSA and MSSA each time of the testing), available in sufficient amount for further assays 
and are mid-polar fractions which means they can be further separated using the LC 
methods employed in this study.  
 
3.4.3 Minimum inhibitory concentration of crude extracts D. grandiflora and 
fractions 
 
The MIC of D. grandifloraǯ   ȋ ? ?-L), bark extract (75EA-B) and their 
respective major fractions were determined. Crude extract 75EA-L and 75EA-B yielded 10 
and 9 fractions respectively. Antibacterial effects against MRSA and MSSA for 75EA-L were 
encouraging with an MIC of 3 mg/ml against both strains (see Table 3.5). However, all major 
fractions from the leaves extract did not affect MRSA and MSSA survival with exception of 
75EA-L-F10 with relatively low MIC of 0.75 mg/ml.  This is the major fraction that 
possessed the most potent anti-staphylococcal activity amongst the entire plant sample 
tested in this study  
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 MIC for 75EA-B against MRSA and MSSA was 3 mg/ml (Table 3.5). After 
fractionation, only 6 out of 9 major fractions exhibited antibacterial activity. The MIC of 5 of 
these major fractions (75EA-B-F5, 75EA-B-F6, 75EA-B-F7, 75EA-B-F8 and 75EA-B-F9) 
remained at 3 mg/ml for MRSA. Three of these major fractions (75EA-B-F6, 75EA-B-F7 and 
75EA-B-F8) also have same MIC (3 mg/ml) for MSSA. The other two major fractions (75EA-
B-F5 and 75EA-B-F9) have MIC value of 1.5 mg/ml against MSSA which was 2-fold lower 
compared to the crude, 75EA-B. 
 
 The major fraction 75EA-L-F10 was not further fractionated because the fraction 
was highly polar, therefore unsuitable to be fractionated via LC methods used in this study. 
Nevertheless, this fraction was selected for kinetic growth curve study. 75EA-B and major 
fractions derived from it was excluded from further fractionation and kinetic growth curve 
study due to poor yield. 
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Table 3.4 Minimum inhibitory concentration of crude extract A. wilkesiana (9EA) and its fractions 
against MRSA ATCC 43300 and MSSA ATCC 11632. Values represent triplicates of three 
independent experiments. 
 
 - not active, did not exhibit any inhibitory activity in the assay 
a Fraction selected for kinetic growth curve study 
b Fraction selected for further separation via LC methods (Chapter 2) 
 
 
 
 
 
 
 
 
Test Agents 
MIC (mg/ml) 
MRSA ATCC 43300      MSSA ATCC 11632 
Crude extract 
9EA 
 
 
12.0 
 
6.0 
Major fractions   
9EA-FA - - 
a9EA-FB 1.5 1.5 
a,b9EA-FC 6.0 3.0 
a,b9EA-FD 12.0 6.0 
9EA-FE 6.0 1.5 
9EA-FF 
 
3.0 1.5 
Semi-pure fractions   
FC-A 1.5 1.5 
aFC-B 3.0 3.0 
FC-C 3.0 3.0 
FC-D - - 
FC-E - - 
FC-F - - 
FC-G - - 
FD-A 3.0 3.0 
FD-B - - 
FD-C 3.0 - 
FD-D 3.0 - 
FD-E - - 
FD-F -  
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Table 3.5 Minimum inhibitory concentration for MRSA ATCC 43300 and MSSA ATCC 11632 against 
crude extracts of D. grandiflora (75EA-L and 75EA-B) and fractions. Values represent 
triplicates of three independent experiments.  
 
 
 
Test Agents 
MIC (mg/ml) 
MRSA ATCC 43300      MSSA ATCC 11632 
Crude extracts   
75EA-L 3.0 3.0 
75EA-B 
 
3.0 3.0 
Major Fractions (75EA-L)    
75EA-L-F1 - - 
75EA-L-F2 - - 
75EA-L-F3 - - 
75EA-L-F4 - - 
75EA-L-F5 - - 
75EA-L-F6 - - 
75EA-L-F7 - - 
75EA-L-F8 - - 
75EA-L-F9 - - 
a75EA-L-F10 
 
0.75 0.75 
Major Fractions (75EA-B)   
75EA-B-F1 - - 
75EA-B-F2 - - 
75EA-B-F3 - - 
75EA-B-F4 1.5 3.0 
75EA-B-F5 3.0 1.5 
75EA-B-F6 3.0 3.0 
75EA-B-F7 3.0 3.0 
75EA-B-F8 3.0 3.0 
75EA-B-F9 3.0 1.5 
      - not active, did not exhibit any inhibitory activity in the assay 
      a Fraction selected for kinetic growth curve study 
 
 
 
 
 
 
 
96 
 
3.4.4 Kinetic growth curves- effects of A. wilkesiana and ampicillin 
 
Combination treatments of ampicillin and plant samples from A. wilkesiana generally 
exhibited a larger inhibitory effect on the growth of MRSA compared to a single agent 
treatment. A maximum inhibition of up to 80% was observed when MRSA was treated with 
crude extract A. wilkesiana (9EA) alone indicating their antibacterial effects (see Figure 3.2). 
 
 
Figure 3.2 Effects of A. wilkesiana crude extract (9EA) on MRSA ATCC 43300 growth survival curve 
over 24 hours. The concentrations used were below the agents MIC (i.e. 1/4 x MIC, 1/8 x 
MIC and 1/16 x MIC). Cell growth was measured by using OD at 600 nm at indicated time 
point. The curves represent triplicates of three independent experiments. Error bars 
show the standard deviation (AMP= ampicillin, MIC= minimum inhibitory 
concentrations). 
 
 
 Ampicillin when tested at concentrations ranging from 1/2 x MIC (25 µg/ml) to 
1/64 x MIC (0.78 µg/ml), demonstrated a concentration dependant antimicrobial activity on 
MRSA. Treatment with ampicillin alone (1/32 and 1/64 x MIC) depicted an exponential 
growth similar to control MRSA (Figure 3.3).  
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Figure 3.3 Effects of ampicillin on MRSA ATCC 43300 growth survival curve over 24 hours. The 
concentrations used were below the agents MIC (i.e. 1/64 x MIC to 1/2 x MIC). Cell 
growth was measured by using OD at 600 nm at indicated time point. The curves 
represent triplicates of three independent experiments. Error bars show the standard 
deviation (AMP= ampicillin, MIC= minimum inhibitory concentrations). 
 
3.4.4.1  Effects of crude extract 9EA and ampicillin 
 
Combination treatment of 9EA and ampicillin showed total suppression of the bacterial 
survival (see Figure 3.4). The OD of MRSA growth started declining from the 5th hour and 
continued to decrease to a point below zero suggesting bacterial cells lysis Treatment with 
9EA alone appeared to have rapid antibacterial action based on sharp decline of OD within 2 
hours of incubation. However, after 12 hours MRSA seemed to have a slow and steady 
increase in the cell number.  In contrast, the combination treatment indicated potent anti-
MRSA activity.  
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Figure 3.4 Effects of ampicillin alone, 9EA alone and in combination on MRSA ATCC 43300 growth 
survival curve over 24 hours. The concentrations used were below the agents MIC (i.e. 
1/64 x MIC AMP and 1/8 x MIC 9EA). Cell growth was measured by using OD at 600 nm 
at indicated time point. The curves represent triplicates of three independent 
experiments. Error bars show the standard deviation (AMP= ampicillin, MIC= minimum 
inhibitory concentrations). 
 
3.4.4.2  Effects of bioactive fraction 9EA-FB and ampicillin 
 
Fraction 9EA-FB exhibited anti-MRSA action as shown in the Figure 3.5. Fraction 9EA-FB did 
not demonstrate any additive inhibitory effect on MRSA when combined with ampicillin. 
When 9EA-FB was introduced as treatment at different concentrations (1/2 to 1/16 x MIC), 
MRSA growth were seen to be affected adversely in concentration dependant manner 
(Figure 3.5a). At 1/16 x MIC 9EA-FB, there was no obvious antibacterial effect and the 
growth curve is similar to control MRSA. Experiment conducted on combination of 9EA-FB 
and ampicillin (Figure 3.5b) revealed that the combination treatment had poorer anti-MRSA 
activity compared to treatment with 9EA-FB alone which suggested presence of antagonistic 
effects in presence of ampiciilin. The examination on MRSA growth curves in 9EA-FB (1/2 to 
1/8 x MIC) treated cultures suggested that the fraction may have affected the lag phase in 
which this phase was extended up to 7 hours compared to control MRSA that progressed to 
grow into exponential phase by the 4th hour. Besides that, the growth curves of 9EA-FB 
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treated cultures also demonstrated shorter exponential with slow growth as a result of 9EA-
FB antimicrobial action.  
 
 
 
 
 
 
Figure 3.5 Effects of a) 9EA-FB alone and b) 9EA-FB in combination with ampicillin alone on MRSA 
ATCC 43300 growth survival curve over 24 hours. The concentrations used were below 
the agents MIC (i.e. 1/32 x MIC AMP and 1/16 x MIC to 1/2 x MIC 9EA-FB). Cell growth 
was measured by using OD at 600 nm at indicated time point. The curves represent 
triplicates of three independent experiments. Error bars show the standard deviation 
(AMP= ampicillin, MIC= minimum inhibitory concentrations). 
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3.4.4.3  Effects of bioactive fraction 9EA-FC and ampicillin 
 
Fraction 9EA-FC was experimented in growth curve assay at 1/4 x MIC, 1/8 x MIC and 1/16 
x MIC. The concentration 1/4 x MIC showed the most potent inhibitory activity on MRSA 
upon combination with ampicillin and 1/16 x MIC were devoid of any effect. Hence, we 
chose to present combination treatment of 1/4 x MIC 9EA-FC and ampicillin in this section.  
  
 Figure 3.6 represent MRSA growth in combination treatment of 9EA-FC with 
ampicillin. The graph revealed that combination of ampicillin and 9EA-FC managed to 
reduce MRSA growth curve to a below zero point with no increase detected in the OD during 
the incubation time compared to treatment of ampicillin or 9EA-FC alone.  This indicated 
that no growth occurred during incubation and possible cells lysis occurring at 19th hour. 
Also evident was the introduced treatments (1/32 x ampicillin- blue line, 1/4 x MIC 9EA-FC- 
red line and combination of both- green line) have similar growth rate during the first four 
hours of incubation. Nevertheless, as the bacterial cultures continued to grow into 
exponential stage (around 5th hour), suppression of cell division took place in the cultures 
that were exposed to 9EA-FC. This observation enable us to deduce that, besides attenuating 
MRSA growth throughout the exponential stage, 9EA-FC also appeared to act more actively 
in inhibiting MRSA growth at starting point of stationary phase (18th hour) based on the 
trend of declining OD.  
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Figure 3.6 Effects of ampicillin alone, 9EA-FC alone and in combination on MRSA ATCC 43300 
growth survival curve over 24 hours. The concentrations used were below the agents 
MIC (i.e. 1/32 x MIC AMP and 1/4 x MIC 9EA-FC). Cell growth was measured by using OD 
at 600 nm at indicated time point. The curves represent triplicates of three independent 
experiments. Error bars show the standard deviation (AMP= ampicillin, MIC= minimum 
inhibitory concentrations). 
 
3.4.4.4  Effects of bioactive fraction 9EA-FD and ampicillin 
 
Fraction 9EA-FD was studied at 1/4 x MIC, 1/8 x MIC and 1/16 x MIC. The concentration 
1/4 x MIC demonstrated the most potent suppression on MRSA growth when combined 
with ampicillin (Figure 3.7).   Combination treatment has displayed marked inhibition on 
MRSA growth during the entire incubation time.  Examination of these growth curves 
showed that during the first 4 hours, similar OD was recorded for cultures from all three 
treatments. However OD of cultures exposed to ampicillin (blue line) started to increase at 
5th hour showing similar trend as observed for control untreated. The increasing trend for 
these two growth curves (blue and purple line) at 5th was showing that the bacterium was 
progressing to grow into exponential phase. Whereas, the lower OD recorded from 5th hour 
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onwards in MRSA cultures treated with 9EA-FD alone showed that inhibitory activity by this ǯǤ 
 
 
Figure 3.7 Effects of ampicillin alone, 9EA-FD alone and in combination on MRSA ATCC 43300 
growth survival curve over 24 hours. The concentrations used were below the agents 
MIC (i.e. 1/64 x MIC AMP and 1/4 x MIC 9EA-FD). Cell growth was measured by using OD 
at 600 nm at indicated time point. The curves represent triplicates of three independent 
experiments. Error bars show the standard deviation (AMP= ampicillin, MIC= minimum 
inhibitory concentrations). 
  
3.4.4.5  Effects of bioactive fraction FC-B and ampicillin 
 
Fraction FC-B was tested at 1/4 x MIC, 1/8 x MIC and 1/16 x MIC. The concentration 1/4 x 
MIC suppressed MRSA growth the most when combined with ampicillin and presented here 
in Figure 3.8.  
 
MRSA growth in all treatments appeared similar for the first 3 hours of incubation. 
As the incubation time continues, growth curves of cultures exposed to FC-B (red and green 
lines) were substantially lower compared to cultures grown in ampicillin alone. This 
suggests that the antibacterial action possibly took place at 4th hour of incubation which is at 
the beginning of exponential phase. The OD of MRSA in FC-B alone although approximately 
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2-fold lower in contrast to control MRSA and ampicillin, the growth curve indicated that 
bacteria continues to grow. Whilst, in combination treatment, the OD had a very minor 
increase till the end of incubation period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Effects of ampicillin alone, FC-B alone and in combination on MRSA ATCC 43300 growth 
survival curve over 24 hours. The concentrations used were below the agents MIC (i.e. 
1/32 x MIC AMP and 1/4 x MIC FC-B). Cell growth was measured by using OD at 600 nm 
at indicated time point. The curves represent triplicates of three independent 
experiments. Error bars show the standard deviation (AMP= ampicillin, MIC= minimum 
inhibitory concentrations). 
 
3.4.5 Kinetic growth curves Ȃ effects of D. grandiflora and ampicillin  
 
Combination treatments of ampicillin and plant samples from D. grandiflora resulted in 
strong inhibition on MRSA growth with limited growth throughout incubation period.  
MRSA when grown in presence of ampicillin alone showed a concentration dependant 
inhibitory activity (see section 3.4.4). 
  
When tested alone, the crude extract D. grandiflora (75EA-L) demonstrated 
suppression on MRSA growth approximately 40% at 1/4 x MIC (Figure 3.9). At 1/8 x MIC 
(red line), 75EA-L displayed certain level of inhibition on MRSA growth with the OD was 
seen increasing steadily but still lower compared to control MRSA. Whereas, 75EA-L at 1/16 
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x MIC (green line) showed a weak antibacterial activity based on growth curve that was 
similar to control MRSA till 15th hour of incubation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Effects of D. grandiflora crude extract (75EA-L) on MRSA ATCC 43300 growth survival 
curve over 24 hours. The concentration used were below the agents MIC (i.e. 1/4 x MIC, 
1/8 x MIC and 1/16 x MIC). Cell growth was measured by using OD at 600 nm at 
indicated time point. The curves represent triplicates of three independent experiments. 
Error bars show the standard deviation (AMP= ampicillin, MIC= minimum inhibitory 
concentrations). 
 
 
3.4.5.1  Effects of crude extract 75EA-L with ampicillin  
 
Figure 3.10 is showing the effects of 75EA-L and ampicillin on MRSA growth. Combination 
treatment of 75EA-L with ampicillin was able to completely inhibit MRSA growth as no 
increase in OD recorded during incubation time. In fact, a very strong antibacterial effect 
was exhibited in the combination treatment. Although the OD of culture grown with 75EA-L 
alone (red line) increased steadily till the 18th hour before declining, the growth was still 2-
fold lower compared to cultures grown in 1/64 x MIC ampicillin alone (blue line) and 
control MRSA (purple line). Inhibition of growth possibly began during lag phase and 
continued through the exponential stage based OD that increased slowly from 0 to 18th  hour 
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in treatment of 75EA-L alone while in untreated cultures, increase in OD was noted from the 
4th hour onwards with a clearly defined exponential stage.  
 
 
Figure 3.10 Effects of ampicillin alone, 75EA-L alone and in combination on MRSA ATCC 43300 
growth survival curve over 24 hours. The concentrations used were below the agents 
MIC (i.e. 1/64 x MIC AMP and 1/4 x MIC 75EA-L). Cell growth was measured by using OD 
at 600 nm at indicated time point. The curves represent triplicates of three independent 
experiments. Error bars show the standard deviation (AMP= ampicillin, MIC= minimum 
inhibitory concentrations). 
 
3.4.5.2  Effects of bioactive fraction 75EA-L-F10 with ampicillin  
 
Fraction 75EA-L-F10 in combination with ampicillin successfully prevented MRSA growth 
and remained constant from the start of the experiment until the end of incubation time 
(Figure 3.11). In presence of 75EA-L-F10 (red line), the growth of MRSA was suppressed by 
about 2-fold. It was evident that MRSA was suppressed at lag phase which possibly 
prevented the bacterium from growing into exponential phase. This can be visualized in the 
graph between the 5th to 7th hour, in which the curve of control MRSA increased rapidly, but 
growth curves of 75EA-L-F10 treated cultures were demonstrating almost a still OD.  
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Figure 3.11 Effects of ampicillin alone, 75EA-L-F10 alone and in combination on MRSA ATCC 43300 
growth survival curve over 24 hours. The concentrations used were below the agents 
MIC (i.e. 1/64 x MIC AMP and 1/4 x MIC 75EA-L-F10). Cell growth was measured by using 
OD at 600 nm at indicated time point. The curves represent triplicates of three 
independent experiments. Error bars show the standard deviation (AMP= ampicillin, 
MIC= minimum inhibitory concentrations). 
 
3.4.6 FIC index interpretation for combination treatments 
 
 Interpretation of FIC index was carried out for combination treatments consisting of 
ampicillin and plant test agents. In total, 108 combinations were tested. The FIC index for 
each combination is summarized in Table 3.6. 
 
 Forty-eight combinations showed synergistic based on FIC < 0.5. Out of these, 27 
combinations were with plant test agents at 1/4 x MIC. A drop in the number of synergistic 
interaction recorded with a lower concentration of these plant test agents. There were only 
17 and 4 synergistic combination recorded for 1/8 x MIC and 1/16 x MIC of the plant test 
agents respectively. Similar observation was recorded for ampicillin where the highest 
number of synergistic interaction was recorded in combination treatment containing 1/4 x 
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MIC ampicillin. At lower concentration of ampicillin, there is increasingly more combination 
treatment exhibiting no antibacterial effect. Interestingly, presence of 1/2 x MIC ampicillin 
in combination treatments produced almost all indifference and two treatments without any 
antibacterial effect.  
 
Further examination on the FIC indices indicated that the synergy interactions in 
inhibiting MRSA growth depends on concentration of both of the agents as lesser 
combinations with FIC index < 0.5 (synergy) was observed when concentration of the test 
agents were reduced. When both of the agents were present at the lowest tested 
concentration (1/16 x MIC plant test agents and 1/64 x MIC ampicillin), no synergistic 
interaction or antimicrobial action was observed. At 1/8 x MIC, only crude extract 9EA was 
seen to interact synergistically with 1/64 x MIC ampicillin.  
 
Each plant test agent was compared individually, and crude extract A. wilkesiana 
(9EA) interacted synergistically with ampicillin in 11 synergistic combinations.  This was 
followed by crude extract D. grandiflora (7EA-L) and its bioactive fraction, 75EA-L-F10 with 
9 combinations each. Fraction FC-B, 9EA-FC and 9EA-FD recorded 8, 6 and 5 combinations 
with synergistic interaction respectively. Combination of 1/8 x MIC 9EA + 1/64 x MIC 
ampicillin was identified as the combination expressing the highest synergistic interaction. 
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Table 3.6 Fractional inhibitory concentration indices interpretation for combinations of sub-MIC 
ampicillin with sub-MIC crude extract and bioactive fractions from A. wilkesiana and D. 
grandiflora. Experiments were carried out in triplicates on three separate occasions 
(MIC= minimum inhibitory concentrations).  
 
 
 
 
Sub-MIC  
extract/fraction 
(mg/ml) 
FIC Index (Interpretation) 
 
 
 Combined with Sub-ȋɊȀȌ 
 
1/2 x MIC 
(25.00) 
1/4 x MIC 
(12.50) 
1/8 x MIC 
(6.25) 
1/16 x MIC 
(3.13) 
1/32 x MIC 
(1.56) 
1/64 x MIC 
(0.78) 
 
       
9EA       
1/4 x MIC (3.00) 0.75 (I) 0.50 (S) 0.38 (S) 0.31 (S) 0.28 (S) 0.27 (S) 
1/8 x MIC (1.50) 0.63(I) 0.38 (S) 0.25 (S) 0.19 (S) 0.16 (S) 0.14 (S) 
1/16 x MIC (0.75) 0.56(I) 0.31(S) c- - - - 
       
9EA-FC       
1/4 x MIC (1.50) 0.63(I) 0.38 (S) 0.25 (S) 0.19 (S) 0.16 (S) - 
1/8 x MIC (0.75) 0.57(I) 0.31 (S) 0.19 (S) - - - 
1/16 x MIC (0.38) - - - - - - 
       
9EA-FD       
1/4 x MIC (3.00) 0.75(I) 0.50 (S) 0.38 (S) 0.31 (S) 0.28 (S) - 
1/8 x MIC (1.50) 0.63(I) 0.38 (S) - - - - 
1/16 x MIC (0.75) - - - - - - 
       
FC-B       
1/4 x MIC (0.75) 0.75(I) 0.43 (S) 0.38 (S) 0.31 (S) 0.28 (S) - 
1/8 x MIC (0.38) 0.65(I) 0.36 (S) 0.25 (S) 0.19 (S) - - 
1/16 x MIC (0.19) 0.56(I) 0.31 (S) - - - - 
       
75EA-L       
1/4 x MIC (0.75) 0.75 (I) 0.50 (S) 0.38(S) 0.31(S) 0.28(S) 0.27(S) 
1/8 x MIC (0.38) 0.63(I) 0.38(S) 0.25(S) 0.19(S) - - 
1/16 x MIC (0.19) 0.56(I) 0.31(S) - - - - 
       
75EA-L-F10       
1/4 x MIC (0.19) 0.75(I) 0.50(S) 0.38(S) 0.31(S) 0.28(S) 0.27(S) 
1/8 x MIC (0.09) 0.63(I) 0.38(S) 0.25(S) 0.19(S) - - 
1/16 x MIC (0.05) 0.53(I) 0.28(S) - - - - 
       
I= abbreviation for indifference 
S= abbreviation for synergy 
 - = no effect was observed/ no antimicrobial activity  
For interpretation of FIC index; synergism 0.5, indifference >0.5 but 4.0, and antagonism 4 
(White et al. 1996).   
 
109 
 
3.4.7 Summary of synergistic interaction for combination treatment with ampicillin 
and plant test agents 
 
The two methods applied in studying synergism between plants test agents and ampicillin 
confirmed that the combination treatments can potentiate the antibacterial effects against 
MRSA. Growth curve experiments presented possible synergistic interaction visually whilst 
the FIC index gave a definite quantitative measure of the synergism present. Based on these 
two experiments, a reduced MIC of ampicillin against MRSA was determined in presence of 
these plant test agents (see Table 3.7). 
 
 Interestingly, all the major fractions (9EA-FC and 9EA-FD) and semi-pure fraction 
(FC-B) appeared to have a lower ability to reduce the MIC value of ampicillin compared to 
the crude extract A. wilkesiana (9EA). There was only 32-fold reduction compared to 64-fold 
reduction of MIC value of ampicillin respectively (see Table 3.7). However, the 
concentration of FC-B needed to suppress MRSA in combination treatment is 0.75 mg/ml is 
2-fold lower compared to 9EA. This can be readily justified based on the fact that FC-B is a 
semi-pure fraction, hence, the active metabolites in this fraction is concentrated. Both plant 
test agents from D. grandiflora exhibited similar ability to reverse MRSA sensitivity to 
ampicillin by 64-fold. Our results showed that we could reverse the resistance of MRSA to 
ampicillin via combination treatment.  Based on the results from these two experiments we 
selected two combination treatments for the study of PBP2a expression in MRSA. The two 
combinations are 1/32 x MIC ampicillin + 1/4 x MIC FC-B and 1/64 x MIC ampicillin + 1/4 x 
MIC 75EA-L-F10 which lowered MIC of ampicillin to 1.56 µg/ml and 0.78 µg/ml.  
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Table 3.7 Minimum inhibitory concentration ampicillin in combination treatment of extracts and 
fractions from of A. wilkesiana and D. grandiflora. Experiments were carried out in 
triplicates on three separate occasions (MIC= minimum inhibitory concentrations).  
 
Combined with  
(sub-MIC= mg/ml) 
New MIC ampicillin 
ȋɊȀȌ 
 
Ampicillin alone 50.00 
                  + 9EA (1/8 x MIC =1.50) 0.78 
                  + 9EA-FC (1/4 x MIC = 1.50) 1.56 
                  + 9EA-FD (1/4 x MIC = 3.00) 1.56 
                  + FC-B (1/4 x MIC = 0.75) 1.56 
                  + 75EA-L (1/4 x MIC =0.75) 0.78 
                  + 75EA-L-F10 (1/4 x MIC = 0.19) 0.78 
 
3.4.8 Inhibition of PBP2a by FC-B 
 
PBP2a band was absent in MSSA strain which was used as control in our study, thus 
confirming that this strain is methicillin susceptible and do not produce the resistant 
protein, PBP2a. GAPDH which is the housekeeping protein was expressed in all the tested 
samples  
 
 Ampicillin was tested at two different concentrations; 1/16 x MIC (3.13 µg/ml) and 
1/32 x MIC (1.56 µg/ml), and from Figure 3.12a (lane 3 and 4), it is evident that the 
antibiotic intensified production of PBP2a in MRSA as represented by the very intense Ǥ ?ǯ
to control MRSA suggesting induction of PBP2a production in presence of ampicillin. 
Densitometry analysis showed that the expressed bands were 124.02% and 148.10% for 
1/16 x MIC ampicillin and 1/32 x MIC ampicillin respectively, compared to control MRSA.  
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Based on Figure 3.12a (lane 5 and 6), FC-B at 1/4 x MIC (0.75 mg/ml) and 1/8 x MIC 
(0.38 mg/ml) have adverse effect on PBP2a production. No band was observed at 1/4 x MIC 
of FC-B. Weak band intensity was recorded at 1/8 x MIC FC-B and densitometry analysis 
showed only 6.15% of PBP2a expression (Figure 3.12b).  In the combination treatment (1/4 
x MIC FC-B + 1/32 x MIC ampicillin - Figure 3.12a, lane 7) no PBP2a band was found.  
 
3.4.9 Inhibition PBP2a by 75EA-L-F10 
 
The results of the treatments consisting ampicillin alone, 75EA-L-F10 alone and in 
combination is depicted in Figure 3.13. As expected the MSSA strain did not express any 
PBP2a band indicating absence of the protein. Bands for the housekeeping protein, GAPDH 
were expressed in all treated cultures.  
 
MRSA cultures in ampicillin alone (1/32 x MIC = 1.56 µg/ml and 1/64 x MIC= 0.78 
µg/ml), expressed a very intense PBP2a bands (Figure 3.13a, lane 3 and 4). These bands 
were expressed as high as 157.82% in treatment of 1/64 x MIC ampicillin in contrast to 
control MRSA when quantified using the densitometric analysis. Therefore suggest that 
presence of ampicillin induces production of PBP2a. 
 
Based on the Western blot image (Figure 3.13a, lane 5 and 6), 75EA-L-F10 has 
suppressed production of PBP2a at 1/4 x MIC (0.19 mg/ml) and 1/8 x MIC (0.09 mg/ml) in 
MRSA. Faint PBP2a bands were observed at 1/4 x MIC and 1/8 x MIC of 75EA-L-F10. 
Densitometry analyses showed their expression were 17.35% and 18.30% respectively 
(Figure 3.13b).  No PBP2a band was detected in combination treatment of 1/64 x MIC 
ampicillin + 1/4 x MIC 75EA-L-F10 (Figure 3.13a, lane 7).    
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a) 
 
         
 
   
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
Figure 3.12 a) Western blot of PBP2a expression in MRSA cells treated with FC-B and ampicillin. The 
extracted protein (3 µg/ml) was subjected to 12% SDS-PAGE prior to the blotting and 
presence of PBP2a was detected with mouse anti-PBP2a primary antibody and anti-mouse 
horseradish peroxidase-linked secondary antibody. b) Quantitative densitometric analysis 
of PBP2a expression in MRSA. PBP2a bands expression were normalized to GAPDH control 
(AMP= ampicillin, MIC= minimum inhibitory concentration, n=2).  
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Figure 3.13 a) Western blot of PBP2a expression in MRSA cells treated with 75EA-L-F10 and 
ampicillin. The extracted protein (3 µg/ml) was subjected to 12% SDS-PAGE prior to 
the blotting and presence of PBP2a was detected with mouse anti-PBP2a primary 
antibody and anti-mouse horseradish peroxidase-linked secondary antibody. b) 
Quantitative densitometric analysis of PBP2a expression in MRSA. PBP2a bands 
expression were normalized to GAPDH control (AMP= ampicillin, MIC= minimum 
inhibitory concentration, n=2).  
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3.5  DISCUSSION  
 
Experiments conducted in this chapter aimed to 1) evaluate antibacterial effects of 
selected crude extracts and fractions from A. wilkesiana and D. grandiflora, 2) investigate 
their possible synergistic action with a beta-lactam antibiotic, ampicillin as antibacterial 
agent and 3) study the effect of selected synergistic combination treatments on PBP2a 
expression. Assessment of the MIC values revealed that the selected plant test agents 
demonstrated anti-MRSA and anti-MSSA activities. Study of combination treatment has 
shown that synergistic interaction occurred between the plant test agents and ampicillin 
in suppressing MRSA growth. We also observed that we can reverse MRSA resistant to 
ampicillin by using combinational therapy with plant metabolites.  Study on PBP2a 
expression indicated that the combination treatments suppressed the production of this 
protein.  
 
3.5.1 Evaluation of Antimicrobial Activity 
 
Susceptibility testing was employed initially to confirm resistance of MRSA strain used 
in this study. The MIC of methicillin against MRSA (strain ATCC 43300) value was 20 ɊȀ confirmed that this strain is resistant based on breakpoints interpretations; of   ?  ?ɊȀ  ?  ?ɊȀȋ ? ? ? ?ȌǤt to methicillin 
also means resistant to all other beta-lactams and cephalosporins (CLSI 2007). We also 
observed that this strain (MRSA ATCC 43300) showed high res ȋ  ?  ? ? ?ɊȀȌ    Ǥ  The MIC of ampicillin against MSSA ATCC 11632 
strain was 6.2 ? ɊȀǡ is within the acceptable range of susceptibility. A beta-
lactam antibiotic inhibits the PBPs involved in late stage of peptidoglycan biosynthesis. 
Interference with peptidoglycan biosynthesis causes deformities in the bacterial cell wall 
and eventually leads to cell death due to high internal osmotic pressure (Lambert 2004). 
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Nevertheless, there are at least two mechanisms that Staphylococci can evade beta-        ?    Ⱦ-lactamases 
(Gillespie et al. 1985).  Due to expression of these two proteins, MRSA confers resistance 
to beta-lactams which was evidently shown by the high MIC values recorded for these 
antibiotics in this study. To counteract the resistant mechanism displayed by MRSA, we 
tested crude extracts and fractions from A. wilkesiana and D. grandiflora as potential 
anti-MRSA agents. 
  
 Evaluation of crude extract of A. wilkesiana (9EA) showed that the extract has 
modest anti-MRSA activity (MIC = 12 mg/ml).  When the extract was fractionated, the 
obtained major fractions and semi-pure fractions demonstrated a better antibacterial 
action based on a decrease of the MIC ranging from 1.5 to 6.0 mg/ml. This showed an 
increase of up to 8-fold for anti-MRSA activity among the bioactive fractions.  9EA 
demonstrated anti-MSSA activity with MIC of 6 mg/ml. The major fractions and semi-
pure fractions exhibited a better activity as represented by MIC values between 1.5 to 
3.0 mg/ml. Based on these MIC values, it is likely that 9EA and its fractions contained 
bioactive plant metabolites that contributed to the observed antibacterial activities.   
 
 The anti-staphylococcal activities shown by 9EA and its respective fractions is in 
agreement with previous studies on isolation of antibacterial compounds such as 
corilagin, ethyl gallate and geraniin from A. wilkesiana extracts (Adesina et al. 2000; 
Shimizu et al. 2001; Sato et al. 2004). Investigation on mode of action has shown that 
these compounds cause cell lysis leading to bacterial death in S. aureus species (Din et al. 
2013a). This indicates that the similar phenomena could have contributed to anti-MRSA 
and anti-MSSA activity of plant test agents obtained from A. wilkesiana. Besides, the 
compounds corilagin and geraniin were found to infer with the mechanism of resistance 
displayed by MRSA namely, production of PBP2a (Shimizu et al. 2001). In a separate 
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study, tannins (which are frequently isolated from A. wilkesiana) have been reported to 
be capable of binding to peptidoglycan and destroy the bacterial cell wall integrity which 
eventually results in growth inhibition (Zhao et al. 2001; Zhao et al. 2002).  The 
information compiled from previous studies shows A. wilkesiana may affect S. aureus Ǥǡǯ
activities against both MRSA and MSSA in this study.   
  
MIC evaluation of D. grandiflora extracts (75EA-L and 75EA-B) indicated that 
these extracts are more active in inhibiting MRSA growth compared to 9EA based on the 
MIC value of 3 mg/ml. This value is 4-fold lower compared to MIC of 9EA against MRSA, 
which was 12 mg/ml. Despite of the relativity better antibacterial activity, only 7 out of 
19 isolated major fractions from the D. grandiflora extracts affected MRSA growth. There 
was only one active fraction (75EA-L-F10) derived from 75EA-L and 6 active fractions 
from 75EA-B. These major fractions displayed minimal improvement in the antibacterial 
effect after the fractionation process. The crude extracts and the major fractions 
exhibited similar antibacterial effects on MSSA. MIC of crude extracts against MSSA is 3 
mg/ml. This value remained the same in some of the major fractions. Whilst in others 
the MIC value decreased by just 2-fold except in 75EA-L-F10 in which we observed a 4-
fold decrease.  
 
The inhibitory activity shown by both the crude and fractions from D. grandiflora 
in this experiment suggested prospective existence of antimicrobial properties since 
earlier research conducted in our lab has shown that these extracts have anti-
staphylococcal activities and contain biologically active phytochemicals such as tannins, 
alkaloids, flavonoids, and steroids (Othman et al. 2011a, Othman et al. 2011b).  
Literature search indicated limited studies on antibacterial agents of D. grandiflora while 
most of the isolated active compounds reported to have anti proliferative actions against 
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cancer cells (Tsukiyama et al. 2010; Kaweetripob et al. 2012). Hence, while we are able 
to deduce that the antibacterial effects exhibited by D. grandiflora are contributed by the  ǡ          ǯ
antibacterial activity at this stage due to limited research on the plant.  
 
 Evaluation of MIC on crude extracts and fractions obtained from A. wilkesiana 
and D. grandiflora has enabled us to identify the fractions that exhibited antibacterial 
activity. However, we observed that the bioassay-guided fractionation process has 
resulted in the loss of activity in some of the major fractions when they were further 
separated into semi-pure fractions. Some fractions simply retained their activity after 
the fractionation process when we hypothesized an improvement in the bioactivity as 
this process was supposed to concentrate the active metabolites. Our observation 
suggests that the active metabolites may be spread across several fractions from the 
extract. The possible reason is that less pure fractions contain a number of compounds 
that work synergistically to produce the observed antibacterial effect. Fractionation has  ǡ ǲǳ  ǲǳ    (Bucar et al. 2013). Hence, the 
fraction loses or shows no improvement in its antimicrobial activity when it is separated 
into smaller units.  These reasons explain why a major fraction from 9EA (9EA-FD) 
exhibited similar MIC value as the crude extract and that all the fractions from 75EA-L 
lost their antibacterial effect. In the plant kingdom, it is known that the secondary 
metabolites produced typically have weak antibacterial activity. Nonetheless, since 
plants adopt strategy of synergism, the produced metabolites interact with each other 
synergistically in overcoming infections (Hemaiswarya et al. 2008). Hence, this 
phenomenon may clarify the lost or no change in bioactivity of some fractions.  
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3.5.2 Combination of crude extracts or bioactive fractions from A. wilkesiana and 
 D.  grandiflora and ampicillin synergistically inhibits MRSA growth  
 
Concept of synergism is applied to treat infections caused by deleterious pathogens to 
tackle the complex multi-drug resistance issues (Hemaiswarya et al. 2008). A review by 
Gibbons, compiled antibacterial and modifying resistance properties of compounds from 
plant origin against Staphylococcal species showing use of plant products as anti-
staphylococcal agents (Gibbons 2004).  Several compounds, such as epicatechin gallate, 
totarol and corilagin reversed methicillin-resistance in MRSA by reducing MIC of beta-
lactams when combined (Nicolson et al. 1999; Hamilton-Miller and Shah 2000; Shimizu 
et al. 2001). These findings impetus the hypotheses that usage of plant extracts, 
especially of ethnobotanical value, in combination with beta-lactam could be a rational 
strategy in manipulating resistance factor of MRSA, subsequently inhibit MRSA growth. 
 
 Results obtained from kinetic growth curve assay and FIC index interpretations 
have demonstrated that the crude extracts and bioactive fractions from the medicinal 
plants, A. wilkesiana and D. grandiflora work synergistically with ampicillin in 
suppressing MRSA growth. This was evidently depicted in MRSA growth curves in which 
growth suppression was observed in cultures that were grown in combination 
treatment. Subsequently, the FIC index interpretation further affirmed the synergistic 
action. The results from these two experiments also indicated the reversal of ampicillin-
resistance in these cultures (MIC of ampicillin changed from 50 µg/ml to 1. 56 µg/ml and 
0.78 µg/ml) in the presence of plant test agent. Therefore, proposing that presence of 
these extracts or fractions potentiate antimicrobial action of ampicillin against MRSA.  
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3.5.2.1  Kinetic growth assay for plant test agent in combination with  
  ampicillin  
 
Kinetic growth assay provided a platform to observe ǲǳantibacterial action of all 
different treatments against MRSA growth curve. All the test agents were tested at 
concentration below MIC to ensure the concentration used is not affecting cell survival. 
From our findings, we deduced two prominent patterns of growth curves in combination 
treatments of ampicillin and plant test agents; 1) growth curves that were reduced with 
time and reached OD below zero and 2) growth curves that indicated very minimal 
increase in OD and remained constant during the incubation period.   
 
Generally, the results showed an improved suppression on MRSA growth when 
the plant test agent and ampicillin were combined. Our findings also revealed that 
ampicillin when tested alone at 1/32 x MIC and 1/64 demonstrated a very poor 
inhibition of MRSA growth. In fact, the growth curve in these treatments resembles 
control MRSA. However, the same concentration of ampicillin when combined with plant 
test agents exhibited marked suppression on MRSA growth. Therefore, we propose that 
presence of plant test agent potentiates antibacterial effects of ampicillin. 
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a)  A. wilkesiana extract and fractions  
 
Examination of MRSA growth curve in presence of 9EA (crude extract A. wilkesiana) 
alone showed a strong antibacterial effects (~80% inhibition). Whilst growth curves of 
MRSA treated with fractions from 9EA (9EA-FC, 9EA-FD and FC-B) alone revealed that 
these fractions were less effective (~30 to 40% inhibition) in suppressing MRSA growth 
compared to 9EA. Nevertheless, both 9EA and these fractions demonstrated an 
enhanced inhibition on MRSA growth when combined with ampicillin. This shows that 
9EA and the fractions possess antibacterial properties that contributed to the observed 
activities either alone or in combination treatment. These antibacterial properties may 
have several mechanism of action which affected MRSA growth. 
 
Previous studies have shown that metabolites from A. wilkesiana affected growth 
of S. aureus by causing bacterial cell lysis and interfering with bacterial protein 
production (section 2.5.1). While this offer plausible explanation for suppression of 
MRSA growth by the plant agents alone, the enhanced anti-MRSA in the combination 
treatment indicates the plant test agents may target resistance factors in MRSA.  
Interference with the resistance factor makes the bacterium susceptible to ampicillin, 
hence, resulting in suppressed MRSA growth curve. 
 
In combination treatment of 9EA and ampicillin, MRSA survival curve was 
observed to plunge to a point below zero by the 4th hour. The plunging trend in the 
combination treatment and the strong inhibition by 9EA alone suggests a rapid killing of 
bacterium possible through lytic action. This is because an aggressive lytic action will 
disrupt the cell wall and following this event cells are being fragmented and become 
debris (Jackson and Kropp 1992; Leekha et al. 2011). As such, OD of the bacterial culture 
may reduce to a point below zero. Extract of A. wilkesiana has been previously 
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recognized to contain an active ingredients ellagitannin that was shown to act 
synergistically with ampicillin in suppressing S. aureus growth. The same research also 
reported that upon exposure to extract containing ellagitannin, the bacterial cells were 
observed to have deformed cell surface in addition to indentation which compromised ǯ ȋǤ  ? ? ? ?ȌǤ
ampicillin is not clear, but the research suggested the synergistic action resulted in S. 
aureus cell lysis. From these reports, we deduced that similar antibacterial action took 
place in combination treatment leading to total bacterial cell lyses. However, the 
enhanced antibacterial action can also be an outcome from synergistic interactions such 
as 1) multi-target effects that cooperate in agonistic way due to the mixture of plant 
metabolites in 9EA or 2) adverse interaction with resistance mechanism, since our study 
was carried out on MRSA (Wagner and Ulrich-Merzenich 2009). 
 
An improved antibacterial activity was observed when A. wilkesiana fractions 
(9EA-FC, 9EA-FD and FC-B) were combined with ampicillin. Fraction 9EA-FB although 
did not exhibit any synergism in inhibiting MRSA growth when combined with 
ampicillin, the fraction still demonstrated anti-MRSA activity alone. The MRSA growth 
curve remained almost constant during the incubation period with no or very minimal 
increase in OD. This indicated the prevention of bacterial growth and reproduction. 
Exhibition of such effect suggest a potential bacteriostatic action in the combination 
treatments. Bacteriostatic action is when an agent limits the bacterial growth via 
interference with bacterial protein production, DNA replication and other aspects of 
bacterial cellular metabolism (Pankey and Sabath 2004; Leekha et al. 2011). Since PBP2a 
is a bacterial protein, it is possible that the suggested bacteriostatic action occurred as 
result of inhibition of this protein. In addition, PBP2a is a resistant protein and 
interference of its production by the plant test agent could lead to synergistic action as 
observed in the combination treatments. We postulate this event reversed methicillin 
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resistance in MRSA and cause the bacterium to be susceptible to ampicillin again in 
combination treatments. This is further supported by findings of the compounds 
corilagin and gallic acid in A. wilkesiana extracts (Adesina et al. 2000; Madziga HA et al. 
2010; Din et al. 2013b). These compounds in a separate study were found to reverse 
methicillin-resistance in MRSA via PBP2a inhibition (Shimizu et al. 2001).   
 
b)  D. grandiflora extract and fractions  
 
Investigation on the crude extract of D. grandiflora (75EA-L) and a bioactive fraction 
isolated from it (75EA-L-F10) revealed that both of these plant test agents have similar 
antibacterial effect on MRSA growth (~40% inhibition) when tested alone. Combination 
of these plant test agents and ampicillin showed an increased suppression on MRSA 
growth. The combination of crude extract 75EA-L and ampicillin was observed to exhibit 
greater inhibition on MRSA compared to combination of 75EA-L-F10 and ampicillin. This 
is because presence of 75EA-L in the combination treatment was observed to reduce the 
OD of the bacterial growth to below zero. Whereas 75EA-L-F10 and ampicillin although 
did not reduce the bacterial growth to below zero, the combination still effectively 
suppressed MRSA growth since the OD recorded remained almost constant with  minor 
increase .   
 
 Growth curve of MRSA in combination treatments consisting plant test agents 
from D. grandiflora displayed a minor or no increase in OD during the incubation period. 
This observation is identical to growth curve of MRSA in presence of 9EA and ampicillin 
which represent a bacteriostatic action to a certain extent. The similar MRSA growth 
curves pattern in presence of 75EA and 75EA-L-F10 implies that same plant metabolites 
may occur in these test samples and are involved in inhibiting MRSA growth. So far, no 
antibacterial compound has been isolated from D. grandiflora. However, Othman et al. 
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(2011a and 2011b) detected alkaloids, tannins, saponin and flavonoids in the D. 
grandiflora extracts that showed antibacterial activity. 
 
Plant metabolite such as flavonoid is often attributed to biological activities. 
Earlier, the compound licoricidin from flavonoid group has been reported to work 
synergistically with oxacillin and the combination was found to have bacteriostatic 
action on MRSA. .  Mechanism of action of licoricidin is attributed to the compoǯ
affinity to bind to bacterial cell membrane. Since licoricidin targets bacterial cell ǡ ?ǯ
indirectly (Hatano et al. 2005). Hence the finding of flavonoid in D. grandiflora offers 
some rationale for the observed anti-MRSA activity of the test agents in growth curve 
study both alone and in combination. Besides that, previous studies show plant 
metabolites have tendency to bind protein including PBPs or cell-wall building blocks 
which explains their antibacterial activity against MRSA (Hatano et al. 2005; Hu et al. 
2001; Hu et al. 2002; Shiota et al. 2004).  Taken this information together, we 
hypothesize that D. grandiflora test agents contains metabolites which influence    ?     ǯ   
treatments. Nevertheless, the occurrence of mixture of plant metabolites in D. 
grandiflora suggests several mechanisms may be involved in its antibacterial activity.  
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3.5.2.2  Transpiration point of inhibition 
 
Besides giving indication of the type of antibacterial activity, kinetics growth curves can 
be used to determine the transpiration point of inhibition especially in closed liquid 
batch culture as implemented in this study. Bacterial reproduction and growth kinetics 
is divided into four phases; lag or adaptive phase, exponential phase, stationary phase, 
and death phase (Figure 3.14).  
 
Figure 3.14 A schematic diagram of different stages of bacterial growth in a liquid 
culture.  
 
 ǯ
its mechanism since different metabolic and physiological processes occur during each 
of these phases. Our findings from MRSA growth curves experiment revealed that 
inhibition occurred mainly at the growth phase as depicted in Table 3.8. 
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Table 3.8 Effects of extracts or fractions from A. wilkesiana and D. grandiflora on MRSA  
  growth phase based on results from kinetic growth curve assays. 
 
Extracts/ fractions Affected growth phase 
 
9EA Exponential 
9EA-FC Exponential  
9EA-FD Exponential 
FC-B Exponential 
9EA-FB Lag phase and exponential phase 
75EA-L No clear indication 
75EA-L-F10 Lag phase and exponential phase 
 
  
 
 More than half of our plant test agents affect the exponential growth phase i.e. 
9EA, 9EA-FC, 9EA-FD, FC-B, 9EA-FB and 75EA-L-F10 (Table 3.8). Kinetic growth curve 
experiments results showed that the plant test agents treated cultures experienced a 
shorter exponential phase with a lower growth compared to control and ampicillin 
treated cultures. Moreover, in many of the combination treatments, the curves were flat 
which suggests that the bacteria division was completely suppressed. This indicates 
probable interference in cell division which involves multiple rounds of DNA synthesis 
that is controlled by variety gene regulators (Navarro et al. 2010; Rolfe et al. 2012). 
Besides that, in the case of 9EA-FB and 75EA-L-F10, an extended lag phase was detected 
for MRSA treated in the respective fraction alone. Lag phase is a particular stage when 
bacteria equilibrate to adapt to the new environment by undergoing macromolecular 
repair and synthesis of cellular growth through DNA replications (Dukan and Nyström 
1998).  Hence, we deduced that a lengthy lag phase in culture treated with these 
fractions is due to inhibition of DNA replications that delays the cellular growth process. 
This observation also is reminiscent of the action of fluroquinolones that caused 
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inhibition of DNA replication in MRSA, leading to a longer lag phase (Venezia et al. 
2001). 
 
3.5.2.3  FIC index interpretations for plant test agent in combination with 
 ampicillin  
 
Results of FIC index interpretation can be summarized into 48 combinations of 
synergistic effects, 16 combinations of indifference interaction (zero-interaction) and 44 
combinations that did not exhibit any antibacterial activity. The results also showed that 
presence of extract or bioactive fraction from A. wilkesiana and D. grandiflora reduced 
the MIC of ampicillin to  ?Ǥ ? ?ɊȀȋ ? ?-fold decrease) from the initial value of  ? ? ɊȀǤ These findings bear similarities to previous research that used FIC index 
interpretation method to report increased susceptibility of MRSA to beta-lactam drugs 
upon combination with active compounds from medicinal plants (Shiota et al. 2004; 
Hatano et al. 2005).  
 
 A smaller value of FIC index indicates better synergism (White et. al. 1996) and 
analyses of indices showed  ǯ   from 0.14 to 0.50 for combinations 
with synergistic effect. A study of interpretation of checkerboard experiment using FIC 
index concluded synergism as 4-      	    ? ?Ǥ ? 
marked synergism as 8-	 ? ?Ǥ ? ?ȋ
Rybak 1996). Based on these definitions, we were able to demonstrate that 32 of the 
tested combinations exhibited marked synergism with a decrease in MIC ampicillin 
ranging from 8 to 64-fold, attesting credibility of the synergistic activity observed.   
 
 At the same time, it was observed that, all combinations that consist 1/2 x MIC 
ampicillin or 1/2 x MIC plant test agents produced an index > 0.5 but < 4.0 indicating 
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indifference activity. The term indifference for interaction between two drugs defined as 
combined activity equals to the most active agent used alone (Singh et al. 2000). Hence, 
inhibitory activity observed can be principally attributed to one of the agents in the 
combination. 
  
3.5.3  Interference of bioactive fractions FC-B and 75EA-L-F10 with PBP2a  
 
Data from Western blot experiment show that production of PBP2a was completely 
inhibited in combination treatments (1/32 x MIC ampicillin + 1/4 x MIC FC-B and 1/64 x 
MIC ampicillin + 1/4 x MIC 75EA-L-F10).  The bioactive fraction FC-B was also found to 
totally suppress production of PBP2a without being combined with ampicillin. Hence, 
FC-B alone may serve as a good candidate for anti-MRSA agent.  Both FC-B and 75EA-L-
F10 when were tested at 1/8 x MIC indicated attenuation of PBP2a production in MRSA. 
Based on these results, we deduced that inhibition of PBP2a is one of the mechanisms 
involved in antimicrobial activity demonstrated by the bioactive fractions in         ǯ Ǥ
Evidence pointing out to PBP2a inhibition suggests that the inhibitory mechanism may 
have occurred as a result of interference with the expression of mecA gene encoding for 
PBP2a or a direct degradation of PBP2a by the fractions. 
 
 The mecA gene transcription is regulated by mecR1-mecI-mecR2 system, a unique 
three-component arrangement, consisting of a transcriptional repressor (mecI), a 
sensor-inducer (mecR1) and an anti-repressor (mecR2) (Archer and Bosilevac 2001; 
Zhang et al. 2001; Arêde et al. 2012). Presence of beta-lactam antibiotics has shown to 
trigger expression of PBP2a in MRSA (Derensinski, 2005). In fact, this is confirmed in our 
observation where a higher expression of PBP2a was found in MRSA cultures grown in 
ampicillin.  MRSA when exposed to beta-lactams; binding of the antibiotic molecules to 
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MecR1 domain (sensor-inducer receptor) induce expression of mecA and mecR1-mecI-
mecR2 genes (see Figure 3.15). Induction of mecA by MecR1 was identified weak and 
extremely slow (Ryffell et al. 1992; Hackbarth and Chambers 1993). This inefficiency 
however is compensated by presence of MecR2, an anti-repressor which inactivates the 
function of MecI (repressor) by destabilizing the binding of this repressor to mecA 
promoter via proteolytic cleavage. Hence, mecRI-mecI system is up regulated enabling 
full induction of mecA gene (Arêde et al. 2012). This model has described the essentiality 
of MecR2 for complete transcription of mecA for optimal expression of beta-lactam 
resistance in MRSA, particularly, PBP2a. Considering the mechanism of mecA expression, 
any substantial inhibition on PBP2a production as observed in our study possibly 
occurred due to effects of the bioactive fraction on MecR2 or MecR1 or both (Figure 
3.15).  We suspect that the active molecules from the bioactive fraction are capable of 
interfering with binding of beta-lactam antibiotic to MecR1 domain therefore preventing 
the signal transduction for mecA activation.  Besides, it is also possible that presence of 
the active molecules from the bioactive fractions have an adverse effect on MecR2 
therefore cripples its ability to ensure full induction of mecA transcription. In both 
postulations, we propose that interaction of the bioactive fraction with the receptors as 
described above hinder full expression of mecA and consequently prevent or inhibit 
production of PBP2a. Figure 3.15 represent a model of mecA expression and the possible 
interference of the bioactive fractions in the mechanism.  
 
The other proposition here is properties of the bioactive fractions are able 
deactivate PBP2a activity or degrade PBP2a at certain point (Figure 3.15). Older reports 
have suggested potential of plant products belonging to polyphenols or diterpenes 
groups in suppressing PBP2a expression (Nicolson et al. 1999; Shimizu et al. 2001; 
Shiota et al. 2004) but none that actually describes their ability to deactivate PBP2a 
activity or degrade this particular protein. Although, the mechanism of deactivation or 
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degradation is elusive, we predict interaction between active components from the 
bioactive fractions with PBP2a can result in considerable conformational changes in the ǯǤǡ
cell wall biosynthesis in MRSA is expected to be deprived and following that MRSA 
becomes susceptible to ampicillin again.   
 
 Treatments of ampicillin alone at low concentrations were observed to aggravate 
PBP2a expression based on high intensity PBP2a bands in Western blot experiment. A 
low concentration of beta-lactam antibiotic was described to induce processes which 
foster genetic exchange and antibiotic resistance in S. aureus species (Kaplan et al. 
2012). This may shed some light on the high expression of PBP2a upon exposure to 
ampicillin at low concentrations in this study. Furthermore, the expression of PBP2a is 
restricted to small sub-population in absence of beta-lactam antibiotics and presence of 
these antibiotics was reported to form a homogenous resistance population (Zapun et al. 
2007). Hence, it is likely that the formation of homogenous population in presence of 
ampicillin contributed to higher expression of PBP2a in our study.  
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Figure 3.15 A schematic diagram showing induction of mecA by mecR1-mecI-mecR2 regulatory 
genes in presence of beta-lactam antibiotics. The mode of action of the bioactive 
fractions (BF) on the PBP2a induction system are postulated due to 1) interference 
of BF with binding of MecRI to ampicillin, 2) impediment of MecR2 function by BF or 
3) degradation of PBP2a by presence of BF. BF is represented by red stars in the 
diagram. 
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3.6 CONCLUSION 
 
The concept of synergism demonstrated by plant test agents from A. wilkesiana and D. 
grandiflora in combination with ampicillin was noted potent with > 90% inhibition was 
observed on MRSA growth. This was based on FIC indices that primarily indicated 
synergism and rarely indifference. Likewise, growth curves experiment demonstrated 
that the combination treatments were able to prevent and suppress MRSA growth 
markedly compared to treatment with one agent alone. Furthermore, the results of 
growth curve experiments implied that the combination treatments influence bacterial 
cell division which can be related to DNA replications and other cellular metabolism 
such as protein production. 
 
 MRSA strain used in this experiment carries mecA gene which positively encodes 
for PBP2a which confers resistance to ampicillin. Consistently, MIC ampicillin for this 
particular strain was 50 µg/ml. This value has exceeded MIC breakpoints for 
susceptibility to beta-lactam drugs (Brown 2001). Nevertheless, by combining plant test 
agents from A. wilkesiana or D. grandiflora with ampicillin, we managed to increase the ǯ        a reduced MIC 
ampicillin. The restoration of amǯ     
treatments indicates that the plant test agents may interact with the resistance factor, 
PBP2a. Hence, we pursued the study of effects of combination treatments on PBP2a.  
 
In Western blot assay, presence of FC-B and 75EA-L-F10 alone and in 
combination with ampicillin inhibits production of PBP2a. Therefore, we conclude that 
one of the mechanisms involved in enhancement of antibacterial effects in combination 
treatment is inhibition of PBP2a. The mechanism in which PBP2a is affected by the plant 
test agent is unknown at this stage. Our postulations were that these plant test agents 
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could interrupt the expression of mecA gene or interact with PBP2a and compromised its 
action. These postulations however, needs further study for confirmation. Besides that, 
FC-B and 75EA-L-F10 consist of mixture of plant metabolites; hence involvement of 
several mechanisms in attenuation of PBP2a and the antibacterial effects overall, is 
undisputable. 
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CHAPTER 4 
 
INHIBITION OF BIOFILM PRODUCTION IN MRSA 
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4.1  BACKGROUND 
 
Biofilms are known as surface-adhering bacterial communities encapsulated in 
extracellular complex comprising DNA, bacterial polysaccharides and proteins by 
forming a slimy layer (Costerton and Stewart 1999; Mulcahy et al. 2008). They play an 
intrinsic role in protecting bacterial cells from any fluctuations of the environment 
including protecting the colonies from any potential antimicrobial agents (Costerton and 
Stewart 1999). It is well studied that the physiological properties of sessile biofilm 
populations are different from their planktonic counterparts and these contribute to 
their better survival within the infected hosts. Biofilm protected bacterial cells present a 
different mode of growth compared to planktonic cells, and the peculiarity of the mode 
of growth contributes to manifestation of antibiotic resistances which are distinct from 
their planktonic counterparts. The biofilm-specific antibiotic resistance mechanisms are 
1) delayed or reduced antimicrobial diffusion into biofilm cells, 2) presence of persister 
cells, 3) antimicrobial destroying enzymes, 4) quorum sensing signaling, and 5) global 
stress response leading to over expression of antimicrobial resistance (Petrelli et al. 
2003; del Pozo and Patel 2007).  
  
The biofilm forming ability of MRSA represents a major factor for nosocomial 
infections (Costerton et al. 1999). In fact, a recent research has shown that, multi-drug 
resistant clinical S. aureus strains produce more biofilm implying that the biofilm 
forming ability is crucial for the bacteria survival in presence of antibiotics (Kwon et al. 
2008). Similarly, a clinical study in 2012 concluded that S. aureus species with biofilm 
forming properties were observed to express higher antibiotic resistance, thus more 
difficult to treat (Agarwal and Jain 2012). The currently available antimicrobial agents 
have not been specifically developed to target bacterial biofilms (del Pozo and Patel 
2007). As such, these agents are typically ineffective in treating biofilm-associated 
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infections (Lynch and Abbanat 2010). Often, removal of the infected devices is the most 
effective clinical solution in most of the biofilm-related infections cases (Donlan and 
Costerton 2002; Petrelli et al. 2008). Recently, new approaches such as antimicrobial 
peptide, bioengineered agents (bacteriophages), ultrasonic treatments, quorum sensing 
inhibitors, and natural products are being developed for treatment of biofilm-associated 
infections (Sun et al. 2013).  
 
 The steps involved in biofilm production are complex and the process can be 
categorized into four distinct phases: attachment, accumulation, maturation and 
dispersal (Christensen et al. 1994). In staphylococcal biofilms, there are two essential 
steps that have been emphasized; 1) cell-surface attachment, in which the bacteria 
attach to a surface in order to form colonies and this is also known as the primary 
attachment step; and 2) cell-cell interaction, which is an accumulative phase where the 
bacteria form microcolonies for construction of multilayer structure leading to biofilm 
development (Mack 1999; Götz 2002; Mack et al. 2004; Beenken et al 2004). These two 
processes are mediated by different types of adhesins. A group of surface-exposed 
proteins generally termed as microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs) is responsible for the primary attachment of cells to surface 
including native tissues and biomaterials (Patti et al. 1994). In accumulative phase, the 
bacterial cells rely on polysaccharide intercellular adhesin, or poly-N-acetylglucosamine 
(PIA/PNAG) that facilitates interactions between the cells for formation of microcolonies 
(Götz 2002).  These polysaccharides adhesins are encoded by icaADBC genes and they         ȋǯ  Ǥ 2007) (see 
Figure 4.1a).  
 
 MRSA strains however were found to produce ica independent biofilm. Deletion 
of icaADBC has no effect on biofilm production in these strains. Study on some MRSA 
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isolates also showed that PIA/PNAG was not detected in the produced biofilm despite 
the transcription of icaADBC. This is because accumulative phase in development of 
MRSA biofilm is promoted by protein adhesins namely fibronectin-binding proteins ȋ	ȌȀ
ȋǯǤ2007; Szczuka et al. 2013) (Figure 
4.1b). FnBPs plays a vital role in intercellular accumulative phase of MRSA biofilm 
formation and deletion of genes (fnbA and fnbB) encoding for these proteins resulted in 
failure to form biofilm (McCourt et al. 2014). Therefore MRSA strains produce 
proteinceous biofilm unlike polysaccharide based biofilm formed by MSSA. 
 
The requirement of FnBPs and other surface proteins which function as adhesins 
in MRSA biofilm production indicates the importance of proteins in promoting the cell-
cell interaction during the accumulative phase. The resistant protein, PBP2a is acquired 
and expressed in MRSA to overcome antimicrobial action of beta-lactam antibiotics and 
this protein was also found to mediate biofilm formation in MRSA. It was hypothesized 
that PBP2a facilitates cell-cell interactions in the biofilm production possibly by 
changing the bacterial cell wall architecture (Berger-Bächi and Rohrer 2002; Pozzi et al. 
2012) (Figure 4.1b). Hence, development of anti-biofilm agents that disrupt PBP2a 
expression not only will be able to reverse methicillin resistance in MRSA but 
concurrently interfere with biofilm formation. This would be a sensible approach in 
developing a new treatment for recalcitrant MRSA infections 
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Figure 4.1 Graphic representations of biofilm phenotypes produced by a) MSSA and b) MRSA.  
MSSA strain forms ica-dependent PIA mediated biofilm whereas MRSA strain biofilm 
is independent of PIA and requires surface proteins such as FnBPs during the 
accumulative phase. Expression of PBP2a by mecA suppresses production of 
PIA/PNAG and the protein is suspected to exerts direct or indirect (e.g. via altered 
cell wall architecture) effects on MRSA biofilm production. 
 
 
 
In recent reviews, plants products were found to have anti-biofilm activities 
(Manefield et al. 2002; Abreu et al. 2012; Kim and Park 2013).  It is interesting to    ǯ      resence of bioactive 
fractions from the plant A. wilkesiana and D. grandiflora as shown in Chapter 3. Hence, 
we suspect these bioactive fractions may possess antibacterial properties that are able 
to inhibit biofilm production.  In this chapter, experiments were designed to investigate 
the effects of the bioactive fractions on MRSA biofilm forming capacity and PBP2a 
expression in the biofilm matrix. 
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4.1.1 Biofilm Assays 
 
Biofilm assays in this chapter are divided in two main parts; 1) inhibition of MRSA 
biofilm production and 2) microtiter attachment assay. Inhibition of biofilm production 
assay provides information on final mass of biofilm production upon treatments. Whilst, 
microtiter attachment assay will indicate if the antimicrobial agent is preventing cell-
surface association which is the first step involved in biofilm development (O'Toole et al. 
2000; Watnick and Kolter 2000). In both assays, quantification of biofilms   and cell 
attachment to surface were done by measuring optical density (OD) of crystal violet        ȋ©  Ǥ  ? ? ? ?Ǣ©Ǥ ? ? ? ?ȌǤ The crystal violent staining works according to the ability of the 
bacterial cell wall to reserve the dye during the staining procedure. Besides that, crystal 
violet dye also stains extracellular matrix which is useful in study of biofilms (Welch et 
al. 2012).  Christensen et al. (1982 & 1985) first described the staining of bacterial film 
lining culture with a cationic dye and measuring of the OD using a spectrophotometer. 
The results although qualitative in nature, lack of completeness because only biofilm on ǯȋ©Ǥ ? ? ? ?ȌǤ
accuracy of the assay, a modified test with fixing of the bacterial cells, staining with 
crystal violet, decolourizations of the stain, and finally measuring the OD as described ȋ©Ǥ  ? ? ? ?ǢǤ  ? ? ? ?Ǣ-Colleran et al. 2010; 
Mataraci and Dosler 2012) was employed in this study.  Decolourization of the stain 
leeches the dye and the solvent gathers the solubilised dye in the bottom of the well. As 
such, the cell film lining attached around the well are not discriminated.  
   
Commonly used media to grow biofilm of Staphylococcus species is tryptic soy  ȋȌ    ȋ©  Ǥ  ? ? ? ?Ǣ   Ǥ  ? ? ? ?Ǣ
Mataraci and Dosler 2012).  According to Fitzpatrick et al. (2006), MRSA strains are 
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more likely to form biofilm in media supplemented with glucose. A following study in 
2009, explained that biofilm are normally found to be colonizing medical device like 
catheters and heart valve that are in direct contact with blood. Based on a previous 
report study, in vitro biofilm formation in S. aureus lineage is positively correlated to 
physiological concentration of glucose (Croes et al. 2009).   
 
4.1.2 Study of biofilm phenotype and PBP2a latex agglutination 
 
Biofilm study in this chapter is also extended to determine the biofilm phenotype 
produced by MRSA ATCC 43300.  Two chemical agents, proteinase K and sodium 
metaperiodate were used in previous studies to determine the biofilm phenotype. Based 
on these studies, dispersal of biofilm caused by either of this agent indicates whether the 
biofilm is protein or polysaccharide based (Holland et al. 2011; Pozzi et al. 2012). 
Proteinase K is an enzyme that has broad specificity and is able to degrade many 
proteins at native state. It predominantly cleaves peptide bonds in protein leading to its 
breakdown subsequently disperse proteinaceous biofilm. Sodium metaperiodate 
degrades PIA-dependent biofilm due to its ability to oxidize and cleaves cis-diols in 
carbohydrate sugars.  
 
 PBP2a latex agglutination assay is usually used for detection of PBP2a from 
MRSA cultures grown on plate.  In a PBP2a latex agglutination kit, the latex reagent is 
sensitized with monoclonal antibody against PBP2a.  Therefore, when the extracted 
supernatant is mixed with latex reagent, a visible clumping is formed indicating 
presence of PBP2a. An elaborate study by Pozzi et al. (2012) demonstrated that biofilm 
produce by an induced Ȃmethicillin resistant strain carrying mecA gene was reduced 
when the strain was grown in presence of monoclonal PBP2a antibody suggesting the 
role of PBP2a in MRSA biofilm development.  Hence, a PBP2a latex agglutination test was 
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conducted to study effects of the bioactive fractions on PBP2a level in MRSA biofilms.  A 
commercially available kit is used for the test and this kit was reported suitable to detect 
PBP2a rapidly in less complicated manner (Doern et al. 1994; Cavassini et al. 1999).  
Earlier, a PBP2a latex agglutination kit was used to evaluate inhibition of PBP2a by plant 
metabolites and the method was described to yield semi-quantitative results based on 
intensity of the agglutination (Zhao et al. 2001).   
 
4.2 AIMS AND OBJECTIVES 
 
Experiments in this chapter were aimed to investigate anti-biofilm properties of the 
bioactive fractions FC-B and 75EA-L-F10 alone and combination with ampicillin. The 
specific objectives is to investigate the effects of the selected combination treatments on 
biofilm production in MRSA  
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4.3 MATERIAL AND METHODS 
 
Based on results from chapter 3, two bioactive fractions FC-B and 75EA-L-F10 (from A. 
wilkesiana and D. grandiflora respectively) were selected for this biofilm study. These 
two plant test agents demonstrated synergism with ampicillin by reducing MIC of 
ampicillin the most compared to the other plant test agents used in this study. In this 
chapter, these bioactive fractions and ampicillin were tested at MIC and sub-MICs to 
investigate the effect of these agents on MRSA biofilms. The MIC values of the bioactive 
fractions and ampicillin used in this biofilm study were the MIC against MRSA growth in 
planktonic state obtained from experiments in Chapter 3 (broth microdilution assay).  
 
4.3.1 Microtiter attachment assay  
 
This assay was performed based on previously reported method with a minor 
modification (Overhage et al. 2008). A 96-well microtiter plate prepared with ampicillin 
alone, bioactive fraction alone and in combination of both as explained in section 4.3.4 
kinetic growth curve assay (Chapter 3). MRSA culture that was grown 24 hours prior to 
experiment was diluted with TSB (Hi-Media, India) + 1 % glucose (Merck, Germany) and 
added to these wells containing different treatments. The inoculums size in each well 
was 1 x 107 	Ȁ ? ? ?ɊǤ ?our at 35°C.  
After the incubation, quantification of cell attachment to surface was done based on 
methods described in section 4.3.3. Experiment was done in triplicates on three separate 
occasions.  
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4.3.2 Inhibition of biofilm production 
 
This experiment was conducted according to Mataraci and Dosler 2012 with a slight 
modification. Similar to the microtiter attachment assay, a 96-well microtiter plate was 
prepared with bioactive fraction alone, ampicillin alone and in combinations. MRSA 
suspension that was grown 24 hours prior to experiment was diluted with TSB + 1 % 
glucose to correspond to 1 x 105 	Ȁ  ? ? ?Ɋ
each well. The plate was incubated for 24 hours at 35°C. After the incubation, 
quantification of biofilm production was done based on methods described in section 
4.3.3. Experiment was done in triplicates on three separate occasions.  
 
4.3.3 Quantification of cell attachment and biofilm production 
 
Quantification of cells attachment in microtiter attachment assay and inhibition of 
biofilm production assay were determined via crystal violet staining method (Durham-
Colleran et al. 2010). After the incubation, media was aspirated and the wells of the         ? ? ? Ɋ  physiological buffered saline 
(PBS) to remove unattached bacteria and left to dry. Upon dryingǡ  ? ? ? Ɋ f 99% 
methanol (Fisher Scientific Chemicals, USA) was added into each well for fixation. Then, 
the solvent was removed and plates were allowed to dry for 15 minutes. Following that, 
the wells were stained with 0.1% crystal violet (v/v in water) (R&M Chemicals, UK) for 5 
minutes. Using tap water, the excess stain was discarded gently and plates were air 
dried. Stain was dissolved  ? ? ?Ɋ ? ? ?ȋ	ǡ
USA) with the plates left on orbital shaker (Fisher Scientific 260300 Ocelot Orbital, USA) 
at 50 rpm for 30 minutes. Finally the OD was read at 595 nm using a multimode plate 
reader (Varioskan Flash, Thermo Scientific, USA).  Percentage of MRSA cell-surface 
attachment and biofilm production was determined by measuring absorbance of every 
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treated well at 595 nm subtracting absorbance of control MRSA (treatment free) which 
was used as 100 % growth reference.  
  
4.3.4 Determination of MRSA biofilm phenotype 
 
The experiment was conducted as described previously (Mack et al. 1992; Holland et al. 
2011).  An overnight MRSA culture was diluted with TSB + 1 % glucose and 30 µl aliquot 
of the suspension was added to the wells of microtiter plate. The inoculums size in each 
well was 1 x 107 CFU/ml when the final volume was made up to 200 µl by adding the 
growth media. Plate was incubated for 24 hours at 35°C. After incubation, media was 
removed and the wells were washed with 100 µl PBS. The microtiter plate was then 
allowed to dry for 15 minutes. Proteinase K (50 µl, 100 µg/ml) (Sigma, USA) or sodium 
metaperiodate (50 µl, 10 mM) (Sigma, USA) was added to the wells and the microtiter 
plate was further incubated for 2 hours at 35°C. Following incubation, the chemical 
agents were removed by washing the wells with sterile distilled water (100 µl) and the 
plate was dried at 65°C for 1 hour. The absorbance of adhered biofilm was measured 
using the methods described in section 4.3.3. Experiment was done in triplicates on 
three separate occasions. 
 
4.3.5 PBP2a latex agglutination test on MRSA biofilm  
 
Prior to the latex agglutination test, MRSA was cultured in 50 mm diameter petri dishes 
in 10 ml of TSB + 1 % glucose supplemented with MIC and sub-MICs of ampicillin alone, 
bioactive fraction alone and in combination of both. The petri dishes were incubated for 
24 hours at 35°C. After incubation, the broth was carefully removed and 500 µl PBS was 
added to the petri dishes. Using a sterile 5 µl inoculating loop, the biofilm layer was 
scraped off just to fill the internal diameter (gives approximately 1.5 x 109 CFU/ml). The 
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obtained bacterial biofilm was processed according to MRSA screening kit (Cat. no.  ? ? ?ǡȌǯ
PBP2a.  
 
Briefly, PBP2a in the obtained bacterial biofilm was extracted by using extraction 
reagents (0.1 mol/L NaOH and 0.5 mol/L KH2PO) found in the assay kit. The extracts 
then were mixed with test latex that was sensitized with a monoclonal antibody against 
PBP2a.  Presence of PBP2a was indicated by formation of agglutination in the extract.  
Semi-quantitative estimation of PBP2a agglutination strength in the extract was done 
based on protocols described in Zhao et al. (2001) in which the agglutination strength 
was observed and scored between + and + + +, where the control latex which showed no       ?    ǲ-ǳǤ The control latex is sensitized 
with a monoclonal antibody of the same IgG subclass but against a human protein 
showed no reactivity with proteins of S. aureus. 
 
4.3.6  Statistical analysis 
 
Results for biofilm attachment and inhibition assays were shown as means ± standard 
deviation of three independent experiments. A one-way analysis of variance with 
Bonferroni multiple comparison tests was used to compare difference between the 
control and combination treatment group biofilms.  A P value of < 0.001 was taken as 
statistically significant (Mataraci and Dosler 2012). 
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4.4 RESULTS 
 
 
4.4.1 FC-B and 75EA-L-F10 prevent cell-surface attachment in MRSA 
 
MRSA cell-surface interaction was studied by growing the cultures in the presence 
ampicillin ranging from 1/64 x MIC (0.78 µg/ml) to MIC (50 µg/ml). Overall, ampicillin ǯǯȋ	 ?Ǥ ?ȌǤ
At all tested concentrations, >50% of cells were found to attach and remain on the 
microtiter plate. The percentage (%) of attachment appeared to be concentration 
dependant as the highest cell-surface attachment (81.16%) was recorded for 1/64 x MIC 
of ampicillin and lowest for MIC of ampicilin (62.20).  
 
 
Figure 4.2 Effects of ampicillin on MRSA cell-surface attachment. Three wells were used for 
each treatment. Experiment is representative of three independent tests, and error 
bars indicate the standard deviation. All difference between control and treated 
MRSA were statistically significant (p<0.001) (MIC= minimum inhibitory 
concentration, AMP= ampicillin). 
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Bioactive fractions, FC-B and 75EA-L-F10 were evaluated at concentrations 
ranging from MIC to 1/16 x MIC. Briefly, both fractions at their MIC were found to 
markedly reduce cells attachment to the growth surface.  
 
Figure 4.3 shows % of MRSA cell-surface attachment in presence of FC-B.  At the 
MIC FC-B (3.00 mg/ml), less than 10% of cells attached to the surface. FC-B inhibits 
attachment of MRSA cells to the well surface in a concentration-dependant manner. The 
inhibitory action on cell- surface attachment was observed to be considerably potent at 
1/2 x MIC FC-B (1.50 mg/ml, 28.56%) and 1/4 x MIC (0.75 mg/ml, 42.59%).  
Nevertheless, at lower concentrations, the effect of FC-    ǯ
(Figure 4.3).  
 
 
Figure 4.3 Effects of FC-B on MRSA cell-surface attachment. Three wells were used for each 
treatment. Experiment is representative of three independent tests, and error bars 
indicate the standard deviation. All difference between control and treated MRSA 
were statistically significant (p<0.001) (MIC= minimum inhibitory concentration). 
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Based on Figure 4.4, results for MRSA cell-surface attachment revealed that the 
presence of 75EA-L-F10 at MIC (0.75 mg/ml) markedly inhibits MRSA cells from 
attaching to the growth surface as shown by a mere 5.33% of cell attachment.  At 1/2 x 
MIC 75EA-L-F10 (0.38 mg/ml), this fraction was still effective in preventing cell 
attachment. 75EA-L-F10 shows similar concentration-dependant inhibitory effects as 
FC-B. At lower concentrations, 75EA-L-F10 produces similar magnitude of inhibition as 
ampicillin. 
 
 
 
Figure 4.4 Effects of 75EA-L-F10 on MRSA cell-surface attachment. Three wells were used for 
each treatment. Experiment is representative of three independent tests, and error 
bars indicate the standard deviation. All difference between control and treated 
MRSA were statistically significant (p<0.001) (MIC= minimum inhibitory 
concentration). 
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The combined effects of the bioactive fractions, FC-B and 75EA-L-F10 and 
ampicillin  in preventing cell-surface attachment were studied by investigating two 
combination treatments; 1/32 x MIC ampicillin + 1/4 x MIC FC-B and 1/64 x MIC 
ampicillin + 1/4 x 7EA-L-F10. Ampicillin only inhibits less than 23% cells from attaching 
to the surface but presence of FC-B and 75EA-L-F10 inhibit more than 47% and 50% 
cells attachments (Figure 4.5).  In combination treatment ampicillin + FC-B, a 
significantly increased inhibitory action in preventing cell-surface attachment was 
observed (75.8%). Treatment of 75EA-L-F10 and ampicillin produced similar results 
(48.8%) as fraction 75EA-L-F10 alone (50%) (Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Effects of ampicilln, FC-B and 75EA-L-F10, alone and in combinations. Three wells 
were used for each treatment. Experiment is representative of three independent 
tests, and error bars indicate the standard deviation. All difference between control 
and treated MRSA were statistically significant (p<0.001) (AMP= ampicillin, MIC= 
minimum inhibitory concentration, *** = significance difference between the plant 
test agent alone and in combination). 
 
 
 
 
 
 
*** 
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4.4.2 Inhibition of MRSA biofilm production by FC-B and 75EA-L-F10  
 
Effects of ampicillin, FC-B and 75EA-L-F10 on MRSA biofilm production were 
investigated. The results demonstrated that MIC of ampicillin (50 µg/ml) markedly 
suppressed MRSA biofilm production with just 15.51% of biofilm formed compared to 
untreated MRSA culture (Figure 4.6). Biofilm production in different concentrations of 
ampicillin was shown to be concentration-dependant and at 1/2 x MIC ampicillin (25 
µg/ml), the antibiotic inhibited about 35% of biofilm production. As ampicillin 
concentration was lowered, the biofilm production increased and eventually at 1/64 x 
MIC ampicillin (0.78 µg/ml), the formation of biofilm was hardly affected (92.3%). This 
results indicated that a high concentration of ampicillin (MIC = 50 µg/ml) is needed to 
suppress MRSA biofilm formation, nevertheless, this concentration did not totally inhibit 
the biofilm synthesis. 
 
 
Figure 4.6 Effects of ampicillin on MRSA biofilm production. Three wells were used for each 
treatment. Three wells were used for each treatment. Experiment is representative 
of three independent tests, and error bars indicate the standard deviation. All 
difference between control and treated MRSA were statistically significant (p<0.001) 
(AMP= ampicillin, MIC= minimum inhibitory concentration). 
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The inhibitory activity of FC-B on MRSA biofilm formation is concentration 
dependant.  Hence, the highest tested concentration (MIC= 3 mg/ml) was observed to 
result in the strongest inhibition in which the biofilm production was only 18.44% 
(Figure 4.7).  At sub-MICs from 1/2 x MIC (1.50 mg/ml) to 1/8 x MIC (0.38 mg/ml), a 
considerable inhibition on MRSA biofilm (> 2-fold) was achieved with the % of inhibition 
ranged from 46.15% to 69.78%. Further reduction in concentration (1/16 x MIC= 0.19 
mg/ml) appeared to have weaken anti-biofilm action, as the biofilm production reached 
69.24% (~70%). Comparable to results of ampicillin treatment, FC-B exhibited strong 
anti-biofilm activity at MIC level and likewise the high concentration was unable to 
suppress the biofilm production entirely.  
 
 
Figure 4.7 Effects of FC-B on MRSA biofilm production. Three wells were used for each 
treatment. Three wells were used for each treatment. Experiment is representative 
of three independent tests, and error bars indicate the standard deviation. All 
difference between control and treated MRSA were statistically significant (p<0.001) 
(MIC= minimum inhibitory concentration). 
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tested concentrations) which shows small variability. At MIC 75EA-L-F10 (0.75 mg/ml) 
a moderate activity against MRSA biofilm formation (33.90%) was observed which was 
less effective compared to ampicillin at the respective MIC. From this data, it is 
reasonable to conclude that presence of 75EA-L-F10 generally has moderate action on 
MRSA biofilm production. 
 
 
Figure 4.8 Effects of 75EA-L-F10 on MRSA biofilm productions. Three wells were used for each 
treatment. Experiment is representative of three independent tests, and error bars 
indicate the standard deviation. All difference between control and treated MRSA 
were statistically significant (p<0.001) (MIC= minimum inhibitory concentration). 
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The effects of combination treatment between the bioactive fractions and 
ampicillin on biofilm production were studied by investigating two combination 
treatments; 1/32 x MIC ampicillin + 1/4 x MIC FC-B and 1/64 x MIC ampicillin + 1/4 x 
7EA-L-F10. Treatment with ampicillin alone as observed earlier has very weak activity 
on the biofilm formation.  Presence of the bioactive fractions at 1/4 x MIC exhibited 
appreciable activity against biofilm production, where the biofilm production was at 
least 2-fold lower compared to control MRSA (Figure 4.9). In combination treatments, 
the production of biofilm was generally lower compared to treatment with the bioactive 
fractions alone. However, there was no significance reduction in biofilm formation 
between treatment of FC-B alone (41.52%) and in combination with ampicillin (32.7%). 
Whilst combination treatment of 75EA-L-F10 and ampicillin (29%) showed a significant 
difference in biofilm production compared to treatment with 75EA-L-F10 alone 
(45.55%) (Figure 4.9).  
 
 
Figure 4.9 Effects of ampicillin alone, FC-B alone, 75EA-L-F10 alone and in combinations on 
MRSA biofilm production. Three wells were used for each treatment. Experiment is 
representative of three independent tests, and error bars indicate the standard 
deviation. All difference between control and treated MRSA were statistically 
significant (p<0.001) (AMP= ampicillin, MIC= minimum inhibitory concentration, ** = 
significance difference between the plant test agent alone and in combination). 
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4.4.3. High dispersal of MRSA biofilm by proteinase K 
 
 
The cultures treated with proteinase K and sodium metaperiodate were stained with 
crystal violet to observe the extent of biofilm disintegration. This was carried out by 
measuring the OD of biofilm that was still intact in the wells after the treatment. The 
control MRSA (untreated) wells were stained heavily in purple by crystal violet showing 
formation of biofilm (Figure 4.10a). Both proteinase K and sodium metaperiodate 
affected the integrity of MRSA biofilm structure. Analysis of the data revealed more than 
77% of biofilm was dispersed in presence of proteinase K but in sodium metaperiodate 
treated cultures only 22.41% of the biofilm was degraded. Thus, implies that biofilm 
produced by MRSA strain used in this study expressed a higher level of protein 
compared to polysaccharide. 
 
The image of crystal violet staining of biofilms treated with proteinase K  shows ǯȋȌ
and the middle section is clear. This indicates the film lining has been largely dispersed. 
In contrast, wells that contained biofilm treated with sodium metaperiodate were 
entirely stained by crystal violet suggesting the biofilm structure is still intact. When 
compared to control MRSA, wells containing sodium metaperiodate treated biofilm were 
less intense (Figure 4.10a). Thus, implied that sodium metaperiodate may affect 
integrity of the MRSA biofilms but not as extensive as proteinase K. Consistent with 
visual observation, the OD of control MRSA was the highest (1.06), followed by sodium 
metaperiodate (0.78) and proteinase K (0.24) (Figure 4.10b). 
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a)  
 
                      Control MRSA                            + proteinase K                + sodium metaperiodate 
 
b)  
 
Figure 4.10 a) Crystal violet staining of MRSA ATCC 43300 biofilms in the presence of proteinase 
K and sodium metaperiodate in microtiter plate. b) Bar graph representing OD of 
biofilms after treatment with proteinase K and sodium metaperiodate. Three wells 
were used for each treatment. Experiment is representative of three independent 
tests, and error bars indicate the standard deviation. 
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4.4.4  FC-B and 75EA-L-F10 reduced PBP2a in MRSA biofilm 
 
Presence of PBP2a was detected by formation of agglutination when the supernatant 
from the biofilm was mixed with sensitized test latex. Some tested aliquots appeared 
turbid during the assay, but turbidity alone without agglutination is not an indication of 
PBP2a presence. The degree of agglutination was determined by visual observation 
compared to a negative control (no agglutination). Figure 4.11 shows moderate 
agglutination indicating presence of PBP2a in control MRSA. The agglutination was 
predominantly seen around the periphery of the aliquot. Biofilms isolated from 
treatment of MIC of ampicillin (50 µg/ml) formed a stronger agglutination compared to 
control MRSA. Lower concentrations of ampicillin (1/32 x MIC = 1.56 µg/ml and 1/64 x 
MIC =0.78 µg/ml) were found to have similar agglutination strength as the control (see 
Figure 4.11).   
 
 
 
 
 
Treatment                     Control MRSA               + MIC AMP            +1/32 x MIC AMP       + 1/64 x MIC 
AMP 
                                                                                  (50 µg/ml)                  (1.56 µg/ml)               (0.78 µg/ml) 
 
Agglutination                         + +                            + + +                            + +                                     + + 
    strength 
 
Figure 4.11 Formation of latex agglutination in supernatant of MRSA biofilms obtained from 
cultures grown in presence of ampicillin. The presence of white agglutination 
indicates positive for presence of PBP2a. Intensity of agglutination was observed and 
scored between + and + + +, where the control latex which showed no reactivity in 
ƚŚĞĂďƐĞŶĐĞŽĨWW ?ĂŝƐĐŽŶƐŝĚĞƌĞĚĂƐ ?- ? ?ŝŶƚĞƌƉƌĞƚĂƚŝŽŶ PA?A?A?ƐƚƌŽŶŐĂŐŐůƵƚŝŶĂƚŝŽŶ ?
+ + moderate agglutination against turbid background, + slight agglutination against 
turbid background, - no agglutination, AMP= ampicillin, MIC = ampicillin, n=3).  
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 Table 4.1 presents the results for all the treatments studied including the 
bioactive fractions (FC-B and 75EA-L-F10). Treatment with FC-B and 75EA-L-F10 
reduced the agglutination for PBP2a compared to untreated MRSA. This indicates the 
presence of PBP2a in the biofilm but at a lower amount compared to control. The only 
treatment that abolished the agglutination is the combination of ampicillin (1/32 x MIC) 
and FC-B (1/4 x MIC) (see Figure 4.12). This is an interesting observation as the 
combination also presented lowest cell-surface attachment (Figure 4.5).  
 
 
Table 4.1  Semi-quantitative estimation of PBP2a occurrence in MRSA biofilms isolated from 
cultures exposed to different treatments. Intensity of agglutination was observed 
and scored between + and + + +, where the control latex which showed no reactivity 
ŝŶ ƚŚĞ ĂďƐĞŶĐĞ ŽĨ WW ?Ă ŝƐ ĐŽŶƐŝĚĞƌĞĚ ĂƐ  ?- ?  ?ŝŶƚĞƌƉƌĞƚĂƚŝŽŶ P A? A? A? ƐƚƌŽŶŐ
agglutination, + + moderate agglutination against turbid background, + slight 
agglutination against turbid background, - no agglutination, MIC = ampicillin, n=3). 
 
Treatments  Intensity of PBP2a agglutination 
Control MRSA + + 
MIC ampicillin (50 µg/ml) + + + 
1/32 x MIC ampicillin (1.56 µg/ml) + + 
1/64 x MIC ampicillin (0.78 µg/ml) + + 
1/4 x MIC F-CB (0.75 mg/ml) +  
1/8 x MIC F-CB (0.38 mg/ml) + 
1/16 x MIC F-CB (0.19 mg/ml) + 
1/4 x MIC 75EA-L-F10 (0.19 mg/ml) + 
1/8 x MIC 75EA-L-F10 (0.09 mg/ml) + 
1/16 x MIC 75EA-L-F10 (0.5 mg/ml) + 
1/32 x MIC ampicillin +1/4 x MIC F-CB - 
1/64 x MIC ampicillin + 1/4 x MIC 75EA-L-F10 + 
 
 
a) b) 
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                                                   1/32 x MIC AMP +         1/64 x MIC AMP + 
                                                     1/4 x MIC FC-B        1/4 x MIC 75EA-L-F10 
 
Figure 4.12  Formation of PBP2a latex agglutination in supernatant of MRSA biofilms obtained 
from cultures grown in combination treatment. a) 1/32 x MIC ampicillin + 1/4 x MIC 
FC-B- showing no agglutination indicating absence of PBP2a and b) 1/64 x MIC 
ampicillin + 1/4 x MIC 75EA-L-F10- showing very mild agglutination against turbid 
background indicating occurrence of low level of PBP2a. (AMP= ampicillin, MIC= 
minimum inhibitory concentrations, n=3). 
 
4.4.5 Summary of results 
 
In this chapter, the effects of FC-B and 75EA-L-F10 alone and in combination with 
ampicillin on MRSA biofilm forming capacity were studied. The results of the measured 
parameters that were affected by the treatments are summarized in Table 4.2.   
 
The biofilm study, suggested that the bioactive fractions alone are able to reduce 
MRSA biofilm production more than 2-fold compared to control MRSA. The combination 
treatments of FC-B and ampicillin however, were observed not to result in significant 
inhibition MRSA biofilm production compared to treatment with the fraction alone. 
Whereas, a significance improvement was recorded in combination treatment of 75EA-
L-F10 and ampicillin compared to treatment with this fraction alone in suppressing 
biofilm production. Results from microtiter attachment assay revealed that FC-B and 
75EA-L-F10 were able to obstruct MRSA cell-surface attachment with inhibition ranging 
in between 50-60%. The combination treatments similarly, demonstrated prevention of 
cell-surface attachment with significant reduction was observed between 1/32 x MIC 
ampicillin + 1/4 x MIC FC-B and FC-B alone. The PBP2a latex agglutination suggested 
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that presence of FC-B and 75EA-L-F10 reduced the level of PBP2a in the biofilm matrix. 
Interestingly, PBP2a was not detected in biofilm treated with the combination treatment 
1/32 x MIC ampicillin + 1/4 x MIC FC-B which has lowest cell attachment %.  
 
Table 4.2 Summary of results of experiments conducted to study mechanism of anti-MRSA 
action exhibited by bioactive fraction FC-B and 75EA-L-F10 alone and in combination 
with ampicillin (MIC= minimum inhibitory concentration, - = not expressed or 
absent, * = significant difference P< 0.001 ). 
 
                                       Experiments 
 
 
 
Treatments 
 
 
 
Cell- surface 
attachment 
(%) 
Biofilm 
production 
(%) 
PBP2a agglutination in 
MRSA biofilm 
(agglutination strength) 
 
     
     
Control MRSA  a100 a100 + + 
1/32 x MIC ampicillin  77.36 1.6 87.98 1.6 + + 
1/4 x MIC FC-B  42.59 2.2 41.52 7.1 + 
1/32 x MIC ampicillin + 
1/4 x MIC FC-B 
 24.20 0.5*** 32.70 3.3 - 
1/64 x MIC ampicillin  81.16 0.7 92.30 1.4 + + 
1/4 x MIC 75EA-L-F10  50.02 1.5 45.55 2.3 + 
1/64 x MIC ampicilin + 
1/4 x MIC 75EA-L-F10 
 48.80 1.1 29.01 2.0** + 
aTreatment free MRSA control was used as 100% growth reference to determine % of 
MRSA cell-attachment and biofilm production. 
 
 
 The biofilm studies also implied that there is positive correlation between % 
cell-surface attachment and final biofilm production for treatments listed in Table 4.2 
(see figure 4.13). 
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Figure 4.13 A linear regression curve showing relationship between MRSA cell surface 
attachment and biofilm production for treatments of ampicillin, FC-B and 
75EA-L-F10 alone and in combination as described in Table 4.2.  
 
4.5 DISCUSSION 
 
The emergence of MRSA as a globally important human pathogen is attributed to 
combination of multiple factors such as antibiotic resistance, enzyme and toxin 
production, biofilm formation, and immune evasion capacity (Pozzi et al. 2012).  Biofilm 
especially possesses threat in hospital settings where the usage of medical implanted 
devices is common for treatments and diagnostics. Reviews from past have suggested 
that plant products have antibacterial properties including anti-biofilm activities. 
Besides, synergistic effects achieved by applying combination of plant products with 
conventional antibiotics can be employed to suppress the virulent factors in MRSA and 
consequently overcome the resistance problems (Sibandah and Okoh 2007; Schelz et al. 
2010; Abreu et al. 2012). Our research in this chapter focused on the effects of bioactive 
fractions isolated from A. wilkesiana and D. grandiflora on biofilm production in MRSA.  
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4.5.1 Bioactive fractions FC-B and 75EA-L-F10 inhibits MRSA biofilm production 
by preventing cell Ȃsurface attachment and reducing PBP2a level 
 
Generally, the results of biofilm studies have shown that the selected bioactive fractions, 
FC-B and 75EA-L-F10 have anti-biofilm properties, as these fractions suppressed biofilm 
production. 75EA-L-F10 showed significant improvement in inhibiting biofilm 
production when combined with ampicillin. However, combination treatment of FC-B 
and ampicillin did not demonstrate a marked inhibition on biofilm production compared 
to treatment with FC-B alone. Hence, suggesting that FC-B may be solely responsible for 
the anti-biofilm properties observed. Elimination of virulent factor such as biofilm 
forming capacity may generate better antimicrobial activity as compared to activity of 
ampicillin alone which could have contributed improved suppression on biofilm 
production in combination treatment 75EA-L-F10 and ampicillin.  
 
 Study on cell-surface attachment indicated that these fractions are capable of 
preventing attachment of MRSA cell to the growth surface with the highest inhibition 
seen at MIC. At lower concentrations, the inhibition was approximately 50%. The ability 
of FC-B and 75EA-L-F10 to prevent cell-surface attachment is thought to reduce biofilm 
production. Attachment of the bacterial cells to its growth surface is the initial step in 
development of biofilm (O'Toole et al. 2000; Watnick and Kolter 2000) and this factor 
influences the final mass of biofilm production. A lesser cell-surface attachment at the 
initial stage reduces the number of bacteria involved in biofilm development 
subsequently decreases biofilm production or result in weak biofilm structure that may 
be easily eradicated (Overhage et al. 2008).  
 
This is in agreement for results of biofilm studies in this chapter. From the 
correlation curves (see Figure 4.14) we were able to demonstrate that strong correlation 
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exists between cell-surface attachment and biofilm production for treatment of FC-B. 
Treatment with 75EA-L-F10 showed a weaker correlation for the same factors. This 
finding suggests that prevention of cell-surface attachment is one of the mechanisms 
involved in inhibition of biofilm production by the bioactive fractions in this study. In S. 
aureus, surface proteins such as MSCRAMMs and FnBPs induce cell motility and promote 
the bacterial cells to attach to a surface. The attachment process is also catalyzed by a 
group of enzyme called sortases (Schröder et al. 2006; Otto 2008). As such, prevention of 
cell-surface attachment by FC-B and 75EA-L-F10 could be related to the ability of these 
fractions to interact with proteins involved in the attachment process. Figure 4.16 
describes the proposed mechanisms of the bioactive fractions in suppressing biofilm 
production in this study.  
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Correlation curves showing relationship between MRSA cell surface 
attachment and biofilm production for treatments of FC-B and 75EA-L-F10. 
R
2 
value of each curve is depicted on the graph.  
 
In determination of biofilm phenotype produced by MRSA strain used in this 
study, we found out that 77.36% of the biofilm dispersed when treated with proteinase 
K. The remaining 22.64% of biofilm matrix after the treatment are suspected to be other 
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essential structural composition of the biofilm such as DNA and polysaccharide 
(Costerton 2004; Rice et al. 2007; Otto 2008).  The high dispersal of biofilm caused by 
proteinase K in this experiment indicates proteinaceous nature of MRSA biofilm. This is 
consistent with observations from previous studies that reported occurrence protein-
based biofilm in MRSA since in these strains are often found to be dependent on the 
expression on FnFBs in contrast to PIA/PNAG in MSSA (Rice et al. 2007; Kaplan et al. 
2012; Pozzi et al. 2012). The switch of the phenotype is caused by high level of PBP2a 
expression that represses icaADBC genes which are involved in PIA/PNAG-based biofilm 
production, and consecutively after a series of molecular events, promotes a PBP2a-
mediated biofilm formation (Pozzi et al. 2012) (see Figure 4.15). Hence, we pursued to 
investigate if inhibition of PBP2a affects the biofilm production in our study.   
 
Results of the semi-quantitative analysis of PBP2a latex agglutination test 
revealed that FC-B and 75EA-L-F10 reduced PBP2a level in MRSA biofilms.  
Subsequently, the biofilm production in presence of these fractions both alone and in 
combination with ampicillin was shown lower (ranging from 29.01 to 45.55%) 
compared to treatment with ampicillin alone. Earlier in Chapter 3, we have 
demonstrated that both of these fractions attenuated the level of PBP2a in MRSA based 
on Western blot experiments. It was previously suggested that PBP2a mediates biofilm 
production in MRSA, while the altered cell wall structure of MRSA that expresses PBP2a 
promotes cell-cell interactions (Pozzi et al. 2012). Although the mechanism by which 
PBP2a promotes MRSA biofilm production remains unclear it is known that cell-cell 
interaction is an important step in multilayer structure assembly in the development of 
biofilm (ǯǤ  ? ? ? ?; Pozzi et al 2012). Therefore, we propose that reduction of 
PBP2a level by FC-B and 75EA-L-F10 adversely affected cell-cell interaction and this 
leads to a disruption in biofilm production (see Figure 4.16).  
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Figure 4.15  Model of PBP2a-mediated biofilm expression in MRSA. Presence of high level of 
PBP2a in MRSA represses the icaADBC blocking PIA/PNAG production which in turn 
correlates a PBP2a promoted biofilm formation.  
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Figure 4.16 Schematic diagram showing steps involved in biofilm formation. The inhibition of 
biofilm production by the bioactive fractions (BF) is proposed due to 1) prevention 
of cell-surface attachment and 2) reduction of PBP2a level based on the results of 
this study.  
 
 
 
Step 2: The bacterial cells form random attachment 
on the surface 
Step 3: The bacterial cells develop into a 
microcolony by forming cell-cell interactions 
Step 4: The microcolony eventually forms an 
extracellular complex comprising DNA, bacterial 
polysaccharides and proteins  
IIIIIIIIII 
BF 
BF 
1) Prevent the cell- surface attachment 
process (e.g. interacts with 
MSCRAMMs) 
2) Reduce PBP2a level which 
indirectly disrupts cell-cell 
interaction formed by cells 
expressing PBP2a (red circle) 
 
BF = Bioactive fraction 
= Bacterial cell 
= PBP2a 
Step 1: The yellow bacteria represent planktonic 
cells which are propelled by surface proteins to 
attach to a surface 
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4.5.2 MIC ampicillin inhibits MRSA biofilm production  
  
MIC of ampicillin which was included as control, effectively inhibited MRSA biofilm 
production as high as 84.49% however, microtiter attachment assay revealed 62.20% of 
cell-surface attachment in the same treatment.  Findings from microtiter attachment 
assay clearly indicated the inferior activity of ampicillin in preventing cell-surface 
attachment which occurs in first hour of incubation. This suggest that ampicillin does not 
act rapidly in obstructing the cell-surface attachment unlike the bioactive fractions thus, 
indicating a possible delayed antibacterial action by ampicillin. Based on this inference, 
we hypothesized that due to the delayed antimicrobial action; MRSA cells were observed 
to attach to the surface initially. However, continuous exposure to MIC of ampicillin (up 
to 24 hours in inhibition of biofilm production assay) may inhibit or slows the bacterial 
growth which subsequently reduced the final production of biofilm. Nonetheless, this 
does not suggest that ampicillin is a good anti-biofilm agent because delay in 
antibacterial action leads to prolonged and repeated exposure of MRSA to the antibiotic 
which is likely to contribute to the emergence of multi-  ȋǯ  Ǥ
2000; Mataraci and Dosler 2012). Furthermore, the MIC of ampicillin used to treat the  ? ?ɊȀ which exceeded MIC breakpoints for susceptibility to beta-
lactam drugs (Brown 2001). Therefore, ampicillin is not indicated for treatment of 
biofilm related infections.  
 
We also observed a sudden increase (4-fold) in MRSA biofilm production when 
the concentration of ampicillin was reduced from MIC to 1/2 x MIC. As described in 
earlier findings, sub-MIC of beta-lactams antibiotics in fact promotes formation of 
biofilm in S. aureus in vitro as much as 4-fold which we found consistent with results of 
our study. The amplification of biofilm production at sub-MICs of cell-wall active 
antibiotics such as ampicillin, was reported common and the reason was suggested due 
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to global cell stress that leads to physiological changes. In response to these changes, the 
bacteria act to protect the cells by forming biofilms (Carsenti-Etesse et al. 1992; Mah and ǯ ? ? ? ?ȌǤ 
 
4.5.3 High PBP2a level in biofilm from MRSA cultures treated with MIC 
ampicillin did not promote biofilm production 
 
Attenuation of PBP2a level in MRSA biofilm appeared to reduce biofilm production for 
treatments with the bioactive fractions. Likewise, higher level of PBP2a in biofilm 
treated with ampicillin alone (at 1/32 x MIC and 1/64 x MIC) corresponded to increased 
biofilm production (Table 4.2). However, the same was not observed for MIC of 
ampicillin. Despite the occurrence of high level of PBP2a in the biofilm extract, MIC of 
ampicillin was observed to markedly reduce biofilm production. The reason for this 
observation is because the MIC of ampicillin supposedly slowed the bacterial growth 
that consequently led to low biofilm formation.  Furthermore, higher concentration of 
ampicillin may have effectively suppressed PBPs activity (other than PBP2a) that is 
required for biofilm production. Recent research reported that PBPs are involved in 
biofilm formation and motility of bacterial cells (Kumar et al. 2012; Ouyang et al. 2012). 
Due to these reasons, we presume that the high expression of PBP2a in biofilm treated 
with MIC of ampicillin was unable to promote biofilm formation. Even though MIC of 
ampicillin was shown to inhibit biofilm production, the aggravation of PBP2a level at this 
concentration indicates increased resistance that may induce more complications in 
treatment of biofilm in the long run.  
 
 
 
 
167 
 
4.5.4 Conclusion 
 
Overall we have demonstrated that FC-B and 75EA-L-F10 inhibited biofilm formation in 
MRSA by preventing cell-surface attachment and interrupting PBP2a expression, which 
indirectly disrupts cell-cell interaction that is also necessary for biofilm development.  In 
combination treatments, a significant inhibition of biofilm formation was only observed 
for combination of ampicillin and 75EA-L-F10. Nevertheless, both 75EA-L-F10 and FC-B 
was found to possess anti-biofilm properties which may have contributed to improved 
antimicrobial activity as the inhibition of biofilm is expected to result in increased 
uptake of the antibiotic among the biofilm protected cells. Besides affecting the two 
studied factors in this chapter, FC-B and 75EA-L-F1 may also affect other factors 
involved in MRSA biofilm formation such as role of wall teichoic acids, quorum sensing      ȋ  ǯ  ? ? ? ?Ǣ   Ǥ  ? ? ? ?Ǣ
Holland et al. 2011). 
 
Analysis of biofilm production and cell-surface attachment showed a positive 
correlation for treatments with the bioactive fractions alone and in combination with 
ampicillin. Hence, suggesting that prevention of cell-surface attachment is a useful 
strategy in combating biofilm formation. Whereas reduction of PBP2a level in the biofilm 
affirmed our previous finding (Chapter 3) that these bioactive fractions attenuated 
PBP2a. The current finding indicated that PBP2a plays a crucial role in mediating the 
formation of biofilm which renders further resistance in these sessile biofilm 
populations of MRSA.  As such, the ability of FC-B and 75EA-L-F10 in attenuating PBP2a 
is valuable characteristic for development of new treatment for MRSA.
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CHAPTER 5 
 
GENERAL DISCUSSION AND CONCLUSION 
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5.1 BACKGROUND 
 
Resistance issue of MRSA continues to threaten the world population despite the 
availability of new antibiotics (David and Daum 2010).  Production of PBP2a 
accompanied by biofilm-forming capacity contributes to the prevalence of MRSA 
infections.  Beta-lactams that block PBPs action in assembly and regulation cell wall 
biosynthesis are no longer effective. This is because PBP2a which has a lower binding 
affinity to these beta-lactams overtakes the blocked PBPs functions and ensures a 
smooth cell wall synthesis in MRSA (Berger-Bächi 1994; Berger-Bächi and Rohrer 2002). 
The biofilm forming capacity, on the other hand, plays a fundamental role in protecting 
bacterial cells from potential antimicrobial agents in the sessile stage. Besides, bacterial 
biofilm contributes to the manifestation of antibiotic resistances (Costerton et al. 1999; 
Petrelli et al. 2006; Del Pozo and Patel 2007) which further increases the challenges in 
treating MRSA infections.  
 
 ǯǡ
in finding solutions to overcome these virulent factors.  In pharmacology, multi-drug 
therapy which is dubbed as synergism strategy has effectively curb resistance issues 
specifically for treatment of infectious diseases such as tuberculosis (Wagner and Ulrich-
Merzenich, 2009).  Natural products from plants are promising candidates for 
synergistic treatment as these compounds demonstrated ability to modify resistance 
displayed by microorganism such as production of enzymes, MDR efflux pump system 
and altered target site (Hemaiswarya et al. 2008).  Restoration of antimicrobial efficacy 
of conventional drugs against the antibiotic resistant pathogens can be achieved when 
these plant products are used in combination.   
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 In our earlier study, we have shown that ethyl acetate extract from A. wilkesiana 
and D. grandiflora possessed anti-staphylococcal activity (Othman et al. 2011a; Othman 
et al. 2011b). Following that, the current research was designed to evaluate effects of 
these plant extracts and their bioactive fractions in combination with ampicillin on 
MRSA. The results revealed that extracts and fractions from both plants demonstrated 
synergism with ampicillin in suppressing MRSA growth. Mode of action study showed 
that the selected bioactive fractions, FC-B and 75EA-L-F10, were able to attenuate PBP2a 
expression. In biofilm studies, these bioactive fractions inhibited MRSA biofilm 
production via prevention of cell-surface attachment and reduction of PBP2a level which 
may have indirectly disrupt the cell-cell interaction in biofilm development. HPLC 
analysis revealed that these bioactive fractions are complex mixtures of plant 
metabolites. While phytochemical analysis, showed presence of biologically active 
phytochemicals such as tannins, saponins, alkaloids, flavonoids, sterols/steroids, and 
glycosides.  
 
5.2 SYNERGISM OF CRUDE EXTRACTS A. WILKESIANA AND D. GRANDILFLORA 
WITH AMPICILLIN IN INHIBITING MRSA GROWTH  
 
As shown in Chapter 3 crude extracts of A. wilkesiana and D. grandiflora (9EA and 75EA-
L) reduced the MIC of ampicillin against MRSA from 50 µg/ml to  0.78 µg/ml and 1.56 
µg/ml respectively. The kinetic growth curves illustrated a marked suppression on 
MRSA growth in combination treatments compared to treatment with one agent alone. 
From the FIC index interpretation, the combinations of these crude extracts and 
ampicillin indicated synergism interaction based on FIC indices < 0.5.  
 
The combinatorial activities of plant extracts or products with antibiotics in 
which synergism was present is principally attributed to resistance modifying action of 
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the plant test agents (Abreu et al. 2012). The resistance modifying action of plant 
products are implied to attenuate the bacterial resistance mechanism, and hence 
promote the antimicrobial action of antibiotics in combination treatments (Shahverdi et 
al. 2007).  This is supported by the findings that plant produces secondary metabolites 
in response to microbial attack in nature where some of these products were shown to 
fight infections successfully (Sibanda and Okoh 2007). In agreement, phytochemicals 
analysis revealed presence of tannins, saponins, alkaloids, flavonoids, sterols/steroids, 
and glycosides in 9EA and 75EA-L.  These are pharmacologically active phytochemicals 
that were demonstrated to influence bacterial resistance mechanisms in vitro (Abreu et 
al. 2012). 
 
The phytochemicals occurring in 9EA and 75EA-L are suspected to give rise to 
the observed synergism in the combination treatments. Since these extracts contains 
mixture of compounds, it is highly possible for these extracts to have multi targets such 
as bacterial cell membranes or wall, metabolic pathways, production of protein, and 
DNA replication in exhibiting antimicrobial action. Therefore, the mechanism 
underpinning antibacterial and synergistic effects of 9EA and 75EA-L is unclear at this 
stage of experiment. However, previous studies reported that plant metabolites 
classified as tannins, flavonoids and alkaloids are capable of inhibiting MRSA or S. aureus 
growth via synergism with antibiotics and some were found to attenuate the resistance 
mechanisms (Table 5.1). Besides that, other phytochemicals found in the extracts 
namely sterols and glycosides were reported to demonstrate antimicrobial activities 
against MRSA (Nazemiyeh et al. 2008; Singh et al. 2012).  
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Table 5.1 Synergistic activities of selected phytochemicals and their mode of actions against 
MRSA and S. aureus 
 
Phytochemical Antibacterial 
activity 
Mode of action Reference 
 
Tannins 
 
Act synergistically 
with oxacillin 
 
Prevent PBP2a synthesis 
and secretion of beta-
lactamase in MRSA 
 
Yam et al. 1998 
Rocarro et al. 2004 
Shibata et al. 2005 
Marquez et al. 2005 
Hu et al. 2002 
 
Alkaloids  Reduce MIC of 
norfloxacin in 
combination 
treatments 
 
Produced an 
additive and 
synergistic effects 
when combined 
with ampicillin and 
oxacillin 
 
Inhibit MDR efflux pump 
mechanism in S. aureus 
 
 
 
Increase membrane 
permeability and 
intercalate into DNA 
Markham et al. 1999 
Gibbons et al. 2003  
Stavri et al. 2007 
 
 
Yu et al. 2005  
Lewis and Ausubel 
2006 
 
  Flavonoids Reduced MIC 
oxacillin against 
MRSA in 
combination 
treatments 
Target MRSA cell 
membrane and cell wall 
Hatano et al. 2005 
 
The synergism observed in combination treatments pinpoints that these 
phytochemicals could affect the resistance mechanisms in MRSA. This phenomenon is 
thought to improve antibacterial potency of ampicillin. Therefore, a lower MIC of 
ampicillin was recorded in combination treatments. Following that, the fractions 
obtained from 9EA and 75EA-L were evaluated for synergistic activity.  Effects of 
combination treatment on a MRSA resistance determinant; PBP2a was carried out for 
selected bioactive fractions.  The selected bioactive fractions were also evaluated for 
inhibitory effect on MRSA biofilm since PBP2a (encoded by mecA gene) influences 
biofilm phenotype indicating interrelatedness of these virulent factors (McCarthy et al. 
2015).  
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5.3 EFFECTS OF BIOACTIVE FRACTIONS ON PBP2a 
 
5.3.1 FC-B  
 
Fraction FC-B is a fraction obtained from 9EA, crude extract of A. wilkesiana. The fraction 
has a MIC of 3 mg/ml against MRSA and presence of this fraction (1/4 x MIC = 0.75 
mg/ml) enhanced the potency of ampicillin up to 32-fold by reducing MIC ampicillin 
from 50 µg/ml to  1.56 µg/ml for MRSA. Synergy was indicated present by FIC index 
interpretation in which the scored index was 0.28 (< 0.5 = synergism) for combination of 
1/32 x MIC ampicillin + 1/4 x MIC FC-B. The growth curve experiments likewise 
revealed an increased antimicrobial action when FC-B was combined with ampicillin. 
From the Western blot experiments (3), the synergistic activity observed between FC-B 
and ampicillin against MRSA was shown to be associated with inhibition of PBP2a. This 
suggests that FC-B can either inhibit the production of PBP2a or directly inactivate 
PBP2a.   
 
Studies on A. wilkesiana indicated that compounds from class of tannins were 
commonly found in extracts or fractions of this plant which demonstrated antimicrobial 
activity (Oladunmoye 2006; Gotep et al. 2010; Din et al. 2013a; Din et al. 2013b). Some of 
the well-known tannins such as corilagin and tellimagrandin I exceptionally reduced 
MICs of beta-lactams for MRSA when used in combination. The mode of action of these 
compounds was suggested through inactivation of PBP2a (Shiota et al. 2004). We 
postulated that corilagin is present in FC-B, since corilagin was previously isolated and 
identified by our colleagues from the same source of plant materials (Din et al. 2013b). 
This is further supported by phytochemical testing that showed the presence of tannins 
in FC-B.  Based on the Western blot results, FC-B was confirmed to inhibit PBP2a 
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production in MRSA (either alone or in combination with ampicillin) which we found 
similar to mechanism of action of corilagin.  
 
Tannins appeared to play an important role in antibacterial activity of FC-B. 
Along with corilagin, the researchers in our laboratory also identified other tannins; 
geraniin and ellagitannin in the A. wilkesiana fractions. Ellagitannin demonstrated 
synergistic activity with ampicillin against MSSA and the mechanism of action was 
proposed through bacterial cell lysis in which the bacterial cell wall was observed 
damaged (Din et al. 2013a). This shows that tannins may have cell wall or membranes as 
targets. In line with this, a previous study showed that epicatechin gallate (ECg- a 
tannin) which reversed beta-lactam resistance in MRSA did not interact through direct 
binding with PBP2a or influence its enzymatic activity. Instead ECg affects the fluid 
dynamics of the cyctoplasmic membrane by decreasing the fluidity of the lipid bilayer. 
These changes trigger expression of genes involved in preservation and reparation of a 
compromised cell wall which eventually delocalized PBP2a from the cell wall 
biosynthesis process (Bernal et al. 2010).  
 
At present, our studies indicate occurrence of tannins in FC-B could have largely 
contributed to attenuation of PBP2a. Further studies are necessary to determine the 
tannic compounds in FC-B and to elucidate how FC-B inhibits PBP2a production in 
MRSA. The current results leads to suggestions that active compounds from FC-B may 1) 
interact with MecR2 (anti-repressor) or MecR1 (sensor inducer) involved in expression 
of mecA gene encoding for synthesis of PBP2a in MRSA or 2) interact directly with PBP2a 
and cripples its role in cell wall of biosynthesis. 
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5.3.2 75EA-L-F10 
 
Fraction 75EA-L-F10 is a major fraction isolated from the 75EA-L, crude extract of D. 
grandiflora leaves.  MIC of 75EA-L-F10 versus MRSA is 0.75 mg/ml and combination of 
this fraction (1/4 x MIC 75EA-F10 = 0.19 mg/ml) with ampicillin decreased MIC 
ampicillin by 64-fold (from 50 µg/ml to 0.78 µg/ml).  FIC index of 0.25 (< 0.5 = 
synergism) was scored in combination treatment of 1/64 x MIC ampicillin + 1/4 x MIC 
75EA-L-F10 suggesting synergism present between these two components. Similarly, 
the growth curve assay indicated that a better inhibition on MRSA growth was achieved 
in combination treatments in contrast to treatment with ampicillin or 75EA-L-F10 alone. ȋ ?Ȍǯ
potency is related to ability of 75EA-L-F10 to inhibit PBP2a production which was 
identical to antimicrobial action of FC-B.   
 
 In contrast to A. wilkesiana, D. grandiflora is not widely studied for its 
antibacterial properties. The available literatures on this plant are mostly related anti ǡǯ
derived from it (Bhakuni et al. 1971; Sharma et al. 1972; Sharma et al. 1974; Tsukiyama 
et al. 2010; Kaweetripob et al. 2012).  Hence, we could not specifically identify a group of 
phytochemical that is most likely to be responsible for PBP2a inhibition. Nevertheless, 
occurrence of tannins in 75EA-L-F10 explains the antimicrobial properties of this 
fraction to a certain extent, since tannin compounds have been extensively reported to 
exhibit anti-MRSA activity (see section 5.3.1). The mechanisms involved in inhibition of 
PBP2a by 75EA-L-F10 are elusive, but similar to FC-B we postulate that 75EA-L-F10 
could affect the expression of mecA gene or degrade the resistant protein.  
 
 
176 
 
Interestingly, flavonoids that was absent in FC-B, was found present in 75EA-L-
F10. Similar to tannins, several flavonoids such as licoricidin, licochalcone, glyasperins, 
and glabridin demonstrated synergism with oxacillin in halting MRSA growth (Hatano et 
al. 2005). Study of mechanism of action revealed that these compounds were not 
affecting PBP2a production. Instead they were suggested to interact with MRSA cell 
membrane or wall which gave rise to the observed antimicrobial and synergistic (with 
oxacillin) activity (Hatano et al. 2005). This implies that flavonoids in 75EA-L-F10 could 
be one of the potential phytochemicals which contributed to the antimicrobial and 
synergistic activity of the fraction.  
 
5.4. EFFECTS OF BIOACTIVE FRACTIONS ON BIOFILM  
 
The resistance to beta-lactam antibiotics particularly expression of PBP2a seemed to be 
crucial in determination of the biofilm phenotype (McCarthy et al. 2015).  Hence, the 
bioactive fraction FC-B and 75EA-L-F10 were evaluated for anti-biofilm activities. Our 
studies showed that these fractions inhibited biofilm formation via 1) prevention of cell-
surface attachment and 2) reduction of PBP2a level that is necessary for cell-cell 
interaction in development of biofilm. Additionally, we demonstrated that biofilm 
produced by MRSA strain used in this study is proteinaceous.  
 
The biofilm inhibiting properties of FC-B and 75EA-L-F10 are attributed to 
presence of the phytochemicals. Tannins are phytochemicals commonly found in all 
plants, exert antibacterial effects by interacting with bacterial cell wall or membrane. 
They are generally able to penetrate biological membranes easily therefore prevent 
clustering of bacterial cells which negatively affects biofilm production (Blanco et al. 
2005; Cushnie and Lamb 2011). Besides, compounds classified as tannin such as 
epigallocatechin gallate (EGCg) is capable of binding to peptidoglycan and destroy the 
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bacterial cell wall integrity. The weaken cell integrity may hinder the initial phase of 
biofilm production that is the interaction between the bacterial cell wall and the surface 
for attachment (Carpentier and Cerf 1993; Zhao et al. 2001; Zhao et al. 2002; Yoda et al. 
2004).  A recent study that showed tannic acids influences S. aureus cell surface 
hydrophobicity which is an important factor in cell-surface attachment in the process of 
biofilm formation (Chusri et al. 2012). There is also evidence that tannins interfere with 
bacterial quorum-sensing system that catalyze the biofilm formation (Huber et al. 2003). 
It is therefore highly plausible that the occurrence of tannins in FC-B and 75EA-L-F10 
were responsible for the observation made in the microtiter attachment assay, in which 
the fraction remarkably reduced MRSA cell-surface attachment.  
 
Other than tannins, flavonoids which were found only in 75EA-L-F10 are 
suspected to play a vital role in the anti-biofilm activities observed. Previously, 
flavonoids were reported to target cell membrane which subsequently weakens the 
integrity of biofilm structure. It was shown that flavonoid components in propolis 
extracts affect bacterial membrane potential (changes in the permeability) and inhibit 
bacterial motility (Mirzoeva et al. 1997). Inhibition of bacterial motility especially 
reduces the ability of bacterial cells to move towards a surface for the attachment 
process. This eventually, results in lower cell-surface attachment as what we have 
observed in microtiter attachment assay. Besides, influence of flavonoids on membrane 
permeability may have led to increased antibiotic uptake into the biofilm protected cells 
and ultimately result in growth inhibition. In a different study, flavonoids were reported 
to affect the sortase activity, which is known to influence the adhesive property of 
bacterial cell wall, leading to interruption of biofilm development (Tiwari and Sen 2006; 
Mataraci and Dosler 2012).  Hence, events that are described here could be one of the 
potential mechanisms which contributed to the anti-biofilm activities in 75EA-L-F10. 
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Besides affecting the cell-surface attachment process, phytochemicals occurring 
in FC-B and 75EA-L-F10 were found to inhibit PBP2a production (section 5.3). The 
attenuation of PBP2a by these fractions influenced the level of PBP2a in MRSA biofilm 
(PBP2a latex agglutination assay). Since PBP2a was earlier hypothesized to promote 
biofilm production in MRSA (Pozzi et al. 2012), reduction of PBP2a level in biofilm by 
FC-B and 75EA-L-F10 is thought to obstruct cell-cell interaction involved in biofilm 
development.  
 
We also found that in biofilm studies, combination of FC-B and ampicillin did not 
enhance the anti-biofilm activity considerably compared to activity of the fraction alone.  
Combination of 75EA-L-F10 and ampicillin however resulted in a significant decrease in 
biofilm production. Nevertheless, the ability of both fractions in inhibiting biofilm 
production implies elimination of virulent factor which overall may have result in 
improved antibacterial effects.  
 
5.5 ANTIMICROBIAL ACTION OTHER BIOACTIVE FRACTIONS  
 
Along with FC-B and 75EA-L-F10, other bioactive fractions 9EA-FB, 9EA-FD and 75EA-B-
F4 were identified in this study. Nevertheless, due to problems such as low yield and 
unstable activity as described in Chapter 3, some of these fractions and their derivatives 
were eliminated from the experiments. Furthermore, since the aim of this study is to 
identify bioactive fractions which have synergistic action with ampicillin, fractions that 
did not display the desired activity or have weaker synergism were excluded from the 
study. Fraction 9EA-FB and 75EA-B-F4 both inhibited MRSA growth but did not 
demonstrate any synergism with ampicillin. Whereas, 9EA-FD initially had moderate 
anti-MRSA activity however the sub-fractions obtained after VLC/CTLC were inactive in 
the biological assays and some were inadequate in amount.  
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5.6 CONCLUSION AND FUTURE STUDIES 
 
5.6.1 Summary 
 
Findings in this study showed that A. wilkesiana and D. grandiflora yields bioactive 
fractions that have antibacterial effects on MRSA and MSSA. The antibacterial potential 
of the crude extracts and the fractions explains the effectiveness of the plant extracts 
used traditionally to heal infectious diseases. Combining results from HPLC and 
phytochemical analysis together with information from literature reviews, we deduced 
that the antibacterial activity was observed as a result from presence of phytochemicals 
mainly tannins and flavonoids. These plant metabolites could target multiple factors that 
are essential for MRSA growth and survival (see Figure 5.1).  On the other note, our 
study is the first to report the ability of fractions from A. wilkesiana and D. grandiflora; 1) 
to work synergistically with ampicillin in suppressing MRSA growth via PBP2a inhibition 
and 2) to inhibit MRSA biofilm production by preventing cell-surface attachment and 
reducing PBP2a level which is necessary for cell-cell interaction in biofilm development. 
The synergistic activities and the ability of the plant metabolites from A. wilkesiana and 
D. grandiflora in attenuating virulent factors in MRSA (PBP2a production and biofilm 
forming capacity) indicate the potential use these plants metabolites as adjuvant for 
antibiotics to reverse beta-lactam resistance in MRSA. 
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Figure 5.1 A schematic diagram representing multiple targets of tannins and flavonoids in inhibiting bacterial/MRSA growth and biofilm formation based on 
previous studies. Tannins were found in both fractions from A. wilkesiana (FC-B) and D. grandiflora fraction (75EA-L-F10). Flavonoids were only found 
in 75EA-L-F10. Mechanisms of anti-biofilm and antibacterial action demonstrated by the bioactive fractions FC-B and 75EA-L-F10 in this study are 
labeled as *. 
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5.6.2 Future studies 
 
The current study has enabled finding of two bioactive fractions, FC-B and 75EA-L-F10. 
Nonetheless, no active compound in these fractions was identified. Corilagin, geraniin 
and ellagitannin were highly likely to occur in FC-B based on their discovery in A. 
wilkesiana extracts by another group in our laboratory. However, it is essential to 
identify the active compounds in these fractions for a conclusive study of mode of anti-
MRSA action.  Furthermore, in order to commercialize herbal extract or plant products, 
it is important to standardize the active ingredients to maintain the clinical efficacy of 
the product. In the mean time, no antimicrobial compound has been isolated from D. 
grandiflora extracts so far, hence this opens a new facet of study that potentially could 
lead to discovery of novel compounds.  
 
 Mechanism of action study revealed that components from FC-B and 75EA-L-F10 
inhibit PBP2a production.  We postulated that this could be due interruption in mecA 
gene expression that involves the anti-repressor protein MecR2 or the sensor-inducer 
domain MecR1.  This requires further molecular studies involving experiments such as 
DNA manipulations, PCR, ELISA, and transcriptional analysis as conducted in a previous 
research (Arêde et al. 2012). These experiments would be useful to study protein 
interactions and protein content. In addition, since in S. aureus species are known to 
produce at least four types of PBPs, effects of these fractions on other PBPs which can be 
studied via Western blot experiments may provide better understanding of mechanism 
of action. Another interesting dimension of study is the effects of the bioactive fractions 
on beta-lactamase which is an enzyme that confers resistance to penicillins in S. aureus. 
Apparently transcriptional control of mecA encoding for PBP2a and blaz encoding for 
beta-lactamase is regulated by homologous repressors which was demonstrated to 
cross-talk. Recently, the bla regulators were found to stabilize mecA acquisition (Oliveira 
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and de Lencastre 2011) and in fact, the bla regulatory system promotes optimal 
expression of mecA by disrupting the efficient MecI-mediated repression on mecA (Arêde 
et al. 2013). Therefore, study on effects of the bioactive fractions on beta-lactamase 
production may explain the link between the two resistant determinants (PBP2a and 
beta-lactamase) in MRSA.  
 
 We also found that the studied bioactive fractions possess anti-biofilm activities 
related to prevention of cell-surface attachment and reduction in PBP2a level in biofilm.  
The production of biofilm in MRSA is influenced by multiple factors such as bacterial 
motility, surface proteins, quorum sensing systems, and global stress response. Hence, a 
future studies encompassing investigations of genes involved in biofilm development 
through implementation of DNA microarray techniques as shown in an earlier research 
(Overhage et al. 2008) may aid deeper understanding of antimicrobial action of the 
bioactive fractions in relation to biofilm production. 
 
 The observed anti-MRSA activity in the bioactive fractions and extracts is 
attributed to presence of phytochemicals. In this study, tannins, flavonoids and alkaloids 
are theoretically the major components that gave rise to antimicrobial activity. Based on 
preceding works, compounds belonging to these groups were widely reported to target 
cell wall and membrane. Thus, study of MRSA cell membrane polarization accompanied 
by microscopy examination on cell wall upon treatment with these bioactive fractions 
could provide evidence of interaction of the phytochemical components with bacterial 
cell wall or membrane.  
 
 Overall, this research has demonstrated synergism between bioactive fractions 
from A. wilkesiana and D. grandiflora with ampicillin in attenuating a resistant 
determinant namely PBP2a. Likewise these fractions also possess the ability to 
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overcome a virulent factor, biofilm production in MRSA. However since the bioactive 
fractions contains mixture of naturally occurring compounds the mechanism of 
antimicrobial action is very likely to be more complex and involves several targets. 
Therefore the current proposed mode of action as yet incompletely defined mechanism. 
Nevertheless, the presence of pharmacologically active phytochemicals indicates that 
these bioactive fractions may be good candidates for development of new treatment for 
MRSA.
x 
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APPENDICES 
 
APPENDIX 1:  Determination of MIC via broth microdilution assay, the lowest 
concentration of test sample in which no color changes was observed 
(sample in the well remain yellow after addition of MTT) is considered as 
the MIC.  
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APPENDIX 2: MRSA cell-attachment (%) for combination treatments- ampicillin  
  and FC-B 
 
 
 
 
 
 
100 
15.36 
21.65 23.62 23.77 18.62 
24.21 
0 
20 
40 
60 
80 
100 
120 
Control MRSA 1/2 x MIC 
AMP + F-CB 
1/4 x MIC 
AMP + F-CB 
1/8 x MIC 
AMP + F-CB 
1/16 x MIC 
AMP +  F-CB 
1/32 x MIC 
AMP + F-CB 
1/64 x MIC 
AMP +  F-CB 
M
R
S
A
 c
e
ll
-s
u
rf
a
ce
 a
tt
a
ch
m
e
n
t 
(%
) 
Sub-inhibitory concentrations of ampicillin (AMP) + 1/4 x MIC FC-B (0.75 mg/ml) 
100 
24.97 
31.72 
38.32 40.81 41.09 
44.67 
0 
20 
40 
60 
80 
100 
120 
Control MRSA 1/2 x MIC 
AMP + FC-B 
1/4 x MIC 
AMP+ FC-B 
1/8 x MIC 
AMP + FC-B 
1/16 x MIC 
AMP + FC-B 
1/32 x MIC 
AMP + FC-B 
1/64 x MIC 
AMP + FC-B M
R
S
A
 c
e
ll
-s
u
rf
a
ce
 a
tt
a
ch
m
e
n
t 
(%
) 
Sub-inhibitory concentrations of ampicillin (AMP) +  1/8 x MIC FC-B (0.38 mg/ml) 
100 
47.29 49.56 45.43 47.68 47.10 
50.49 
0 
20 
40 
60 
80 
100 
120 
Control MRSA 1/2 x MIC 
AMP + FC-B 
1/4 x MIC 
AMP+ FC-B 
1/8 x MIC 
AMP + FC-B 
1/16 x MIC 
AMP + FC-B 
1/32 x MIC 
AMP + FC-B 
1/64 x MIC 
AMP + FC-B M
R
S
A
 c
e
ll
-s
u
rf
a
ce
 a
tt
a
ch
m
e
n
t 
(%
) 
Sub-inhibitory concentrations of ampicillin (AMP) +  1/16 x MIC FC-B (= 0.19 mg/ml)  
xxxii 
 
APPENDIX 3: MRSA biofilm production (%) for combination treatments- ampicillin and 
FC-B 
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APPENDIX 4: MRSA cell-surface attachment for combination treatments (ampicillin 
and 75EA-L-F10) 
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APPENDIX 5: MRSA biofilm production (%) for combination treatments (ampicillin 
and75EA-L-F10) 
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APPENDIX 6: Crystal violet staining of microtiter plate for quantification of biofilm 
production  
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APPENDIX 7: TLC profile of fractions isolated from 9EA (A. wilkesiana crude extract) 
before being combined into major fractions based on their 
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